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Abstract
Accurate and robust monitoring of product and reactants in a complex 
bioconversion stream is essential for the development of effective process 
control strategies. To monitor a microbially-catalysed Baeyer-Villiger 
bioconversion of a cyclic ketone to an optically pure lactone, a near infrared 
(NIR) spectroscopic method has been developed. The reaction, catalysed by 
cyclohexanone monooxygenase from Acinetobacter calcoaceticus 
(expressed in Escherichia coli) is characterised by substrate (ketone) and 
product (lactone) inhibition at relatively low concentrations. Quantitative 
multivariate calibration of a NIR spectrophotometer for ketone and lactone 
resulted in a standard error of prediction (SEP) at-line of 0.088 and 0.110 g.l"1 
and on-line of 0.130 and 0.180 g.l'1, respectively. The directed modification of 
quantitative models, by the inclusion of spiked process samples improved the 
SEP for lactone prediction where bioprocess development meant existing 
NIR models were not relevant. The monitoring and control of the Baeyer- 
Villiger bioconversion by NIR has allowed intermittent feeding of ketone such 
that the concentration of substrate does not rise above 0.6 g.l'1. Using this 
feeding strategy 5.7 g.l'1 of lactone product has been produced. This 
represents a 2-fold increase in productivity. The application of a technique to 
monitor analytes at low concentration demonstrates the utility of NIR for 
control of biotransformation processes.
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Comment
“W e are not here in this world to find elegant solutions, pregnant 
with initiative, or to serve the ways and modes of profitable 
progress. No, we are here to provide for all those who are weaker 
and hungrier, more battered and crippled than ourselves. That is 
our only good and great purpose on earth, and if you ask me 
about those insoluble economic problems that may arise if the top 
is deprived of their initiative, I would answer, to hell with them. The  
top is greedy and mean and will always find a way to take care of
themselves. They always do.”
Words of Michael Foot during the 1983 General Election.
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1. Introduction
1.1. Biotransformations
1.1.1 Enantiomers and Diastereomers
A biotransformation reaction uses a biocatalyst, either as an isolated enzyme 
or a whole cell, to catalyse a specific chemical reaction in which defined 
substrate(s) are converted to defined product(s) (Lilly, 1994).
Academic study of biotransformations has developed out of the needs of 
industry for enantiomerically pure materials. Biotransformations enable the 
conversion of achiral compounds into enantiomerically pure chiral 
compounds. Conversion resolution techniques include: asymmetric
synthesis, conventional resolution techniques and utilisation of the chiral pool 
(Kelly, 1998).
A molecule is chiral if it cannot be superimposed on its mirror image. Chiral 
molecules, because of their handedness, have two forms that differ only in 
their spatial arrangement. Lactic acid is an example of a molecule (Figure
1.1), which exhibits chirality, the two forms are known as enantiomers. 
Stereoisomers that are not geometric isomers are called optical isomers. 
Enantiomers constitute one way in which optical isomers can occur (Figure
1.2).
Figure 1.1: Lactic acid exhibits molecular chirality.
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Structural isomers
ISOMERS
Stereoisomers
Optical Geometric (cis/trans)
Enantiomers Meso compounds Diastereomers
Figure 1.2: The relationship of various kinds of isomers
With the exception of chirality, the structure of a pair enantiomers is the 
same. This means almost all of their physical and chemical properties are the 
same. For a single pair of enantiomers there are two sets of properties, which 
differ:
• Interactions with other chiral substances, and
• The direction of rotation of the plane of polarisation of plane-polarised 
light.
The difference in optical properties of enantiomers of a molecule is used to 
distinguish the two forms.
To describe the absolute configurations of a pair of enantiomers the Cohn- 
Ingold-Prelog system is preferred (Fessenden et a/., 1982). This system, also 
known as the (R) and (S) system describes actual arrangements of groups 
around a chiral carbon. The letters D and L denote configuration based on
24
Fischer projection formulas. The R and S system has superseded the Fischer 
projection nomenclature. The exception being the description of 
carbohydrates and amino acids.
A mixture containing equal amounts of the two enantiomeric forms of a 
molecule is known as a racemic mixture. A racemic mixture has no optical 
activity. Under some circumstances different proportions of the enantiomers 
will be present in a mixture. The proportion of the enantiomers in the mixture 
is described by the enantiomeric excess (ee)(Equation 1.1).
A + B
Where,
A = proportion of most abundant enantiomer 
B = proportion of least abundant enantiomer
Equation! 1: Definition of Enantiomeric Excess (ee):
In, addition to enantiomers, a molecule can have diastereomic forms. 
Diastereomers arise when there is more than one chiral centre in a molecule, 
or where the molecule is non-linear. Unlike enantiomers, diastereomers have 
different physical properties. An example of two pairs of enantiomers, each 
pair being a distinct diastereomer of the other is 2,3,4-trihydroxybutanal 
(Figure 1.3).
There are also regioisomers (structural isomers); molecules which have the 
same molecular formula (isomers) but different regional order of attachment 
of their atoms. Two regioisomers are therefore distinct molecules (Figure 
1.4).
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(2R.3R) (2S,3S) (2S, 3R) (2R.3S)
CHO
CH2OH
CHO CHO
CH2OH c h 2o h
CHO
H— — OH HO— — H HO— — H H— — OH
H— — OH HO— —  H H— — OH HO— — H
CH2OH
enantiomers enantiomers
Figure 1.3: The four stereoisomers of 2,3,4-trihydoxybutanal. A pair of 
stereoisomers which are not enantiomers are called diastereomers.
(1)
(3)
H
(4)
H
Figure 1.4: The two pairs of lactone enantiomers (1,2) and (3,4) have the 
same molecular formula but are not stereoisomers (i.e. diastereomers). The 
different regional configuration of the functional groups means 1 and 3 for 
example are regioisomers.
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1.1.2 Production of Optically Pure Material
There are a number of strategies available for obtaining single-isomers
(Figure 1.5). For instance at the point in a process of introducing chirality into
a molecule the options include:
• Utilisation of the chiral pool, where the configuration of the molecule 
originates from the asymmetric configuration of the starting material.
• Resolution of racemates. The required isomer is separated at the end of 
the reaction. In some cases, the unwanted isomer can be recycled back 
into the racemate starting material or have its configuration converted to 
the required isomer.
• Asymmetric synthesis involves introducing asymmetry into a non-chiral 
material so that a single isomer is formed.
Chemical
Racemates Asymmetric SynthesisChiral Pool
Preferential crystallisation Kinetic Resolution Diastereomer crystallisation Synthesis Biocatalysis Chemocatalysis
Figure 1.5: Routes to pure stereoisomers. Adapted from (Sheldon, 1996).
1.1.3 The Chiral Pool
The chiral pool refers to optically active compounds, which are available from 
natural sources. These compounds are either isolated directly from natural 
sources or manufactured through bioprocesses. They are typically 
inexpensive and are often produced in significant quantities, 102-105 tonnes 
pa (Federsel, 1993).
Chiral pool compounds are used as building blocks, incorporating into the 
target structure the desired chiral features. Examples of commercially
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available chiral building blocks include amino acids, hydroxy acids, 
carbohydrates, terpenes and alkaloids.
1.1.3.1 Amino Acids
Amino acids are the oldest source of optically active compounds with 
crystalline glutamic acid isolated from gluten hydrolysate in 1866. 
Monosodium L-glutamate is manufactured on a large scale with a capacity of 
350,000 tonnes pa (Harper, 1983). Both L- and D-amino acids are in 
demand, for instance D-alanine is required in the sweetener alitome whilst 
demand for the intermediate L-phenylalanine has also grown.
1.1.3.2 Hydroxy Acids
Hydroxy acids such as lactic acid and malic acid are both available by 
fermentation. Malic acid is also available by asymmetric synthesis (Wynberg 
et al., 1982).
1.1.3.3 Carbohydrates
The long chains of carbohydrates (containing many chiral carbons) have 
meant that they have found limited commercial use as chiral building blocks. 
Use of them necessitates costly transformations of the long carbon chains to 
smaller, more useful species. There are examples of industrial carbohydrate 
chiral building blocks, including D-glucose in the ascorbic-acid producing 
Reichstein-Grussner process. This process produces >35,000 tonnes pa of 
L-ascorbic acid and D-sorbitol (Crosby, 1991).
1.1.3.4 Terpenes
Terpenes are characteristic of many varieties of plant life (odorants) and are 
also important to the pharmaceutical industry. Some of the available, optically 
active terpenes are: (+)-limonene, (-)-menthol, (-)-carvone, (+)-camphor, (+)- 
3-carene, (-)-p-pinene, (+)-a-pinene, (-)-a-phellandrene. Terpenes are used 
mainly as resolving agents or as a source of chirality for asymmetric 
synthesis, rather than as chiral building blocks.
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1.1.3.5 Alkaloids
Alkaloids, which are optically active and mostly dextrorotatory, are organic 
bases and include a number of highly active materials, e.g. morphine, 
caffeine, nicotine, atropine, cocaine. Many alkaloids are used in the 
resolution of racemic compounds on a small scale by crystallisation. Large- 
scale applications require, due to economic factors, that the alkaloid is 
recycled from the resulting salt species.
1.1.4 Resolution of Racemates
1.1.4.1 Classical Resolution
Classical resolution was used by Louis Pasteur during the separation of 
racemic sodium ammonium tartate and is still widely used industrially today. 
The method uses crystallisation, but not of the enantiomers which have the 
same chemical and physical properties and so rarely crystallise separately. 
Instead, a pair of enantiomers undergo a reaction with a chiral reagent or 
chiral catalyst to obtain a pair of diastereomers. As diastereomers have 
different physical properties, they can be easily separated by crystallisation. 
The methodology, principles of the technique, and criteria for good resolving 
agents have been described by Jacques and co-workers (Jacques et a/., 
1981), whilst examples of classical resolutions and factors involved in the 
commercial realisation of such a process have been discussed by Crosby 
(Crosby, 1991).
1.1.4.2 Kinetic Resolution
Kinetic resolutions are stereospecific as one of the enantiomers of a 
racemate is more readily converted to product than the other. In order to 
achieve this preferential conversion of one enantiomer, chemical catalysis or 
enzymatic methods are employed. The kinetics of a stereospecific reaction 
for conversion of a racemate (A,B), which is catalysed by an enzyme, are 
described by equation 1.2.
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The individual rates (Equation 1.3) of the two reactions will depend on the 
size of the two potential energy barriers. The kinetics are dependent on the 
substrate concentrations which changes as the reactions progress.
To describe the efficiency of resolution the enantiomeric ratio (Er) is used. 
The term Er is simply the ratio of the two reaction rates (equation 1.4). 
Provided the reaction is irreversible, the resultant enantiomeric excess (ee) in 
the product will remain unchanged.
Hence, if the Er of a stereospecific resolution is high (>300) then it can be 
said that only the one enantiomer would be transformed and so the reaction 
would stop at 50% conversion (Sheldon, 1996). Crosby (1991) states that an 
Er of >20 is sought for commercial processes such that a high ee (98%) can 
be obtained at <60% conversion. When Er is very high (>50) the product, if 
chiral, is simultaneously obtained with a high ee. However, product ee 
deteriorates as conversion increases. The specificity of an enzyme results in 
a high Er value compared to chemical catalysts.
There are numerous examples of industrial enzymic kinetic resolution 
processes, many of which are discussed by (Crosby, 1991, Liese et al., 
1999b, Pandey et al., 1999). The best examples are lipase-catalysed 
resolutions (Anderson et al., 1998, Jaeger et al., 1998), which are an 
established synthesis route for the production of chiral carboxylic acids (Tosa 
etal., 1995) and enantiomerically pure (R) and (S) amines (Balkenhohl et al., 
1997, Ladner et al., 1999). These kinetic resolutions are limited by enzyme 
stereospecificity to a maximal yield of 50%. To overcome this drawback a 
number of solutions have been developed, including in situ racemisation of 
the unwanted enantiomer (Ebbers et al., 1997, Larsson et al., 1997, Stecher 
etal., 1997, Urn etal., 1998).
30
EA ---------► E + P
kcat
EB  ► E + Q
Where:
E = Enzyme
AB = A pair of enantiomers A and B 
P & Q = Products 
Km = Michaelis constant 
Kcat = Catalytic rate constant
Kr
E + A + B
*<m
Equation 1.2: The kinetics of a stereospecific reaction for a racemate 
which is catalysed by an enzyme.
v= £ s-[E][S]
'm
V = Rate of reaction (mmol.L'1.h'1)
S = Substrate concentration (mmol)
E = Enzyme concentration (mmol)
Equation 1.3: Enzyme reaction rates.
Er= —  
V2
Er = Enantiomeric ratio (-)
Equation 1.4: Enantiomeric ratio.
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1.1.5 Asymmetric Synthesis
Asymmetric synthesis is the production of enantiomerically pure compounds 
through transformation of prochiral1 substrates. Mechanistically the 
transformation from a prochiral compound is biased in preference to one 
stereoisomer product. This reaction always involves an optically active agent 
acting either stoichiometrically or catalytically (including enzymes). This has 
the advantage that potentially all the material can be realised as the required 
isomer.
The lyase class of enzymes is used during asymmetric synthesis of amino 
acids from the corresponding a-keto acid precursors. Aspartase for example 
is used during the manufacture of L-aspartic acid (Schulze et al., 1999). The 
use of Saccharomyces cerevisiae as a whole cell to carry out asymmetric 
ketone reductions is a popular route to optically pure alcohols (Griffin et al., 
2001, Stewart, 2000).
1.1.5.1 Non-Enzymatic Methods
There are many examples of non-enzymatic methods including 
hydrogenation, reduction, oxidation, isomerisation, etc. (Crosby, 1991). 
Crosby has discussed a few examples and makes the point that chemical 
catalysts lack diversity with respect to the possible substrates accepted.
In addition, stereoselective synthetic transformations require an auxiliary e.g. 
a catalyst or ligand that introduces or results in asymmetry in the target 
molecule. The ability of a compound to function as a chiral auxiliary is 
dependent on an number of requirements (Federsel, 1993):
1 Prochiral: molecules where the addition or substitution of a functional group results in a 
chiral centre.
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•  The auxiliary must be available in an enantiomerically pure form (>99%
ee) to guarantee a high stereoselectivity is obtained.
•  As an auxiliary is used in stoichiometric amounts, it should be quite
inexpensive and readily available as well as being recoverable.
•  The auxiliary should be chemically inert under the conditions of the
reaction and easily cleaved once the transformation has been completed.
Synthetic procedures are often able to apply favourable reaction conditions to 
effect chiral induction as the catalyst or auxiliary reagent is more likely to be 
stable than an enzyme or whole-cell. However, a critical drawback of the 
chemical asymmetric synthetic route is the low levels of optical purity 
(Federsel, 1993) that are often observed. The reactions often use a transition 
metal in conjunction with the chiral auxiliary as an inducer. Many transition 
metals are toxic and so their presence in the product would have to be 
reduced to ppm levels in any subsequent processing.
1.1.5.2 Enzymatic Methods
Processes producing enantiomerically pure compounds (McCoy, 1999) are 
increasingly utilise enzyme-catalysed steps. An enzyme can be used in an 
isolated state or as a whole cell (micro-organism).
There is a range of enzyme classes: oxidoreductases, transferases, 
hydrolases, lyases, isomerases and ligases. These enzyme catalysed 
reactions are usually very selective i.e. where there is only one achiral 
substrate for the enzyme then the reaction will be selective for one of the pair 
of enantiomers (enantioselective).An enantioselective reaction can also be 
described by the rate constants Kcat/Km and the relative free enzyme/ 
substrate concentrations (Equation1.5).
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Equation 1.5: Enantioselective reaction kinetics.
1.1.5.3 Biotransformations Compared to Chemo-Catalysis
A large number of enzymes, which can be applied to single or multi-step 
biotransformations, exist. There are many more which have not yet been 
discovered or commercialised. In addition, the ease of isolation of genes 
coding for target enzymes and the genetic manipulation, evolution and 
recombination of them has increased still further access to the diversity of 
enzymes, which can be produced in the amounts required for large scale 
processes (Bornscheuer et al., 2001, Lilly, 1994, Schmidt-Dannert, 2001, 
Stemmer, 1994, Zhao etal., 1998).
It is the diversity of enzymes that provides the greatest advantage compared 
to chemical catalysts. This is because enzymes can often introduce a 
functional group (and chiral centre) at otherwise unreactive positions. 
Sometimes conventional (non-enzyme) methods can produce the 
stereoisomers but often not without the use of environmentally hazardous 
chemicals (Bull et al., 1999). Biotransformation steps may be used to 
catalyse reactions that are difficult or impossible to perform using chemical 
catalysts, or they may demonstrate significant process benefits in a 
manufacturing operation (Cheetham, 1994). Biotransformations can also be 
used to carry out conversions that would otherwise require difficult or multiple 
synthetic chemical protection and de-protection steps. These are often 
difficult and reduce the atom efficiency of a process (Sheldon, 2000).
Enzymes used need to be produced by way of a fermentation process. This 
can be expensive, especially if the enzyme is to be used in an isolated form. 
Production of an isolated enzyme involves purification of the enzyme from 
the fermentation broth. This typically requires, homogenisation, separation, 
purification and concentration unit operations. An example is the purification 
of Penicillin G acylases (PGA). Erarslan and co-workers (Erarslan et al., 
1991) purified the enzyme 350-fold by disrupting the cells, removing the cell 
debris by centrifugation and the nucleic acid material by precipitation. The 
supernatant fluid from precipitation was further precipitated, the precipitate 
was subsequently collected by centrifugation. Finally the precipitate was 
dissolved in phosphate buffer, dialyzed and applied to a DEAE-cellulose 
column. Specific enzyme fractions from the column were collected. Such a 
biocatalyst manufacturing process represents a significant cost to the overall 
biotransformation (Parmar et al., 2000). Further steps are therefore taken to 
optimise the stability of the enzyme including the use of immobilisation 
technology (Shewale et al., 1989). Other disadvantages of enzymes are their 
limited stability, the propensity for inhibition (and/ or toxicity for whole cells) 
by substrate/ product (Held et al., 1999) and the requirement for regeneration 
of the enzyme (and or co-factors for isolated enzymes) (Alphand et al., 
2003). Enzyme specificity, an advantage of enzyme-catalysed reactions, can 
under certain circumstances act as a disadvantage. For instance, the 
adaptation of a developed process for new substrates could be problematic 
without substantial changes to the enzyme.
The advantages and disadvantages of biotransformations compared to 
chemo-catalysis are given in Table 1.0. Each application of chiral technology 
will have its own specific requirements and priorities. The decision to use 
biocatalysts or not has been discussed by Tramper (1996) who concluded 
that at present, experience indicates that only when most or all odds are 
greatly in favour of use of a biotransformation, or when there is no chemical 
alternative, will it be the process of choice. Thus to transform prochiral 
substrates or favourably resolve a racemate using an enzyme requires all 
aspects of a biotransformation to be addressed.
35
Advantages Disadvantages
• Reduced number of reaction steps
• Fewer and (sometimes) cheaper 
reagents
• High stereoselectivity, 
regioselectivity, and chemoselectivity.
• Milder reaction conditions
• Number and diversity of enzymes 
available
• Specific in action
• Can introduce functional group at 
otherwise unreactive positions
• Can be applied as a green 
technology
• Lack of process knowledge and 
experience
• Poor integration of biotransformations 
step into overall process
• Biocatalysts can be expensive to 
produce.
• Enzymes are often unstable and so 
are not re-usable
• Absolute substrate specificity may 
make the process inflexible.
• Low volumetric productivities are 
common.
Table 1.0 Advantages and Disadvantages of biotransformations compared to 
chemocatalysis (adapted from Cheetham, 1994).
1.1.6 Significance of Chirality to Industry
Industrial biotransformations cover a wide range of applications, from the use 
of enzymes as constituents of detergents and analytical tests, the application 
of biotransformations in the manufacture of active pharmaceutical ingredients 
(API’s), to their use in the paper and textile industries and their application in 
the brewing and dairy industries (Tramper, 1994). A number of papers review 
the application of biotransformations to industrial manufacture (Bommarius et
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al., 1998, Bruggink eta l., 1998, Fessner, 1999, Liese eta l., 1999a, McCoy, 
1999, Ogawa et al., 1999, Schmid etal., 2001, Schulze etal., 1999, Shanley, 
1998, Sheldon, 1990, Stinson, 2000, Yagasaki et al., 1998). Over 150 
processes to date have been implemented in industry (Liese et al., 2000), 
and increasing number of which are environmentally clean (Bull et al., 1999, 
Sheldon, 1996, Sheldon, 1997).
There has been an expansion in the number of pharmaceuticals produced as 
single stereoisomers over the last decade, a trend which looks set to 
continue (Borman, 1990). In 1999 single stereoisomer drugs represented 
32% of the worldwide pharmaceutical market, up 16% from 1998, with sales 
‘of $115 billion (Stinson, 2000). Enantiomers can differ considerably in their 
pharmacological effects. However many licensed drugs are racemates, and 
evidence is growing that a mixture of two enantiomers can cause 
complications when each enantiomer exhibits differences in biological activity 
(Richards et al., 1997, Stinson, 2000). The reason being that the body’s 
receptors for a given drug are often chiral. This results in the formation of 
diastereomeric complexes between chiral drugs and drug receptors. It is the 
difference in physical properties of the two-diastereomeric complexes that 
causes the observed differences in biological activity of a pair of 
enantiomers.
Drugs that are racemates can be classified into groups depending on what 
kind of activity and potency they exhibit:
•  Both enantiomers have identical (or nearly identical) pharmacological 
activity and potency.
•  The enantiomers have similar pharmacological activities but different 
potencies.
•  The isomers have qualitatively different pharmacological activities.
•  All activity resides in one enantiomer, and the other enantiomer is 
essentially an impurity.
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Thalidomide serves as an excellent example of a racemic drug. Thalidomide, 
first synthesized in 1953 as a racemate, was widely prescribed for morning 
sickness from 1957 to 1962. However, Thalidomide became an athema in 
1961 when it was found to be seriously teratogenic (creating malformation in 
embryos) having caused serious birth defects in more than 10,000 babies 
(Cheymol, 1965). Thalidomide has a stereogenic carbon atom, and so exists 
as two enantiomers. Tests with mice in 1961 suggested that only one 
enantiomer was teratogenic while the other possessed the therapeutic 
activity. The clinical use of thalidomide was stopped until recently. In 1998, 
FDA approved the use of thalidomide for the treatment of the debilitating and 
disfiguring lesions associated with erythema nodosum leprosum, a 
complication of Hansen’s Disease, commonly known as leprosy (Muller, 
1997).
Where one enantiomer interacts with a cell receptor to produce the desired 
outcome and the remaining enantiomer is biological ‘ballast’ then there are 
obvious benefits from developing the drug as the single isomer to enhance 
safety and tolerability. Such an approach may also speed the progress of the 
drug through regulatory channels.
The latter point has become increasingly important since 1992 when both the 
US Food and Drug Administration (FDA) and the European Committee for 
Proprietary Medicinal Products required manufacturers to research and 
characterise each enantiomer in all drugs proposed to be marketed as a 
racemate (FDA policy statement for the development of new stereoisomeric 
drugs, 1992).
Due to some single isomer drugs e.g. the anti-obesity drug Redux, having 
reduced side effects the FDA has been considering incentives (Richards et 
al., 1997), for developing single enantiomer drugs, including enantiomers of 
previously approved racemates.
There is therefore an increasing interest by industry in chiral technology. 
Pharmaceutical companies have responded to regulatory pressures and 
growing drug complexity by recognising a distinct capability can be gained
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from integrating isomeric purity into process design. Concurrently there is 
also increasing pressure on drug companies to reduce prices.
These issues provide impetus for industry to re-asses the approach taken to 
drug production. A drug today will typically need around a dozen steps for its 
synthesis from basic organic chemicals (Richards etal., 1997). However, the 
application of enzyme-based catalysts has the potential to reduce the 
number of steps, and increase the productivity of producing high value 
complex molecules e.g. Crixivan (Patel, 2001, Schulze et al., 1999), which 
have multiple chiral centres. This applies particularly to those processes, 
which requires the use of conventional chemistry requires a number of 
protection/ deprotection steps to realise the chiral molecule.
Some examples of bioconversions that have become commercial processes 
include the production of high fructose com syrup and low lactose milk 
(Cheetham, 1994), the production of acrylamide (Yamada et al., 1996) and 
the use of penicillin acylase to produce 6-aminopenicillic acid (Ospina, 1991, 
Parmar et al., 2000, Schulze et al., 1999). Bioconversions used in the 
manufacture of API are high value low volume fine chemical intermediates 
(Liese et al., 1999b). In these cases the complexity of the product often 
makes a bioconversion route the only realistic option.
The biocatalysts most commonly used are hydrolases, such as lipases 
(Anderson et al., 1998, Matsumae et al., 1993), amidases (Sonke et al.,
1999), and dehydrogenases (Ladner et al., 1999). These biocatalysts are 
readily available and easily applied at a process scale. Other classes of 
biotransformations have yet to be fully exploited commercially despite the 
ability of many of these biocatalysts to perform chemically difficult reactions 
(Faber et al., 2000). These bioconversions include asymmetric synthesis by 
decarboxylases (Ward et al., 2000), asymmetric C-C bond formation (Turner,
2000), aldolases (Blayer et al., 1999, Guengerich, 2001) and 
oxidoreductases (Boyd et al., 2001, Holland et al., 2000). The main reason 
for the limited application of these bioconversions is because it has been 
found to be difficult to implement economic processes due to constraints
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imposed by the biocatalyst, the reaction substrates and products and 
interactions between them (Lilly et al., 1996).
1.1.7 Whole-Cell and Isolated Enzyme Biotransformations
Both the chemical and pharmaceutical industries are actively seeking 
innovation driven solutions for the development of both established and new 
products. One approach for process chemists is to consider 
biotransformations as a synthetic tool. Enzymes are being used either in their 
isolated form or contained within microorganisms to catalyse a considerable 
number of chemical reactions (Liese et al., 1999b, Liese et al., 1999a, 
Margolin, 1993, Schulze et al., 1999). Enzymes are typically highly specific 
and selective, and it is these attributes that can help avoid byproducts such 
as toxic or carcinogenic intermediates (Li et al., 1998), so simplifying the 
downstream part of a process.
Where optically pure products are desired then the ability of a biocatalyst to 
assist in stereo- and or regiochemistry is of very significant interest. Typically, 
optical purity can be achieved in two ways using biocatalysts: first, by 
resolving a racemic mixture and secondly via asymmetric synthesis of a 
prochiral reactant. Both approaches are being pursued in the case of 
selective oxidation reactions, which are of particular industrial interest. 
Currently 80% of industrial biotransformations are achieved by a kinetic 
resolution where the biocatalyst acts stereospecifically on a racemic 
substrate, either to convert a single enantiomer to the desired product or to 
remove an unwanted enantiomer from the starting mixture (Schulze et al., 
1999).
In such reactions, the biocatalyst is often used as an intact microorganism. 
The use of whole cells as catalysts has the advantage that cofactors (such as 
NADPH) can be recycled in-situ. For example, D-p-hydroxyphenylglycine is 
an important intermediate for the synthesis of amoxicillin and other 
antibiotics. To produce the D-amino acid on an industrial scale the enzymes 
hydantionase and carbamylase are combined in a recombinant whole cell
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E.coli system, which constitutively expresses the two enzymes (Grifantini et 
al., 1998).
A comparison of whole cell and isolated enzyme biocatalyst is given in table 
1 . 1 .
Whole cells Isolated Enzymes
Cheap to manufacture
Down stream processing of product 
complicated due to presence of biomass 
and side-reaction.
Large volume reaction mixtures are 
required to transform small amounts of 
material.
Multiple biotransformation steps
Expensive to manufacture
Often require co-factors which can cost 
more than that of the enzyme itself
Increased selectivity
Performed in more concentrated 
solutions
Can be performed in organic solvents, 
Single biotransformation step
Table 1.1: A generalised comparison of whole cell and enzyme 
biotransformations.
The development of biotransformation processes has exploited technology 
associated with advances in biotechnology, including:
• Optimisation of enzyme activity by site selection and or mutagenesis
•  Heterologous expression of gene of interest to increase productivity of 
enzyme and or simplify the fermentation process.
•  Over expression by incorporation of a suitable promoter into the gene
For instance, the gene for cyclohexanone mono-oxygenase which catalyses 
Baeyer-Villiger reactions has been transferred from the class 2 pathogen 
Acinetobacter calcoaceticus into a yeast (Stewart, 1997) and independently 
Escherichia coli Top10 [pQR239] (Doig et al., 2003b).
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1.2 Near Infrared Spectroscopy
1.2.1 Monitoring Biotransformations
Monitoring a bioprocess on-line using analytical techniques where the data is 
fed into quantitative or qualitative models could allow a process to be 
controlled for improvement of productivity (Rani et al., 1999, Riesenberg et 
al., 1999). Bioprocess variables that are routinely measured on-line include; 
temperature, impeller speed, aeration rate, pH, p02 , composition of outlet 
gasses (O2 and CO2), turbidity, and foam detection.
Microbial cell growth and product formation can be optimised by control of 
these variables. Erythromycin biosynthesis in batch operation was optimised 
(Cherug et al., 1979) by evaluating optimal temperature and pH profiles. 
However, the compositions of bioreactor medium and reactant bioprocess 
streams are not routinely monitored on-line. This is due to the complexity of 
on-line sensors, which are often required to provide real-time information, be 
sterility friendly, of known accuracy and be reliable. This means substrate, 
product concentrations etc. are typically measured, if at all, off-line using 
techniques such as HPLC and GC. These assays are often tedious, invasive, 
requires sample handling and difficult to do in real time. Sample preparartion 
and analysis typically takes 10s of minutes. Conventional laboratory 
techniques are therefore not suitable for rapid and effective process control.
Traditional spectroscopic techniques in the UV and visible electromagnetic 
regions cannot be used easily in a bioprocess environment because the 
turbid nature of the broths can cause light scattering effects. Off-line analyses 
such as HPLC and GC are capable of determining the concentrations of by­
products and nutrients in cell culture (Christensen et al., 1996, Ozturk et al.,
1997). However, they also require samples to be removed from the reactor 
prior to analysis. Removing samples from a process stream or reactor can 
cause problems including:
•  Bioreactor contamination
• Limited measurement frequency
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• Complicates automation schemes
• Poor response times
Despite these problems, significant progress has been made in the design of 
sampling systems and devices (Christensen etal., 1996).
The lack of any on-line information concerning substrates, products and the 
biocatalyst during a biotransformation delays a fast response, which is 
required for control. The same is true for metabolites in a fermentation broth. 
Usually off-line data have large sampling times, and thus the number of 
process data points is limited. This dictates the number of meaningful 
parameters that can be estimated. A rapid and more direct method of 
analysis would yield more timely process information and improved 
bioprocess control.
Mid-infrared (mid-IR) and near-infrared (NIR) technology has been used on­
line or rapid off-line (at-line) to monitor substrate and product concentrations 
in fermentation processes (Almond et al., 1999, Arnold et al., 2000, Doak et 
al., 1999, Hall eta l., 1996, Pollard eta l., 2001, Shaw ef al., 1999). The NIR 
region is ideally suited for the non-destructive analysis of percent levels of 
components in highly scattering and strongly absorbing matrices, such as 
fermentation broths (Brimmer et al., 1993). It is the application of this 
technology to a biotransformation environment which is the subject of this 
thesis.
Process optimisation requires an advanced level of control. Understanding 
and monitoring a process can achieve control, allowing for the maintenance 
of optimum conditions. Suitable on-line sensors are therefore required 
(Christensen et al., 1996, Galindo et al., 1998, Marose etal., 1999, Schuster, 
1999, Vaidyanathan et al., 1999b). Once process information is available, 
advanced control strategies require the development of mathematical 
models, which are able to describe the behaviour of processes (Konstantinov 
et al., 1991, Shioya et al., 1999). Examples of control model programmes 
include the optimisation of baker’s yeast production (Kurtanjek, 1998,
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Ramirez et al., 1981) lactic acid production (Shi et al., 1998), and ethanol 
production (Karim etal., 1997).
1.2.2 Control and Optimisation
When it comes to optimisation of a bioprocess using the existing monitoring 
and control technologies a gap is often observed between the mathematical 
model/s and the real process (Karim et al., 1997, Kurtanjek, 1998, Schuster,
1999). The reasons for this discrepancy include the descriptive power of the 
knowledge inputs i.e. often a complex system is being described by a limited 
number of factors; the mathematical models are non-linear with time 
dependent-parameters, and a limited number of operational variables are 
available in spite of many control objectives. In addition to the lack of 
appropriate process information the problem of data processing is important. 
A large amount of data is often collected along with noise. This noise must be 
minimised by treating the data in some way. This problem is observed also 
with NIR calibration model building (Blanco etal., 2001, Ding etal., 1999).
Bioprocesses are usually operated in the batch or fed-batch mode, and only 
rarely in continuous culture mode. Thus, the process state changes 
dynamically during a microbial cultivation. Similar time-dependent dynamics 
occur during a whole-cell biotransformation. However as previously 
mentioned, it is not possible in many cases to directly measure the important 
state variables such as product concentration or production rate for on-line 
optimisation. In addition, the various perturbations of initial conditions are 
rather extensive. Consequently, the sophisticated control systems mentioned 
are required.
The work reported here aims to develop a chemometrics based quantitative 
model for one or more bioprocess state variables using NIR as an on-line or 
at-line sensor. This sensory evaluation of a biotransformation process will 
yield information that can be exploited by a control system, which, is 
designed to increase productivity. The nature of the process control is to be 
determined but may be used for one or more of the following:
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• Substrate feed control/ monitoring
•  Product rate formation monitoring
•  Monitoring control of process state
•  Down stream unit operation optimisation
1.2.3 Infrared Monitoring
1.2.3.1 Advantages of NIR and IR Spectroscopy
IR and NIR have considerable scope for bioprocess monitoring and or 
control. Advantages of the technology include:
•  Analysis times under 1 minute are possible on-line (Macaloney, 1996).
•  Often, no sample preparation is required and the sample may be re­
introduced into the bioreactor. This is advantageous in a process 
environment where time is an important factor in the analysis (Howard et 
al., 1998).
• Non-invasive and non-destructive analysis is possible. Flow injection 
systems and off-line analysis require that the samples be removed from 
the reactor prior to analysis (Christensen et al., 1996, Ozturk et al., 1997). 
This removal step can create concerns for bioreactor contamination, and 
restrict the number of samples taken from a small bioreactor (Riley et al.,
1998).
•  Cost per analysis is very low (no reagents are used).
•  Spectral bands in mid-IR and NIR can have clearly assignable spectral 
response. For most bioprocesses, spectral bands (especially in the NIR) 
are overlapped, broad with poor baseline resolution. This is because a 
typical NIR spectrum encompasses information relating to all the 
constituents of the sample matrix. Such sensitivity to process variability 
has been used to investigate bioprocess quality assessment monitoring in 
a composite manner (Hagman et a!., 1998, Vaidyanathan et al., 2001)
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allowing for the physiological status of bioprocesses to be monitored at 
the cellular level (Schuster, 1999).
•  Automated correction of background and interference is performed in 
instruments using computer algorithms. Second derivative pre-processing 
of spectral data can enhance spectral features and eliminate baseline 
offset. Aeration and cellular matter in the sample matrix cause light 
scattering altering the effective sample path-length, producing spectral 
base-line offset (Shaw et al.} 1999). Background information such as that 
attributable to water (a strong IR absorber) may be subtracted or used as 
a ratio (Riley et al., 1997, Small et al., 1993), although in some cases this 
correction has not affected the modelling ability of the algorithm (Yano et 
a/., 1997).
•  Detection limits can be very low. The NIR region is ideally suited for non­
destructive analysis of fraction of percent levels (<0.1 %) of components in 
highly scattering and strongly absorbing matrices, such as fermentation 
broths (Brimmer etal., 1993).
•  Molecular structural information can be derived from spectra (Pollard et 
al., 2001, Silverstein etal., 1981).
•  Simultaneous monitoring of several chemical species. Monitoring of 
bioprocesses requires sensors providing real-time measurements of 
several variables to analyse, model and control optimally the time course 
of these processes in bioreactor vessels (Acha et al., 2000, Macaloney et 
al., 1997).
However, the application of the technology to a bioprocess environment and 
specifically to a biotransformation environment compared to simpler chemical 
reaction processes is not straightforward. The complexity of the reaction 
matrix and significant changes in concentrations of substrates, products and 
by-products with time complicate the design of quantitative calibration 
models.
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1.2.3.2 NIR/ Mid-IR: a comparison
Exposing a molecule to radiation results in it undergoing rotational, 
vibrational, electronic or ionisation processes. Both mid-IR and NIR measure 
the absorption or emission of radiation as a consequence of vibrations within 
a molecule. The electromagnetic waves can be described using wavelength 
(nm), or wave number (1/A, cm'1). The mid-IR spectral region has been 
defined as 400- 4000 cm'1 (2500- 25000 nm). NIR spectra are >4000 cm'1 
(700 -  2500 nm), and extend to the visible region (Figure 1.6). The upper 
limit is defined by the extent of all the fundamental molecular vibrations whilst 
the lower limit is defined by the sampling method, matrix or optics of the 
instrument. A detailed explanation is given by (Ciurezak et al., 2001, Shaw et 
al., 1999, Workman etal., 1997).
Table 1.2 compares NIR and mid-IR spectroscopy for application to liquid 
mixtures.
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NIR mid-IR
780-2500 nm
12800-4000 cm'1
High energy vibrations
Compatible with optical fibre signal 
transduction
Overtone and combination vibrations 
Low absorbtivities of absorption bands
2500 -  25000 nm
4000 -  400 cm'
Low energy vibrations
Only conduit optical fibres can be used
Fundamental vibrations
High signal more resolved peaks
Suitable for analysis of samples containing a Very high water absorbtivities may result in
high proportion of water the signal flooding the detector
Cell path lengths typically 1 - 3 0  mm Cell path length typically < 0.5mm
No sample preparation required Sampling maybe required
Table 1.2: A comparison of NIR and mid-IR spectroscopy applied to aqueous 
matrixes.
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Figure 1.6: The electromagnetic spectrum.
1.2.3.3 Vibrational Energy Oscillations.
Vibrational spectroscopy (mid-IR, NIR) measures energy transitions in a 
molecule that is exposed to IR radiation. At room temperature, most 
molecules are at zero energy level. That is, they are vibrating at the least 
energetic state allowed by quantum mechanics (Ciurezak etal., 2001). These 
energy transitions are due to molecular vibrations that are analogous to 
harmonic oscillations. This should not be confused with other spectroscopic 
methods. UV, visible and x-ray spectra result from excitation of electrons in a 
molecule or atom respectively. Hooke’s law (Equation 1.6) describes an 
harmonic oscillation. The harmonic oscillation describes well the fundamental 
vibrational frequency of a diatomic molecule but not polyatomic molecules. In 
actual molecules, the electron withdrawing or donating properties of 
neighbouring atoms and groups determines the bond strength and length, 
and thus the frequency of vibration. It is these species-specific vibrations that 
determine a substance’s characteristic spectra.
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F = -kx
Where,
F= resting force
x= displacement from equilibrium 
k= force constant
Equation 1.6: Hooke’s law
The energy of an oscillator is discontinuous. Changes in energy content 
occur by means of transitions between discrete energy levels. Vibrational 
oscillations caused by absorption by the molecule of quanta of 
electromagnetic radiation produces transitions in discrete energy states. This 
means only certain amplitudes of the vibrational motion are possible. For an 
ideal diatomic molecule, which would behave as a harmonic oscillator, Figure
1.7 depicts potential vibrational energy levels. In reality, real diatomic and 
polyatomic molecules do not obey Hooke’s law and give rise to 
anharmonicity. Figure 1.7 also describes an anharmonic oscillator where 
energy levels dissociate. Anharmonic motion occurs for the following 
reasons:
•  As two atoms approach, the repulsion between the nuclei causes the 
potential energy to rise more quickly than the harmonic approximation.
•  When the interatomic distance approaches the dissociation point, 
potential energy levels off.
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Figure 1.7 : Harmonic and anharmonic oscillations.
1.2.3.4 Fundamental, Overtone and Combinational Molecular 
Absorptions.
Imparting energy in the form of radiation to a molecule causes molecular 
vibrations to jump from one energy level to another. Transitions between 
ground state to energy level one give the fundamental absorption if this leads 
to a change in the molecular dipole moment. Transitions between ground 
state to energy level two give the first overtone. Transitions between ground 
state to energy level three give the second overtone. There are often 
transitions between multiple states giving rise to combination bands.
Harmonic motion explains fundamental molecular absorption that occur in the 
mid-IR region. The weaker bands that occur in the NIR region due to 
anharmonicity are 1-2 orders of magnitude weaker than in the mid-IR and are 
overtones (Ciurezak et al., 2001). Overtones occur at approximately at V2 and 
1A of the fundamental absorption wavelength. However, anharmonicity 
causes deviations from the predicted.
1.2.3.5 Molecular Vibrations
It is possible to explain molecular vibrations in two ways; stretching (Figure
1.8), a change in inter-atomic distance along the axis of the bond and 
bending, a change in the bond angle.
Figure 1.8: Molecular vibrations: stretching; a change in inter-atomic 
distance along the axis of the bond.
Bond stretching usually has larger vibrational amplitude than bending, so 
stretching vibrations are usually the strongest. Hydrogen is the lightest atom 
and will vibrate with the largest amplitude in stretching, this motion deviates 
most from the harmonic. The intensity of the absorption depends on the 
degree of anharmonicity.
Many organic functional groups e.g. -OH, -CH -NH have characteristic 
frequencies where absorption’s are observed. IR spectra can therefore be 
used to give a characteristic fingerprint to a molecule. The application of mid- 
IR therefore lends itself to identification of unknowns. Since most of the 
absorptions are repeated in the NIR as overtones and, combinations of the 
fundamental vibrations, this region can be used to identify molecules too. 
However due to spectral overlapping NIR spectra are more often used to
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confirm the identity of a species in a matrix which has already been taught to 
the system.
NIR absorption’s are generally 10-100 times weaker in intensity than the 
fundamental mid-IR absorption bands (Ciurezak et al., 2001). The strong 
amplitude associated with mid-IR absorption’s may require sample 
preparation due to light scattering or signal flooding of the detector. In 
contrast, the weakness of NIR absorption bands is an advantage for on-line 
direct analysis of process samples because the radiation path length can be 
adjusted in order to detect appropriate signal intensity.
1.2.3.6 Beer-Lambert Law
Vibrational spectroscopy, like other absorption spectroscopic techniques is 
based on the B eer-Lam bert law (Equation 1.7).
A = Log 1/T = eel
Where,
A = optical density 
T = transmission
e = molar extinction coefficient (pmolmr1cm"1)
I = path length (cm) 
c = concentration (pmolml"1)
Equation 1.7: Beer -  Lambert law
From Equation 1.7 it can be seen that absorbance is proportional to 
concentration of species and path length of radiation. The Beer-Lambert law 
only holds in transmission if there is no reflectance or scatter (typical when
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analysing solids), the monochromatic light is produced in the same way, and 
there is no chemical change (Silverstein etal., 1981).
With infrared transmission spectroscopy, the spectrum recorded is a ratio of 
the radiation intensity emerging from the sample and reaching the detector to 
the incident on the detector in the absence of the sample
1.2.4 NIR Instrumentation
1.2.4.1 Transmittance or Reflectance
A NIR instrument can be configured for transmittance or reflectance (Figure
1.9). There are many different accessories based on transmittance or 
reflectance vibrational spectroscopy and designed to deal with the variety of 
sample matrices. Transmittance is generally applied to opaque liquids where 
the path-length will not be adversely affected by scattering. Solids (e.g. 
pharmaceutical tablets) are analysed using reflectance technology (Herkert 
et al., 2001). The Beer-Lambert law does not hold when the path length 
ceases to be constant (Silverstein et al., 1981). This may occur due to 
scattering. Therefore, log 1/T is not useful for most measurements of solids. 
In such a case log 1/R gives a reasonable approximation to concentration. 
The term reasonable is employed, as there are problems with path length 
related to physical properties of solid samples (porosity etc). Bioprocess 
broths may initially be opaque and suitable for transmission probes. 
However, as the process progresses an increase in turbidity is often 
observed. The nature of the matrix will therefore become highly scattering. 
Under such circumstances a reflectance based NIR probe is used configured 
to have a relatively large path length e.g. 20mm. This produces an infinite 
penetration depth i.e. any change in turbidity (penetration thickness) causes 
no change in the log (1/R) intensity (Vaccari etal., 1994).
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Figure 1.9: Transmission and reflectance configurations of a NIR 
spectrophotometer.
1.2.4.2 NIR Radiation
The source of monochromatic light in the NIR instrument used during this 
work was a tungsten-halogen lamp, which is useful in the region of 380 -  
3000 nm. The tungsten-halogen lamp is very hot. In contrast, IR sources are 
incandescent and emit less energy. Lamps found in NIR systems can reach 
3000K. The combination of a hot source (NIR radiation) and an appropriate 
detector allow for high signal to noise ratios (s/n) in the NIR. This is not true 
for IR instruments, which compensate for lower s/n by the application of 
Fourier Transform Infrared (FTIR) technology (Hirschfeld, 1983). FTIR 
probes use the principle of internal reflection to permit analysis of complex, 
dynamic processes (Doyle et al., 1990, LeBlond et al., 1998, Milosevic et al., 
1995, Sheridan etal., 1991).
The absorption of NIR rays in the 700 to 2500 nm region (14,000 cm'1 -  4000 
cm'1) is related to the overtone and combination bands of the fundamental 
infrared vibrations of the -CH, -NH and -O H molecular groups. The method 
is therefore suitable for monitoring any bioconversion where the constituents 
of interest are organic molecules (Silverstein et al., 1981). Mid-IR absorption
at fundamental frequencies (1500 -  400 cm'1) are typically 10 - 100 times 
stronger than NIR (Brimmer et al., 1996, Stallard, 1997) and capable of 
providing distinct spectral features of a compound from a mixture (Pollard et 
al., 2001). Mid-IR in-situ analysis of aqueous mixtures using attenuated total 
reflection has been demonstrated (Doak et al., 1999, Pollard et al., 2001). 
The mid-IR system uses optical conduit technology containing knuckles with 
internal mirrors as a means of guiding the radiation between the sensor and 
the spectrophotometer.
Since spectral features are broad and overlapped in the NIR region (Ciurezak 
et al., 2001), resolution of spectral data for analyte calibration therefore 
requires chemometric techniques for multivariate analysis. In addition, water 
strongly absorbs IR radiation exhibiting strong OH-bands at 1450 and 1940 
nm (Brimmer et al., 1993), making extraction of quantitative information from 
the NIR spectra more difficult. However, the weak and broad features of 
absorption bands of NIR when applied to complex aqueous based mixtures 
are an advantage since no sample preparation or dilution is required. NIR 
methods use bundles of flexible optical fibres, such that the 
spectrophotometer can be remotely situated some distance from the reactor. 
Since the NIR technique is rapid, requires no reagents for analysis and the 
instrumentation can be located some distance from the reactor site, there is a 
real potential to improve bioprocess operation in the chemical and 
pharmaceutical industries by monitoring conversions with NIR spectroscopy.
1.2.4.3 Sample Preparation
It is often necessary to prepare samples before taking vibrational spectra. 
The choice of sample preparation and NIR or mid-IR accessory is crucial, as 
the spectrum detail is dependent on this (Hirschfeld, 1983). Sampling 
techniques as described refer mainly to studies where the chemical and 
physical nature of solids is of interest. In-order to develop an on-line 
monitoring NIR technique for a biotransformation process, a method is 
required that has no sample preparation. NIR spectroscopy does not require 
sample preparation because the low absorbtivities of bands associated with 
this region are compatible with moderately concentrated samples and longer
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(1-5mm) path-lengths. This allows rapid and non-destructive analysis of 
samples. It might be the case that on-line samples are sub-optimal for 
analytical purposes. For instance scattering by cells will affect path length 
and result in significant scatter around any predicted vs reference regression 
line (Brimmer et al., 1993). Light scattering effects can be removed by 
mathematical treatments that can adjust signals for linear and multiplicative 
effects (Shaw et al., 1999).
1.2.5 Bioprocess Applications of NIR Technology
NIR has only recently been considered as a possible tool in bioprocessing. 
The reasons for not exploiting the technology have included the cost of the 
instrument, the lack of mobility of instruments and remoteness of probes, and 
the complexity of chemometric reduction of data. All these areas have been 
addressed to produce cost effective, remote systems that are controlled 
through user-friendly Windows based software (Hirschfeld, 1983).
There are now examples of NIR-based control systems, which allow for fully 
automated bioprocess production and optimisation. (Gonzalez-Vara et al.,
2000) reported a small-scale pilot-plant lactic acid production process, which 
was fully automated by way of a NIR-based control strategy. This included 
dedicated software enabling on-line NIR data acquisition and reduction, and 
automated process management through feed addition, culture removal 
and/or product recovery by micro-filtration to allow for a continuous 
fermentation process with recycling of culture medium and cells. The control 
of feed rates into the reactor was by automatic adjustments of the flow rate of 
peristaltic pumps. Such developments enable more advanced control 
systems to be developed.
NIR spectroscopy has been successfully applied in agriculture, food 
processing, polymeric, chemical and pharmaceutical industries. Numerous 
NIR spectroscopic methods have been developed including; applications in 
biological systems (Murayama et al., 1998, Qing et al., 1999), enzyme 
reaction (Blanco et al., 2000, Chung et al., 1995, Chung et al., 2000), for 
fermentation processes (Arnold et al., 2002, Arnold et al., 2003), including
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fermentations of yeast (Cavinato et al., 1990, Ge et al., 1994), bacteria 
(Arnold etal., 2001, Vaccari et al., 1994), animal cells (McShane etal., 1998, 
Yano et al., 1994), and insect cells (Riley et al., 1997, Riley et al., 1998). 
Wider bioprocess applications include the monitoring and control of a 
downstream yeast cell homogenate (Yeung et al., 1999). There has been no 
study of the application of NIR spectroscopy to biotransformations, although 
real-time monitoring of nitrile bioconversions by mid-infrared spectroscopy 
(Dadd et al., 2000) has demonstrated the potential of vibrational 
spectroscopy for the study of biotransformations .
The work to date has mainly concentrated on fermentation steps. There are 
no published reports concerning NIR monitored whole-cell biotransformations 
which can have similar physical environments to fermentation reactors.
1.2.6 Chemometrics
NIR absorption bands are broader and can be highly overlapped compared 
to mid-IR bands. Despite the disadvantage of broad and overlapping bands 
not distinguishing individual analytes, the advent of chemometrics has meant 
meaningful information can be extracted from the complex NIR spectra. It 
has been shown (Brimmer et al., 1993) that a NIR spectroscopic calibration 
model can be as accurate as the reference analytical technique method used 
to derive the algorithm.
1.2.6.1 Quantitative Calibration
Prior to a quantitative calibration method the NIR spectra can often be 
improved by performing a derivative mathematical treatment on the data. 
First or second derivative treatments can reduce baseline shifts and improve 
both peak-shape and resolution. However, these treatments can only adjust 
the data for linear effects (Shaw et al., 1999).
Quantitative spectroscopy involves the construction of empirical relationships 
between the absorption of NIR radiation and data from a reference analytical 
technique e.g. HPLC, GC. Any calibration algorithm requires complex 
chemometrics (Thomas, 1994). Approximating, the intensity of the NIR or
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mid-IR spectra is linearly proportional to the number of vibrating species 
responsible for its occurrence. The standard techniques are:
• Multiple linear least squares regression (MLR)
•  Partial least-squares regression (PLS)
• Principle component regression (PCR)
A comparison of the chemometrics techniques has been made by Thomas 
and Hooland (1990).
MLR is the simplest of the calibration approaches but can only be used when 
the unique spectral features can be identified for the analyte of interest. 
Quantitative information can be extracted from single or multiple peak 
intensities after calibration against standards. However, variations may be 
present in sampling (e.g. path-length/ scatter) and instrument performance. 
MLR is less sensitive to subtle matrix variations common to most industrial 
processes. The NIR region of a multi-component system is likely to contain 
absorption bands that overlap and in which the compounds have 
independently variable concentrations. Under such circumstances, MLR is 
not capable of generating a valid quantitative model.
When unique spectral features cannot be identified as is often the case with 
multi-component matrices, then PLS and PCR is used. PLS and PCR are 
full-spectrum methods and can create algorithms for components in complex 
matrices, where NIR spectral bands are highly overlapped by absorption 
bands of other components. The crux of producing a robust calibration 
algorithm for bioprocess broths is to correct for interfering absorptions from 
other materials and scattering differences that affect spectral baselines and 
the effective path length of the NIR radiation.
PLS and PCR use a large number of wavelength variables making these 
methods susceptible to interference’s from un-modelled spectral variations 
compared to MLR. Thus, calibration-training data sets should contain all 
possible variations. However, in the industrial environment it is difficult to
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ensure that all sources of spectral variation have been modelled. 
Temperature, pressure, viscosity, and other process variables fluctuate 
during bioprocesses. When vibrational spectra are measured on or at-line for 
analytical and control purposes, the fluctuations influence the shape of the 
spectra (Wulfert et al., 2001). MLR models are typically developed from 1 or 
2 wavelengths and so are less sensitive to subtle matrix variations.
An overview describing the steps needed to calibrate a NIR 
spectrophotometer is depicted by Figure 1.10 and described in Osborne etal. 
(2002). Regardless of the calibration method to be invoked, the first step 
involves collecting a training data-set which should be representative of the 
population of samples which are expected to be analysed in the future. With 
regard to NIR analysis, measurements are made without dilution from three 
to six process operations to provide suitable sample variability (Arnold et al., 
2002). The sample data set is split in to two, to give training and validation 
data sets. Since NIR models describe empirical relationships using reference 
analytical chemistry, it is important to select a reference method that posses 
the best analytical performance (Lavine, 2000). The integrity and applicability 
of the derived calibration model is dependent on the set of data used to 
create the model. Performance of derived models can be tested using the 
validation data set before routine analysis takes place. The validation data 
set should ideally be independent of the training data-set.
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Collect training data-set covering matrix population diversity
1
Measure spectra for entire training-set
1 1
Select calibration-set Select validation-set
1 1
Perform reference analysis for entire training and validation sets
i
Compute and validate library
i
Perform routine analysis
Figure 1.10: Steps required to develop a quantitative or qualitative 
calibration method.
1.2.6.2 PCR and PLS Calibration Models
PCR and PLS are two commonly applied chemometric techniques used for 
analysing multivariate vibrational spectroscopic data sets. The use of 
complex chemometrics has only been possible due to advances in computer 
hardware and software. However, there are limitations and requirements 
associated with the technology.
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With regard to multi-component systems, the absorbance intensity at a 
particular wavelength {X) for an /? component system may be represented by 
equation 1.8.
Ix ~ K \c\ +  K 2c2 +  K 3c2 +  K ncn
Ci to cn = concentration of component number 1 to n
Ki to Kn = path-length constants of component number 1 to n.
Equation 1.8
Equation 1.8 assumes that the contribution to the intensity of the components 
is additive and therefore linear. Equation 1.9; x equals the number of data 
points over the wave-length range X  to Xx. The x equations can be 
expressed in matrix form, which can be represented by:
T  =T cX x  X xn n
Equation 1.9
With S standard samples there will be S sets of such matrices, represented 
as:
/ ,  = / ,  cA s  A n ns
Equation 1.10
Annotation of spectral data in a matrix form is the basis for PCR and PLS 
modelling. The detail of each method is not addressed here. The
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mathematical procedures are all computer based using chemometrics 
software for data management and reduction.
1.2.6.3 Qualitative Calibration
The steps taken to develop a qualitative method are the same as for 
quantitative methods (Figure 1.10). Qualitative techniques are often 
employed to determine if a sample falls within a defined range of variability. 
Thus, the quality of material can be gauged. The spectrum of a sample is 
unique to the composition of its constituents. Other samples of similar 
composition quality therefore have spectra that are similar to the original 
spectrum. By comparing spectra, the difference between a defined good and 
a bad spectrum can be determined. Chemometric qualitative discriminate 
(sometimes called pattern recognition) models allow unambiguous spectral 
matching to be performed (Lavine, 2000). The discriminate analysis of 
spectra can be performed by applying a number of algorithms (Workman et 
al., 1997).
Characteristic differences between qualitative and quantitative approaches 
are given in Table 1.3.
Qualitative models Quantitative models
Determine quality of a sample within Large number of training samples
a defined range. required.
Indicate if a samples are Large initial time cost.
contaminated
Accuracy limited by accuracy of
Models do not require primary primary method.
calibration data.
Determines the quantity of a specific
Algorithm’s can be determined for constituent but not quality.
very complex mixtures.
Simple pass or fail answers
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Table 1.3: A comparison between qualitative and quantitative models
1.3 Aim of the Project
The aim of this project was to provide an evaluation of the potential use of 
near infrared spectroscopy (NIR) as a means of improving the productivity of 
biotransformation reactions. The development of a system capable of precise 
real-time measurements of individual components of a complex bioprocess 
facilitated the realisation of improved control strategies and therefore 
improvements to bioprocesses productivity.
The biotransformation used to exemplify NIR during this study was the 
conversion of a bicyclic ketone to two chiral lactone products by 
cyclohexanone monooxygenase (CHMO). CHMO is one of a class of 
potentially important biocatalysts, the Baeyer-ViNiger Monooxygenases 
(BVMOs). The enzyme was expressed heterologously in E.coli 
TOP10(pQR239), a whole-cell biocatalyst. The stereo- and regio- selective 
biocatalyst exhibits both substrate and product inhibition making the process 
an ideal model biotransformation.
Monitoring is critical to the success of biotransformations as many continue 
to be optimised by maximising and controlling the stability of enzymes. NIR 
technology has the potential to satisfy the requirements for monitoring. It is 
rapid, reagentless, noninvasive, and suitable for light scattering, 
inhomogeneous, complex mixtures. NIR is also capable of online monitoring 
of several components simultaneously.
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2. The Model System - Baeyer-Villiger Monooxygenase 
Biotransformation
2.1. Cyclohexanone Monooxygenase
The bioconversion investigated during this study is the conversion of a 
bicyclic ketone to two chiral lactone products by cyclohexanone 
monooxygenase (CHMO). CHMO is one of a class of potentially important 
biocatalysts, the Baeyer-Villiger Monooxygenases (BVMOs). The Baeyer- 
Villiger biotransformation was studied as a model system to examine the 
application of NIR spectroscopy to monitoring and control of 
biotransformations.
Oxidoreductases compromise the class of enzymes that catalyse oxidation 
and reduction reactions (Sheldon, 1999). BVMOs are oxidoreductases 
capable of the nucleophilic oxygenation of ketones and aldehydes in a 
manner analogous to the established peracid catalysed organic chemical 
reaction from which they take their name (Baeyer et al., 1899). The 
application of BVMOs and other oxidoreductases to synthetic organic 
chemistry is of interest due to the high chemo-, regio-, and stereo- specificity 
that can be achieved (Fessner, 1999, Patel, 2000).
The monooxygenases employ a range of prosthetic groups including:
•  Iron (e.g. cytochrome P450)
•  Copper (e.g. dopamine p- hydroxylase)
•  Pterins
•  Flavins and cofactors NADPH or vitamin C.
Flavoproteins are conjugated protein dehydrogenases containing flavin and 
are involved in biological oxidation reactions. There are three principal flavins 
found in nature; riboflavin, flavin mononucleotide, flavin adenine dinucleotide
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Flavin mononucleotide and flavin adenine dinucleotide (FAD) act as 
prosthetic groups for flavoenzymes, which have a bright yellow colour and 
are involved in biochemical redox reactions. In biotransformations, 
flavoenzymes are used as oxygenases. Oxygenases have been classified 
into two groups (Kelly, 1998):
• Monooxygenases. These catalyse insertion of one oxygen atom from O2 
into a substrate with the remaining oxygen undergoing reduction to H2O.
•  Dioxygenases. Catalyse the insertion of both oxygen atoms from O2 into a 
substrate.
The catalytic cycle of a flavoenzyme has been depicted by Ghishla and co­
workers (1978). Kelly et al., (1998) described flavoenzymes as a chiral 
hydroperoxide as they oxidise among other reactions, ketones to esters and 
lactones, the so-called Baeyer-Villiger reaction (Figure 2.0). BVMOs are a 
particular group of monooxygenases which use flavin coenzyme as a 
cofactor and nicotinamide adenine dinucleotide phosphate (NADPH) as a 
reductant (Willets, 1997). The general mechanism of Baeyer-Villiger 
reactions has been discussed by the oxidation of cyclohexanone both 
abiotically and biologically by (Kelly etal., 1998).
The Baeyer-Villiger oxidation in synthetic organic chemistry is achieved by 
the use of a peracid as the main reactant. This makes any industrial process 
risky. Preparation of a peracid implies the use of stoichiometric amounts of a 
peroxide (essentially 90% hydrogen peroxide) as a primary reactant. 
Peroxide oxidations such as this are hazardous, running the risk of reactions 
occurring with explosive violence. If the starting material is chiral the 
chemical route will produce a racemic mixture because the peracid reagent 
can attack either face of the molecule (Renz et al., 1999).
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Figure 2.0: The generalised Baeyer-Villiger reaction. The enzyme 
driven Baeyer-Villiger reaction has an absolute requirement for NADPH 
and O2.
A diverse range of microorganisms have been found to produce BVMOs that 
mimic the chemical reaction (Willets, 1997). Unlike the chemical reaction, 
BVMO catalysed bioconversions often show high regio- and stereoselectivity. 
Recently, some limited enantioselectivity has been achieved at low ee values 
in chemical Baeyer-Villiger reactions by various transition metal based 
reagents (Corma et al., 2001). The Baeyer-Villiger oxidation of cyclohexanol 
to adipic acid has been undertaken using: Nocardia globerula CL1 (Norris et 
al., 1971) and Acinetobacter sp. NCIMB 9871 (Barclay et al., 2001, 
Donoghue etal., 1975, Gagnon etal., 1994). The enzyme responsible for this 
biotransformation was found to be cyclohexanone monooxygenase (CHMO) 
(Donoghue et al., 1976). CHMO consists of a single polypeptide chain, which 
binds one FAD as a prosthetic group. The flavoenzyme Baeyer-Villiger 
activity has an absolute requirement for NADPH and O2.
Acinetobacter sp. NCIMB 9871 is a class 2 pathogen requiring 
microbiological containment facilities. However, heterologous expression of 
the CHMO gene from Acetobacter sp. has been achieved in yeast (Stewart, 
1997), and Escherichia coli Top10 [pQR239] (Doig et al., 2003b, Stewart et
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al., 2002). The recombinant E.coli has been engineered such that the lactone 
resulting from the Baeyer-Villiger oxidation is not further hydrolysed. Such a 
reaction (Figure 2.1) is now used as a model chiral biotransformation 
process.
CHMO catalyses the nucleophilic oxygenation of a wide variety of linear or 
cyclic ketones to corresponding optically pure esters and ketones (Kelly, 
2000, Mihovilovic et al., 2001, Sheng et al., 2001, Zambianchi et al., 2002). 
CHMO is the best characterised of over thirty BVMOs that have been 
identified. Optically pure chiral synthons produced via CHMO could be used 
for the synthesis of a variety of value added fine chemicals and intermediate 
pharmaceuticals. Recent reviews by Stewart (Stewart, 1998) and Roberts 
and Wan (Roberts et al., 1998) detail the catalytic range of the CHMO  
enzyme. A number of models for the CHMO active site have been proposed 
to explain and predict the specificity of the enzyme (Kelly et al., 1995, 
Ottolina etal., 1996, Wright etal., 1994, Zambianchi etal., 2001).
H
Figure 2.1: The Baeyer-Villiger reaction on bicyclo[3.2.0]hept-2-en-6-one.
BVMOs have been used either as whole cells or isolated enzymes for the 
transformations of numerous substrates. All BVMOs use molecular oxygen 
and the reduced cofactor NAD(P)H as a reductant to carry out the Baeyer- 
Villiger type oxidation (Kelly, 2000, Willetts, 1997). Because these reactions 
involve NADPH cofactors, the use of whole-cells rather than isolated 
enzymes is prefered to avoid the need for co-factor regeneration. Isolated 
BVMOs require an ancillary enzymatic system for the in situ regeneration of 
these expensive cofactors (Walton et al., 2002, Zambianchi et al., 2002).
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Such a regeneration system has been carried out (Rissom et al., 1997). 
Application of BVMOs to the synthesis of natural products is well 
documented and some key chiral synthons produced via BVMO catalysed 
bioconversions are shown in Table 2.0. Of specific interest is the production 
of optically pure lactones, which are chemically highly versatile and are often 
used as key building blocks for further elaboration of industrially valuable 
targets and, in particular, biologically active products such as 
pharmaceuticals, agrochemicals and flavour constituents. However, there are 
currently no industrial processes, which use a BVMO catalysed step. This is 
primarily because of low volumetric productivities resulting from bioprocess 
issues such as product and substrate inhibition and cofactor requirements 
(Schulze etal., 1999).
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Compound Application Bioconversion details Reference
Multifidene Pesticide Precursor synthesised 
from a bicycloketone, 
using CHMO.
(Carnell etal., 
1991)
( R )-(-)- b Neurotransmi Precursor synthesised (Mazzini et al.,
Baclofen
tter derivative from a substituted 
cyclobutanone.
1997)
Sordidin Pesticide Precursor synthesised 
from a 2,6 disubstituted 
cyclohexanone
(Beauhaire et 
al., 1995)
Azadirachtin Insect Precursor synthesised (Petit et al.,
antifeedant from a bicycloketone, 
using CHMO.
1995)
Sarkomycin A Antibiotic Precursor synthesised 
from a bicycloketone.
(Konigsberger 
etal., 1994)
lonomycin Antibiotic Precursor synthesised 
using CHMO.
(Taschner et 
al., 1991)
Carbocyclic Antiviral Precursor synthesised (Levitt et al.,
nucleosides agents from norbornanone using 
CHMO.
1990)
Table 2.0: Chiral synthons produced via BVMO catalysed bioconversions
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2.2. A Model Industrial Biotransformation
Biocatalysts are increasingly used during the production of industrially 
significant compounds (Liese et al.t 1999a, Rozzell, 1999, Tramper, 1996). 
Novel, optically pure products can be synthesised efficiently in a single unit 
operation by means of a biotransformation due to the characteristically good 
chemoselectivity, regioselectivity and stereoselectivity of enzymes. Where an 
alternative chemical conversion is also available for product synthesis, a 
greater number of reaction steps are typically required. In addition, reaction 
conditions for biotransformations are often aqueous based, using mild 
operating temperatures and pressures. Thus, a bioprocess can have 
convincing advantages with respect to process economics and environmental 
impact when compared to chemical conversions. However, under operating 
conditions, the substrates and products are frequently toxic or inhibitory to 
the biocatalyst. This necessitates the use of advanced control systems 
(Collins et al., 1995, Collins et al., 1998, Freeman et al., 1993, Hack et al., 
2000) requiring process monitoring of the analytes of interest (see section
1 .1).
The model reaction (Figure 2.1) is a stereo-selective Baeyer-Villiger oxidation 
of bicyclo[3.2.0]hept-2-en-6-one to the two corresponding regio-isomeric 
lactones. The whole cell catalyst, E.coli TOP10(pQR239) expressing CHMO  
from Acinetobacter calcoaceticus exhibits regio and enantiospecific oxidation 
of bicyclo[3.2.0]hept-2-en-6-one (from this point will be referred to as ketone).
The stereoselective oxidation of ketone to its corresponding regio-isomeric 
lactones (-) 1 (S), 5(R)2-oxabicyclo(3.3.0)oct-6-en-3one (ee = 94%) and (-) 
1 (R), 5(S) 3-oxabicyclo(3.3.0)oct-6-en-2-one (ee = 99%) is achieved by E.coli 
TOP10(pQR239). This reaction has been reported previously (Doig et al., 
2002, Doig et al., 2003b). The fed-batch biotransformation was undertaken, 
in the broth of the preceding fermentation, using an agitated stirred tank 
(Figure 2.2). From this point lactones (-) 1 (S), 5(R)2-oxabicyclo(3.3.0)oct-6- 
en-3one and (-) 1 (R), 5(S) 3-oxabicyclo(3.3.0)oct-6-en-2-one will be referred 
to as combined lactone.
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Under typical bioconversion concentrations, the substrates and products are 
toxic (Hack et al., 2000) or inhibitory to the bioctalyst (Doig et al., 2003b). The 
use of a fed-batch stirred tank reactor with feed back control enables the 
substrate concentration to be maintained in the optimum range. Such a 
system typically requires monitoring of the substrate at low concentration 
whilst maintaining a minimum sampling and analysis time. Where a 
bioconversion is characterised by product inhibition then strategies to 
circumvent the problem can be adopted (Becker et al., 1997, Collins et al., 
1995) or the process can be run to maximise productivity according to the 
enzyme kinetics (Doig et al., 2003b). The kinetics of the whole-cell Baeyer- 
Villiger bioconverson of ketone to its corresponding regio-isomeric lactones 
have been described (Doig et al., 2002). The optimum specific activity of 55 
pmol/min/g was observed at a ketone concentration between 0.2 and 0.4 gl'1, 
whilst at 5 gl"1 ketone this was reduced by more than 90%. In addition, when 
the combined lactone concentration was greater than 4.5 gl'1 the specific 
activity was zero. It is clear that control and optimisation of this bioconversion 
would be significantly improved by an effective on-line or rapid at-line 
monitoring technique. Substrate and product inhibition in biotransformations 
is a frequently observed phenomenon (Table 2.1) making this an excellent 
representative biotransformation.
Ketone
air air
r r
CT U  U
Lactone
Batch fermentation Resting-cell
bioconversion
Figure 2.2: The fed-batch Baeyer-Villiger whole-cell biotransformation.
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Example reaction Example biocatalyst Reference
N-acetyl-D-neuraminic 
acid (Neu5Ac) 
condensation
Neu5Ac Adolase (Blayer etal., 1996, 
Bla yer etal., 1999)
Acrylonitrile conversion Nitrile hydratase (Gradley et al., 1994, 
Graham etal., 2000, 
Layh etal., 2002)
Synthesis of D-malate Maleate hydratase (Michielsen et al., 
2000)
Esterification of benzoic 
acid
Lipase (Leszczak etal., 1998)
Carbon -  carbon bond 
synthesis
Transketolase (Brocklebank et al., 
1999, Lye etal., 1999, 
Turner, 2000)
Hydroxylation at the C 3 -  
poaition of a variety of 2- 
substituted phenols.
Monooxygenase (Held etal., 1999)
Table 2.1: Substrate and product inhibition in biotransformations is a
frequently observed phenomenon.
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3. Biocatalyst Production and Biotransformation
3.1. Materials and Methods
3.1.1. Biocatalyst Production
Cyclohexanone monooxygenase (CHMO) was produced during batch growth 
of recombinant Escherichia coli TOP10 [pQR239]. Heterologous expression 
of the CHMO gene present on pQR239 was under the control of the araBAD 
promoter induced with L-arabinose. In addition, the plasmid contained a gene 
conferring ampicillin resistance to the microorganism. Escherichia coli TOP10  
[pQR239] was a gift from Dr. John Ward, Department of Biochemistry and 
Molecular Biology, University College London.
Reverse Osmosis water was used in all experimental work. All other reagents 
were of analytical grade and were obtained from Sigma-Aldrich (Dorset, UK) 
unless otherwise stated.
3.1.1.1. Storage and Maintenance of the Biocatalyst
Stock cultures of E.coli TOP10 [pQR239] were stored at -70°C in 1ml culture 
aliquots containing 50% sterile glycerol v/v. To prepare stock cultures an 
individual colony of E.coli TOP10 [pQR239] was grown overnight at 3 7 °C  on 
an agar plate containing a complex growth medium with 1.5% w/v agarose 
and 100 mgl"1 ampicillin. This colony was inoculated into a sterile 1.0 I shake 
flask containing 100 ml of the complex growth medium, to which 100 mg/l of 
ampicillin had been added via a 0.2 pm sterile filter (Pall, Ml, USA). A Stock 
culture was produced once growth at 37°C in an orbital shaker (Edison 
House, Hatfield, Herts, UK) rotating at 200rpm resulted in a biomass 
concentration of approximately 1.0 g dcw.l"1. The complex growth medium 
consisted of 10 g.l"1 of glycerol, 10 g.l“1 of NaCI, 13 g.l"1 of Tryptone Peptone, 
and 27 g.l'1 of yeast extract.
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3.1.1.2. Shake Flask Growth
A 1 litre baffled shake flask containing 100 ml of complex growth medium 
was autoclaved at 121 °C for 20 minutes. To this 100 mg/l of ampiciliin was 
then added via a 0.2 pm filter when the sterile flask had cooled to room 
temperature. A single 1 ml frozen stock culture was then thawed and 
transferred into the flask and incubated at 37°C overnight with shaking 
(250rpm).
3.1.1.3. E.coli Top10 [pQR239] Fermentation
Batch fermentation of E.coli Top10 [pQR239] to produce quantities of CHMO 
biocatalyst was carried out either in an LH210 2 litre stirred tank fermenter 
(Bioprocess Engineering Services, Charing, Kent, UK) or an LH2000, 7 litre 
fermenter (Bioprocess Engineering Services, Charing, Kent, UK). The 
fermenters were fitted with two (LH210) or three (LH2000) top-driven, equally 
spaced six bladed turbines and four diametrically opposed baffles. The 
specification of each fermenter type can be found in Appendix I. pH was 
monitored by the use of an Ingold pH probe (Ingold, Mettler-Toledo, 
Leicester, UK), and DOT was measured with a polarographic oxygen 
electrode (Ingold, Mettler-Toledo, Leicester, UK). The pH was maintained at 
7 (±0 .1 ) via the addition of 3M NaOH and 3M H3PO4, and the temperature at 
37°C (± 0.5 °C). In addition, the vessels were aerated at a rate of 0.67 vvm 
with sterile air, via a submerged sparger.
Inlet and exhaust gasses were filtered using 0.2pm filters (Gelman Sciences, 
Ann Arbor, Ml, USA) and the composition of exhaust gas determined using a 
mass spectrometer (Prima 600, VG Gas Analysis, Winsford, Cheshire, UK). 
On-line data logging of fermenter operating variables, e.g. impeller speed, 
DOT, temperature, pH were recorded with an RT-DAS program (real-time 
data acquisition system) (Acquisition Systems, Guildford, Surrey, UK) along 
with the exhaust gas measurements.
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3.1.1.3.1. LH210 Fermenter
The LH210 fermenter containing 1.5 L of complex growth medium and the 
fermenter auxiliaries were sterilised by autoclaving at 121 °C  for 20 minutes 
prior to the addition of filter sterilised ampicillin (100 mg.L'1). The fermenter 
was then inoculated with 100ml of E.coli Top10 [pQR239] culture, grown 
overnight in a shake flask.
Initially the impeller speed during the batch fermentation was set at a rate of 
800 rpm. This rate was increased incrementally to a maximum of 1200 rpm to 
maintain the DOT above zero until the culture biomass concentration had 
reached 4 g dcw.L’1, when expression of CHMO was induced. Addition of L- 
arabinose solution to the fermenter via a 0.2pm filter to a final concentration 
of 0.15 % w/v induced the heterologous expression of CHMO E.coli Top10 
[pQR239]. In order that the DOT did not rise above 5% (Doig et al., 2001) 
during induction, the impeller speed was reduced when necessary. Three 
hours after induction, the cells were harvested from the fermenter.
3.1.1.3.2. LH2000 series I Fermenter
Fermentations were also performed in a 7 litre (5.3 litre working volume) LH 
2000 series I fermenter. The fermenter containing 5.0 litres complex medium 
was steam sterilised at 121°C for 20 min. Filter sterilised ampicillin was 
added to the medium just prior to inoculation with 300 mL of shake flask cell 
culture .
During the growth phase, the DOT was maintained above 20%. This was 
achieved by increasing the agitation speed, (set initially at 500 to 600 rpm) 
each time the DOT dropped below 30% to a final rate of 1200 rpm or until 
expression of CHMO was induced. Induction was achieved by adding 0.15 % 
w/v L-arabinose once the biomass reached 4 gl'1. Cells were harvested 3 hr 
after induction. The DOT was close to 0% for the entire induction period.
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3.1.1.4. Biocatalyst Storage
The cells harvested from the 2 L or 7 L fermenters were analysed to quantify 
the level of cellular CHMO activity (section 3.1.3.3). The cells were then 
either used immediately in the same medium to carry out a biotransformation 
or where appropriate stored in a fridge at 4 °C . The maximum period of time 
whole cell biocatalyst broth to be used for biotransformation was stored in the 
fridge was 7 days.
3.1.2. Whole Cell Biotransformation
3.1.2.1. Small-scale BVMO Biotransformation
Small scale biotransformations were carried out in 1.0 L baffled shake flasks 
to assay the biocatalytic activity of the whole cell E.coli Top10 [pQR239] 
biocatalyst under various process conditions.
Fermentation broth from whole-cell CHMO production (section 3.1.1) was 
centrifuged at 4000 rpm for 20 minutes at 4 °C  (Heraeus Megafuge, Heraeus 
Instruments Ltd, Brentwood, Essex, UK). Cells were re-suspended in 50 mM 
phosphate buffer, pH 7 (unless stated otherwise) to a final biomass 
concentration of 1 gl"1 and volume of 20ml. Glycerol was then added to a final 
concentration of 10 gl'1. In a shake flask the biotransformation components 
were incubated in an orbital shaker at 37°C and 200 rpm for 10 minutes.
Addition of neat ketone, to a final concentration of 1.0 gl'1 started the 
biotransformation, which was carried out over a 1-hour period in an orbital 
shaker at 37°C and 200 rpm. Samples (1ml) of the biotransformation were 
withdrawn at 10-minute intervals and analysed by GC as described in section
3.1.3.5.
3.1.2.2. Lab-scale (2L) BVMO Biotransformation
Biotransformations were carried out in a LH210 series stirred tank reactor 
(STR), with a working volume of 1.5 L (Bioprocess Engineering Services, 
Charing, Kent, UK). The STR was fitted with two equally spaced six bladed
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turbines, which were top driven and four diametrically opposed baffles. The 
reactor comprised a glass vessel with an aspect ratio of 1.82. The ratio of the 
vessel diameter to the impeller diameter was 2.4. The pH was measured by 
an Ingold pH probe (Ingold, Mettler-Toledo, Leicester, UK), and maintained at 
7 (± 0 .1 ) via the addition 3M NaOH and 3M H3PO4. DOT was measured with 
a polarographic oxygen electrode (Ingold, Mettler-Toledo, Leicester, UK). 
The vessel was aerated with 1 vvm air via a submerged sparger, and 
agitation was controlled to maintain DOT above zero by setting the impeller 
speed at 800 rpm in all biotransformation experiments. The temperature was 
maintained at 37 °C and antifoam (polypropylene glycol 2000) was added 
manually as necessary.
The biocatalyst E.coli Top10 [pQR239] produced by fermentation (Section
3.1.1.3) was transferred, typically suspended in the spent complex growth 
medium to the STR. In some instances, an alternative biotransformation 
medium was used; Table 3.0 lists these media types. The use of an 
alternative medium type required the centrifugation of the biocatalyst 
fermentation broth, by batch centrifugation at 4000 rpm for 20 minutes at 4°C 
(Heraeus Megafuge, Heraeus Instruments Ltd, Brentwood, Essex, UK). The 
wet cell paste was then resuspended in an alternative medium to the 
required biocatalyst concentration. In one experiment the cell paste was 
washed by re-suspension in an equal volume of phosphate buffer, a second 
centrifugation step was then undertaken prior to cell resuspension.
All biotransformations were run at 37 °C, typically for a period of 3 hours. The 
ketone substrate was fed at varying flow rates (0.5 to 2.0 gl"1.h'1) to the STR 
via a peristaltic pump (Model 205U/BA, Watson Marlow, Falmouth, Cornwall, 
UK) from an external reservoir. Approximately every 10 minutes the 
biotransformation was sampled by withdrawing up to 6 ml of reaction broth. 
Analysis of samples was carried out as necessary (section 3.1.3 and section
4.1.1).
78
Media Types Constituents
Complex medium 10 gl'1 of glycerol,
10g l'1of NaCI,
13 gl'1 of Tryptone Peptone, 
27 gl'1 of yeast extract.
Phosphate buffer 50 mM phosphate buffer
Defined medium 4.25 gl'1 KH2P 0 4, 
3.15g l'1NaHP04.12H20 , 
9 gl'1 N aN 03,
0.1 gl'1 M gS04,
0.05 gl'1 CaCb.2H20 , 
0.024 gl'1 F eS 04.7H20 , 
0.009 gl'1 M nS04.H20 , 
0.006 gl'1Z n S 04.7H20 , 
0.004 gl'1 CoCI2.6H20 .
Water medium RO water
Table 3.0: Biotransformation medium. Glycerol, a reductant for the 
biotransformation was added to each medium preparation to a final 
concentration of 10 gl'1 glycerol.
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3.1.3. Analytical Methods
3.1.3.1. Biomass Quantification
Growth of E.coli Top10 [pQR239] in the STR’s was profiled by measuring 
changes in the optical density (OD) of withdrawn samples of culture medium. 
OD measurements were taken at 670 nm (OD670) using an Uvikon 922 
variable wavelength spectrophotometer (Kontron, Watford, Herts, UK). 
Where necessary the samples were diluted appropriately with RO water so 
that the OD measurements were between 0.1-1.0 absorbance units. The 
standard error (Appendix II) for OD67o measurements was determined from 
10 duplicate measurements (biomass concentration range 0.1 -  10 g dcw.L' 
1) of a single batch fermentation and found to be 0.01 absorbance units.
To determine the dry cell weight (dew) biomass concentration of a 
fermentation sample, pre-dried and pre-weighed duplicate 1.5 ml Eppendorf 
tubes were filled with a single 1 ml aliquot of the cell culture sample. Samples 
were then centrifuged at 13,000 rpm for 2 minutes, after which the 
supernatant was discarded. The remaining wet-cell pellet was dried by 
placing the sample in an oven at 100 °C for 24 hours. Dried samples could 
then be weighed to calculate the dew. The standard error (Appendix II) for 
dew measurement was determined from duplicate measurements of each of 
10 cell culture samples (biomass concentration range 5 -  9 g dcw.L'1) from a 
single batch fermentation and found to be 0.37 g dcw/L.
A correlation between OD670 and dew was determined from the OD670 and 
dew measurement of 5 replicate cell culture samples (average concentration 
18.8 g dcw.L'1). One g dcw.L'1 of E.coli Top10 [pQR239] cell culture in 
complex growth medium was determined to equal 1.83 absorbance units.
3.1.3.2. Protein Assay
The protein content of biotransformation samples was determined by means 
of a Bradford Assay (Bradford, 1976). Biotransformation samples were 
clarified by centrifugation at 13,000 rpm for 2 minutes (Heraeus Biofuge 13).
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20 j l i I  of supernatant was then mixed by vortexing with 1  ml of a 1 to 5 RO 
water dilution of Coomassie blue G-250 assay reagent (Biorad Hemel 
Hempstead, Herts, UK). Samples were transferred (after being left to stand 
for 5 minutes) to 1ml cuvettes and the OD at 595 nm measured. All 
measurements were taken on an Unicam UVA/is spectrophotometer 
(Spectronic Analytical Instruments, Leeds, UK) after adjusting the 
absorbance to zero with a sample of RO water. Where necessary the 
biotransformation samples were diluted appropriately with RO water so that 
the OD measurements were between 0 - 1 . 0  absorbance units.
A calibration curve (Appendix III) linking the OD595 to protein concentration 
was constructed using a series of standard samples of known protein 
concentration. Standard samples had bovine serum albumin protein 
concentration in the range of 0.2 to 10 mg.ml'1; prepared in RO water. The 
standard samples were then assayed as for the clarified biotransformation 
samples. This enabled the prediction of biotransformation samples where the 
protein concentration was unknown.
3.1.3.3. CHMO Intracellular Activity Assay
The intracellular activity of CHMO in E.coli Top10 [pQR239] was monitored 
using an NADPH rate assay, as the oxidising power of the co-factor NADP+ 
is used in stoichiometric amounts by the reductant CHMO during the 
formation of the combined lactone from the ketone (Figure 2.1). This was 
undertaken in a 30°C temperature controlled variable wavelength Kontron 
Uvikon 922 spectrophotometer (Watford, Herts, UK). Oxidation of NADPH (e 
= 6.22 ml/pmol/cm) was monitored over time at a wavelength of 340nm. The 
method is described by (Donoghue etal., 1976).
CHMO was prepared from E.coli Top10 [pQR239] culture broth sampled from 
a fermentation or biotransformation experiment. Medium supernatant was 
removed after micro-centrifugation at 13,000 rpm for 1 min (Heraeus Biofuge 
13, Herts, UK). The cell pellet was then re-suspended in a solution of Tris- 
HCL buffer (50 mM, pH 9.0), and bovine serum albumin (5 mg.ml'1). To 
release the CHMO enzyme, cell disruption by sonication (Soniprep 150;
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Sanyo, Crawley, UK) was undertaken in an ice-bath at a wavelength of 8 urn 
for 5 cycles of 10 seconds, with 10 seconds between cycles. Finally, 
clarification was by micro-centrifugation at 13,000 rpm (10,000 g) for 2 
minutes. The supernatant was then used neat or diluted in RO water as the 
CHMO source.
In a final volume of 1ml the following reagents were added to a 1.5ml cuvette: 
Tris-HCL buffer (50 mM, pH 9.0), bovine serum albumin (5 mg/ml), NADPH 
(0.161 mM), CHMO (Concentration was such that rate of activity was initially 
linear). The background rate of NADPH activity monitored at 340 nm (A340) 
was measured over a period of 5 minutes. A second rate of NADPH activity 
was then measured for a further 5 minutes, on addition of cyclohexanone 
(2mM) to the cuvette.
The rate of NADPH oxidation could then be calculated by subtracting the 
background rate from the second NADPH oxidation rate. The activity of 
CHMO (Ca) was expressed in international units (U) with one unit being 
defined as the number of pmoles of NADPH consumed per minute. The 
calculation of the concentration of NADPH was based on Beer’s Law 
(Section 1.2.9) and so to determine the number of units of CHMO activity, 
equation 3.1 was used. The error associated with this assay was ±150 U 
based on the mean standard deviation (Appendix IV).
Ca = ^
I  •£' At
e =extinction coefficient (pmol.ml'Vcm'1), CHMO £ = 6.22 pmol.ml'Vcm'1 
I = light path length (cm)
Equation 3.1
&
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3.1.3.4. Glycerol Assay
An enzymatic assay (Boehringer Mannheim Roche, Roche-Biopharm GmbH, 
Darmstadt, Germany) was used for the determination of glycerol in 
fermentation and biotransformation samples.
Glycerol was phosphorylated by adenosine-5’-triphosphate (ATP) to L- 
glycerol-3-phosphate in the presence of glycerokinase (GK), as shown by 
equation 3.2.
Glycerol + ATP  —GK- >L  -  glycerol -  3 -  phosphate +  ADP  
Equation 3.2
The adenosine-5’-diphosphate (ADP) formed in the above reaction was 
reconverted by phosphoenolpyruvate (PEP) into ATP, a reaction catalysed 
by pyruvate kinase (PK) and resulting in the formation of pyruvate (equation
3.3)
ADP  +  PEP — » ATP + pyruvate
Equation 3.3
In the presence of the enzyme L-lactate dehydrogenase (L-LDH), pyruvate is 
reduced to L-lactate by reaction with reduced nicotinamide-adenine 
dinucleotide (NADH); as shown in equation 3.4.
Pyruvate +  NADH + H +  >(L)lactate + NAD+
Equation 3.4
The amount of NADH oxidised in the above reaction is stoichiometric to the 
amount of glycerol. NADH is determined by measurement of light 
absorbance at 340 nm. The error associated with this assay was ± 0.07 gl"1 
based on 6 independently prepared standard solutions (concentration range 
4 to 9 gl'1)
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3.1.3.5. Ketone and Lactone Quantification
The separation and quantification of ketone and lactone from ethyl acetate 
preparations was performed on a Perkin-Elmer autosystem XL-2 gas 
chromatograph (Perkin-Elmer, Norwalk, CT, USA), fitted with an Alltech 
series AT-1701 (Alltech, Carnforth, Lancs, UK) and linked to an FID detector. 
Data collection and reduction was performed using PE Nelson Turbochrom™ 
software (PerkinElmer, Wellesley, MA USA).
3.1.3.5.1. Sample Preparation and GC Operation
To prepare aqueous samples from biotransformation experiments for GC 
analysis, a 1 ml sample volume was centrifuged at 13,000 rpm for 4 minutes 
(Heraeus Biofuge 13). A 0.5 ml sample of supernatant was transferred to a 
fresh vial before addition of an equal volume of ethyl acetate. The two-phase 
mixture was then vortex mixed for 10 seconds in a 2.2 ml Eppendorf tube. A 
10 second vortex period was determined to be enough for the partioning of 
analytes between phases to reach equilibrium (data not shown). The mixture 
was centrifuged for a further 2 minutes at 13,000 rpm, the organic layer 
removed and if necessary diluted with ethyl acetate before analysis by GC. 
Analyte ethyl acetate samples prepared for calibration of GC chromatographs 
were transferred directly to the GC auto-sampler. The conditions used to 
operate the gas chromatography (GC) apparatus are given in table 3.1.
Operational parameter Configuration
Column Reverse phase silica, (30 m x 0.54 mm)
Injection volume 1pl
Carrier gas flow rate 4.0 ml.min'1
Column temperature program 100 °C held for 5 minutes then raised by 10 
°C/min up to a maximum temperature of 240 °C.
FID temperature 250 °C
Table 3.1: Gas chromatography operating conditions.
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3.1.3.5.2. Quantification of the GC Chromatographs
Unknown analyte concentrations in the ethyl acetate phase of samples were 
calculated using predetermined calibration curves. These curves were based 
on independently prepared solutions (concentration range 0.1 gl'1 to 2.5 gl'1) 
of ketone and lactone1 (lactone1 is depicted in Figure 3.0) in ethyl acetate. 
Typical calibration curves of analyte concentration against FID response are 
shown in Appendix V. Lactone1 is commercially available, but the combined 
lactones; (-) 1(S), 5(R)2-oxabicyclo(3.3.0)oct-6-en-3one and (-) 1(R), 5(S) 3- 
oxabicyclo(3.3.0)oct-6-en-2-one, produced during the model 
biotransformation are not. The GC response time for lactone1 was the same 
as for the combined lactones (Appendix VI), it was therefore considered 
suitable to produce standards for combined lactone calibration. Lactone1 is 
the opposite enantiomer of (-) 1(S), 5(R)2-oxabicyclo(3.3.0)oct-6-en-3one.
The standard error of GC analysis was determined from 10 duplicate sample 
measurements (concentration range 0.1-2.5 gl'1) and found to be 91027 uA/ 
for ketone and 156025 uA/ for lactone1. This equates to a standard error of
0.04 and 0.07 gl"1 for ketone and lactone respectively.
H
H
4
Figure 3.0: Lactone1 1(R), 5(S) 2-oxobicyclo(3.3.0)oct-6en-3one.
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3.1.3.5.3. Ethyl Acetate Partition Coefficient
Quantification of the ketone and lactone concentrations in biotransformation 
samples required the equilibrium water-ethyl acetate partition coefficient to 
be determined for these compounds. Aqueous solutions of the ketone and 
lactone1 were made up at various concentrations between 0.1 -  1.0 gl"1. 10ml 
of each solution was contacted with 10ml of ethyl-acetate at room 
temperature with agitation at 200rpm for 24 hours in sealed glass vials. The 
solvent phase was analysed for ketone and lactone concentration using the 
gas chromatography method. The ethyl-acetate/ water partition coefficient, 
K, was subsequently determined as the ratio between the equilibrium 
concentration of solute in ethyl-acetate, Ce, and the equilibrium concentration 
of solute remaining in the aqueous phase, Caq using equation 3.5. It was 
determined that 100% of the ketone and 88% of the lactone1 was present in 
the solvent phase at equilibrium. The concentration of lactone1 remaining in 
the aqueous was determined by mass balance. The partition coefficient for 
ketone and lactone1 was therefore 1.0 (nearing infinity) and 7.11 ±0.12 
respectively.
K = C'
Equation 3.5
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3.2. Results
3.2.1. Biocatalyst Production
Whole-cell catalysed Baeyer-Villiger type oxidation of cyclic ketones yielding 
chiral lactones require the host to be cultivated and CHMO expressed. E.coli 
TOP10 [pQR239] expressing CHMO from Acinetobacter calcoaceticus 
NCIMB 9871, was cultivated at 2 and 7 litre scale in batch fermentations. The 
cloning and fermentation characterisation of E. coli TOP10 [pQR239] have 
previously been reported (Doig et al.t 2001) as described in section 1.1.
Production of the E. coli TOP10 [pQR239] biocatalyst by batch fermentation 
is described in this section. The aim of the work was to provide a protocol for 
the production of the biocatalyst and to establish a reproducible and 
characterised Baeyer-Villiger bioconversion.
3.2.1.1. Growth Characteristics
The production protocols for E.coli TOP10 fermentation at 2 L and 7 L scales 
were developed to be similar in order that inter-batch variation was 
minimised. For instance, the same complex growth medium was used 
throughout this research. The operation of the reactors was based on 
previously published work (Doig et al.} 2001) and sought to maximise both 
the final biomass concentration and specific intracellular CHMO titre.
A typical 2 L fermentation profile is depicted in Figure 3.1. The growth curve 
is characterised by a short lag phase, which is due in part to the seed 
medium and fermentation medium being identical. This can also be explained 
by the relatively high volume of the seed culture, which was 6% v/v of the 
working reactor volume. The final biomass concentration of 8.5 gdcw.l'1 was 
achieved with a maximum specific growth rate of 0.77 h"1. The average final 
biomass concentration for 2 L fermentations was 7.6 ± 1.1 g dew. I'1. The 
oxygen uptake rate (OUR) and carbon dioxide evolution rate (CER) was 
controlled initially such that it was rapidly increasing. This control was 
achieved by maintaining the dissolved oxygen tension (DOT) above 10% so
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that oxygen supply was not limiting growth. A step-wise increase in the 
agitation speed from 600 rpm provided a means of controlling the DOT above 
10%. DOT levels dropped during the late log-phase of culture growth. This 
was due to the stirrer speed been restricted to a maximum of 1250 rpm and 
the on-set of CHMO expression by induction of the L-arabinose controlled 
promoter. On induction of the CHMO expression by E.coli Top10 [pQR239] at 
225 min, the fermentation was controlled to achieve a DOT <5%, whiist 
maintaining a high OUR since previous work (Doig et a/., 2001) had indicated 
that this approach gave the highest titre of intracellular CHMO. An OUR of 
approximately 110 mmoN'1hr"1 was maintained for 1.5 hours post induction, 
then the OUR dropped to below 60 mmoir1hr"1 as the cells entered the 
stationary phase of growth. At this point the DOT started to increase. The 
fermentation was stopped and the biocatalyst harvested from the fermenter.
A similar profile exists for the 7 L fermentation (Figure 3.2) since the objective 
was simply to produce the same titre of CHMO at a larger scale. As for the 2 
L fermentation the growth curve is characterised by a short lag phase since 
the fermentation and seed medium are identical. The seed volume was 5.7%  
v/v of the working volume of the fermenter. The average final biomass 
concentration for 7 L fermentations was higher than the 2 L at 12 ± 3 g dcw.l'
1. In the example shown the biomass concentration had reached 11 gl'1 with 
a maxium specific growth rate of 0.78 h'1 when the fermentation was 
stopped. The OUR and CER was high in the 90 to 110 mmol.I'1.h'1 region 
and the DOT was recording 0% at the end of the fermentation indicating that 
the culture was yet to enter the stationary phase of growth in the example 
shown. The operating method for the production of CHMO at a 7 L scale 
(section 3.1.1.3.2) is similar to the 2 L scale in that termination of the 
fermentation is timed at 3 hours post induction. It is recognised that the yield 
of biocatalyst and titre of CHMO are not optimised for the fermentation 
method described, although sufficient yields were achieved for the purpose of 
this study.
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Figure 3.1: Representive 2 L fermentation profile for Escherichia coli Top10 
[pQR239]. Biomass concentration. (---) Impeller speed. (— ) Dissolved
oxygen tension (DOT). ( ) Oxygen uptake rate (OUR). (--------) carbon
evolution rate (CER).
The DOT profile in Figure 3.2 falls as OUR increases with increasing 
biomass concentrations. As the DOT falls below 10% at 150 minutes the 
stirrer-speed increases exponentially to a maximum of 1200 rpm. This 
operation was controlled by a programmable logic controller set-up to 
increase the stirrer speed and hence OUR when DOT fell below 10%. 
Fermentations were always operated not to limit oxygen to the growing cells 
up to induction of CHMO expression (180 minutes for figure 3.2), after which 
the level of DOT was maintained at a recorded 0% i.e. all oxygen inputted in 
to the system was being dissolved in to the liquid phase and consumed by 
the cells. The scale-up rationale for the 2 L to 7 L fermentation is discussed 
in section 3.2.3.
89
Figure 3.2 Representative 7 L fermentation profile for Escherichia coli 
Top10 [pQR239]. (c} Biomass concentration. (—) Impeller speed. (— ) 
Dissolved oxygen tension, (DOT), ( ) Oxygen uptake rate (OUR), (
- - )  carbon evolution rate (CER).
3.2.1.2. Medium Protein Content
The volumetric scale at which the CHMO expressing E.coli biocatalyst was 
produced affected the relative concentration of cells contained in the 
fermentation broth. Both fermentation methods used the same complex 
medium (section 3.1.1). Conventionally, the whole-cell biotransformation of 
ketone to combined lactone has been undertaken in the spent complex 
fermentation broth (Doig et al., 2002). Variation in the constituents of the 
spent broth between inter-fermentation batches resulting because of the 
fermentation process will be carried through to the next step in the 
bioprocess, the biotransformation step. To qualify variation between 
biotransformation medium the extra-cellular protein concentration of samples 
was analysed using the Bradford assay.
The scale at which the E.coli cells were grown resulted in different extra­
cellular protein concentration profiles within clarified biotransformation broth 
samples (Figure 3.3). It is apparent by the example shown in Figure 3.3 that 
the broth from 7 L fermentations contains more than twice the concentration 
of extra-cellular protein and that this trend is observed throughout the period 
of the biotransformation. In both cases the relative extra-cellular protein 
concentration increases during the biotransformation.
The whole-cell biotransformation of bicycloheptanone using spent complex 
broth from the 7L fermenter resulted in increased levels of extra-cellular 
protein compared to the 1.5L scale fermenter broth (Figure 3.4). When the 
biocatalyst was separated from the spent fermentation broth and re­
suspended in alternative biotransformation medium (Figure 3.4) a significant 
reduction in the concentration of protein was observed. Such variation 
between biotransformation media types is carried over to subsequent 
biotransformation steps and will contribute to complexities during the analysis 
of operations using near infrared spectroscopy.
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Figure 3.3: Fermenter configuration and protein content of medium 
during biotransformations. (■) Representative 2 L spent fermentation 
broth (T ) Representative 7 L spent fermentation broth. Error-bars are 
based on the standard deviation of 3 replicates for each sample.
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Figure 3.4: Protein content of biotransformation medium. Results show 
the average and standard deviation for 5 samples taken at the start of 
individual biotransformations. (A) = spent medium from a 7 L 
fermentation; (B) = spent medium from a 2 L fermentation; (C) 
biocatalyst resuspended in a minimal defined medium; (D) = biocatalyst 
resuspended in phosphate buffer; (E) biocatalyst resuspended in 
water.
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3.2.1.3. Biocatalyst Activity
The expression of CHMO was induced by the addition of 0.15 % w/v L- 
arabinose to the culture broth. This induction occurred when the optical 
density of withdrawn clarified broth sample reached 9 to 10 absorbance units 
(approximately 5 g dcw.l'1 biomass) at a wavelength of 670 nm. An optical 
density of 9 to 10 represents the late exponential growth phase for the 
operated batch conditions. The results shown in Figure 3.5 show that the 
intracellular CHMO titre of the E.coli biocatalyst increased sharply from the 
point of induction with undetectable CHMO activity prior to this. The cells 
were harvested three hours post-induction, typically as the culture entered 
the stationary growth phase. At the point of harvesting the intracellular 
CHMO titre reached a maximum value, which was 2290 Ul"1 for the 
fermentation data shown in Figure 3.5. The average final CHMO titre for 2 L 
and 7 L fermentations was 2100 ± 380 Ul"1 and 3200 ± 600 Ul'1 respectively. 
The maximum specific intracellular titre for 2 L and 7 L fermentations was 
228 ± 38 U/g and 254 ± 56 U/g respectively.
The whole-cells were harvested from the fermenter in the spent fermentation 
broth. Post harvesting the biocatalyst was either stored suspended in the 
broth in a refrigerator (4°C) or transferred to the biotransformation reactor. 
Storage of the biocatalyst in a refrigerator was possible for up to 7 days 
(approximately 170 hours) without an observable loss in intracellular activity 
(Figure 3.6). Figure 3.6 shows that after a storage time of 170 hours, the 
intracellular activity of the biocatalyst starts to fall. Biocatalyst was routinely 
stored under refrigerated conditions for up to 5 days prior to a 
biotransformation.
The stability of the biocatalyst was observed during a control CHMO  
catalysed Baeyer-Villiger oxidation. The experiment was carried out as 
described in Section 3.1.2.2. No ketone was fed into the reactor during this 
control biotransformation. The absence of ketone and therefore of the 
biotransformation reaction provided samples indicating a measure of the 
biocatalyst stability during operational conditions. At regular intervals during
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the control experiment 100ml samples were withdrawn. The intrinsic specific 
activity of the E.coli biocatalyst samples was assayed over a 1-hour period in 
a small scale batch biotransformation of the ketone substrate as described in 
section 3.1.2.1. Figure 3.7 indicates that the normalised intrinsic specific 
biocatalyst activity was maintained for 4 hours before a significant loss was 
observed. The fitted curve (Figure 3.7) approximates biocatalyst stability and 
has the form shown in Equation 3.6.
Equation 3.6
Y = -1.8004x1 O^t3 + 2.0172x1 O^t2 + 1.3426x1 O^t + 0.99833
where y is the residual biocatalyst activity and t is the duration of the reaction.
As indicated, the specific intracellular CHMO titres of E.coli biocatalyst 
batches stored at 4°C were stable for 7 days. Batches stored over a 7 day 
period were also observed to maintain the intrinsic specific whole cell activity 
(data not shown). The observed decrease in the intrinsic specific CHMO  
activity of the biocatalyst after 4 hours in a STR at 37°C and pH 7 was a 
phenomenon dependent on the operating conditions in the STR.
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Figure 3.5 CHMO expression during a 2 L Escherichia coli Top10 [pQR239] 
fermentation. (■) Biomass concentration. (— ) Dissolved oxygen tension, 
(DOT). (0) Intrinsic CHMO activity.
96
4000
3500
3000
2500
2000
o  1500
1000
500 -
o   l______ i l_____ I l_____i l______ ■ I_____I I_____ 1 l_____ I l_____ I l_____I l____ I l
0 25 50 75 100 125 150 175 200 225 250
Time (h)
Figure 3.6 Intracellular CHMO activity of Escherichia coli Top10 
[pQR239] biocatalyst activity during storage post harvesting. The 
biocatalyst was stored suspended in the spent fermentation broth in a 
refrigerator at 4°C.
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Figure 3.7: Modelled biocatalyst stability. (*) Experimental data derived 
from a 2 L stirred tank under process conditions (— ) fitted curve.(Doig 
et a t , 2003a).
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3.2.2. Whole Cell Biotransformation
3.2.2.1. Glycerol Required for Biotransformation
CHMO is a BVMO which uses a flavin coenzyme as an organic cofactor and 
NAD(P)H as the reductant (Kelly, 1998, Willets, 1997) to carry out the 
Baeyer-Villiger type oxidation. The E.coli TOP10 [pQR239] fermentations 
were carried out using a Glycerol based growth medium. The glycerol 
constituted the carbon source during the growth of the culture and the 
sources of reducing equivalents for whole-cell NAD(P)H cofactor recycle 
during the biotransformation step. It was important to ensure sufficient 
glycerol was available to the cells since it was shown (Figure 3.8) that at 
concentrations of <3 gl-1 the initial specific activity of the cell (method is 
described in section 3.1.2.1) was significantly reduced. The requirement to 
add sufficient glycerol to the biotransformation medium prior to 
commencement of the biotransformation was included in the process 
method. Where the biotransformation medium type was the spent broth of 
the preceding fermentation, glycerol carried over to the biotransformation 
step enabled the operation to proceed as expected (Figure 3.9). In contrast, 
re-suspension of the biocatalyst in defined medium requires the presence of 
glycerol for NAD(P)H cofactor recycle and without this no reaction is 
observed (Figure 3.9). All routine biotransformations including 
biotransformations carried out in broth type medium received a batch addition 
of 10 gl-1 glycerol (Figure 3.10).
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Figure 3.8 : The initial specific activity of whole-cell E.coli TOP10 
[pQR239] at various concentrations of glycerol. Shake flask 
biotransformations of ketone to combined lactone. CHMO activity is 
dependent on reaction mixture glycerol concentration.
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Figure 3.9 Shake flask biotransformations using whole-cell E.coli 
TOP10 [pQR239], (A) Biotransformation in the spent fermentation 
broth; Glycerol (10 gl~1). (B) Biotransformation in defined medium, 
glycerol (10 gl'1). (C) Biotransformation in the spent fermentation broth; 
no glycerol added. (D) Biotransformation in defined medium, no 
glycerol added. (■) Ketone, (•) lactone
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Figure 3.10: Glycerol profile during a representative 2 L E.coli TOP10 
[pQR239] biotransformation. (□) Lactone. (O) ketone. (O) Glycerol. 
Glycerol is added in batch, the ketone substrate is added fed-batch.
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3.2.2.2. Biotransformation Profiles
Figure 3.11 shows a range of biotransformation profiles. All fed-batch 
biotransformations were conducted on a 2L scale in spent fermentation broth 
as described in section 3.1.2.2. From previous kinetic characterisation it was 
found that substrate inhibition is a key characteristic of the E.coli TOP10 
[PQR239] whole cell catalysed oxidation of ketone to its corresponding 
combined lactones (Doig et al., 2002) as described in section 2.1 of the 
introduction. In order to address this issue the ketone substrate was fed neat 
into the reactor to maintain a low ketone concentration in the reaction in an 
attempt to maximise the specific activity and hence final product 
concentration attainable. Figure 3.11(A) depicts a representative 
biotransformation; in this instance ketone was fed at a constant rate of 1.3 g.l' 
1.h'1 into the reactor. Since the ketone feed rate is above the observed 
CHMO volumetric activity of 1.22 g.l"1.h‘\  the rate of lactone production is 
likely limited by:
•  Lactone inhibition of whole cell CHMO activity (Doig et al., 2003b)
• Time dependent whole cell viability (Chen et al., 2002)
•  AND ketone inhibition (Doig etal., 2003b)
On loss of CHMO activity at approximately 160 minutes (Figure 3.11) a 
dramatic increase in the ketone concentration was observed. By 175 minutes 
lactone production had peaked. The continual feeding of ketone then resulted 
in a decrease in the ratio of product formed to substrate added (P/S) (Figure 
3.12) up to 300 minutes at which time the ketone feed was stopped. 
Maximising the yield of P/S is a desirable target for biocatalytic process 
development. Presence of residual substrate from stereoselective synthesis 
complicates DSP since substrate and product often exhibit similar purification 
characteristics. This is the case with ketone, which has been shown to bind 
competitively to an amberlite XAD4 column along with the lactone products 
(Alphand et al., 2003). In addition there is a clear benefit to process 
economics relating to efficient use of raw materials.
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Substrate inhibition can be avoided and a high yield of product on substrate 
can be achieved by stopping the feeding of ketone to the reactor, as shown 
in Figure 3.11B. In this instance the substrate feed was stopped at 115 
minutes after which the yield (P/S) increased significantly (Figure 3.12). 
However, the rate of bioconversion slowed prematurely at 180 minutes due 
to a limiting ketone concentration.
Where the ketone was fed at a rate below the maximum volumetric activity of 
the biocatalyst (Figure 3.11C) the yield of product on substrate was 
optimised. The ketone feed rate limits the maximum biocatalyst volumetric 
activity to 0.71 g.l'1.h'1, which is lower than the maximum biocatalyst 
volumetric activity for reactions A; 1.22 g.l'1.h_1 and B; 1.07 g.r1.h'1.
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Figure 3.11 (A): Whole-cell E.coli TOP10 [pQR239] biotransformation profile with substrate 
continuosly fed to the reactor at a rate greater than the reaction rate i.e. over-feeding. (B): 
Biotransformation with substrate feed curtailment. (C): Biotransformation profile with 
substrate under feeding. (□) Lactone. (0) ketone.
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Figure 3.12: The ratio of product formed to substrate added during 
biotransformation A (O); biotransformation B (+) and biotransformation 
C (A), the profiles of which are depicted in Figure 3.11.
3.2.2.3. Substrate and Product Inhibition
As described in section 2 the biotransformation kinetics for the oxidation of 
ketone to its corresponding regio-isomeric lactones have previously been 
investigated (Alphand et al., 2003). The key kinetic characteristics of this 
strain were found to be severe substrate and product inhibition. This has 
significant implications on the design of the bioprocess; these are discussed 
in the discussion section 3.2.3.
The whole-cell Baeyer Villiger biotransformation has typically been 
undertaken in the spent broth of the preceding fermentation step (Doig et al., 
2001). Alternatives to broth medium include water, phosphate buffer, and 
defined medium. The whole-cell biocatalyst was separated from the broth 
medium and resuspended in an alternative medium type as described in 
section 3.1.2. Small-scale biotransformation experiments conducted in 1L
3.2.2.4. Biotransformation Medium
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shake flasks at a biocatalyst concentration of 1.25 gl'1 indicated that under 
these conditions the biocatalyst performed equally well in all media types 
over the period of the biotransformation (Figure 3.13). All media types 
permitted the Baeyer-Villiger biotransformation to progress, at similar 
volumetric activities (0.6 g.l'1.h"1).
Despite the biocatalyst exhibiting similar activities using the various media 
types, further work was undertaken at low biocatalyst concentration's at the 
2L scale in STR’s. The low concentration of E.coli Top10 [pQR 239] (0.4 gl'1) 
resulted in a reduced demand for O2 such that the OTR rate into the 
biotransformation medium was not limiting i.e. DOT was not zero (Figure 
3.14). The biocatalyst volumetric activity was calculated to be 0.73 g.l'1.h'1. A 
linear increase of lactone was yielded during the time course of the reaction 
at a rate limited by the ketone feed rate. Ideally, the ketone feed rate would 
not be limiting, as this would allow for maximum biocatalyst activity during the 
period of modelled biocatalyst stability. The inability to monitor and control 
substrate and product concentrations meant that it was difficult to operate the 
E.coli Top10 [pQR239] Baeyer-Villiger process as required. At this low 
biocatalyst concentration the specific activity of whole-cell CHMO was at 
least 0.58 g.l'1.h'1.gdcw'1 (4.7 pmol.min'Vgdcw'1) dew initially and at least
0.14 g.l'1.h"1.gdcw'1 (1.1 pmol.min'1.gdcw'1) on termination of the experiment. 
The specific activity dropped due to continued growth of E.coli Top10 
[pQR239]. The growth of E.coli (Expression of CHMO by E.coli was assumed 
to be taking place during growth on the spent fermentation medium.) on the 
spent fermentation broth resulted in a drop in the DOT due to increased 
cellular oxygen demand until DOT became limiting at approximately 250 
minutes.
As indicated in the shake flask experiments (Figure 3.13), the Baeyer-Villiger 
biotransformation is observed to proceed after re-suspension of the 
biocatalyst in the phosphate type medium. At the 2L scale operating the 
bioprocess at a low biocatalyst concentration in water and phosphate 
medium types (Figure 3.15) the whole-cell E.coli culture was not observed to 
grow. Consequently the DOT wasn’t limiting the rate of the biotransformation
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reaction at any point during the experiment. The maximum volumetric and 
specific activity of the whole-cell biocatalyst in phosphate buffer was 0.43 g.l'
1.h'1 and 0.39 g.l'1.h'1.gdcw'1 (3.1 pmol.min'Vgdcw'1). The maximum 
biocatalyst activity observed in phosphate buffer was two thirds that observed 
in the complex medium type. In contrast to the complex medium 
biotransformation profile (Figure 3.14) the period of maximum activity was 
maintained for only 175 minutes in the phosphate buffer after which time the 
volumetric activity dropped. The reduction in biocatalyst activity could have 
resulted from a loss of whole-cell viability. This is indicated by the rise in the 
DOT from 25 minutes, which suggests that the culture was not consuming
0 2 , an important reactant of the Baeyer-Villiger bioconversion.
Re-suspension of the cells in water medium yielded very little lactone and a 
short period of cell viability as indicated by the DOT (Figure 3.15). The 
rationale for using a water/ glycerol mix to undertake the biotransformation 
was that a simple medium type would allow for a controlled biocatalyst 
concentration and simplified reaction matrix on which to undertake near 
infrared spectroscopic sampling. The reaction does not proceed in the water 
medium type because the viability of E.coli Top10 [pQR239] is diminished 
under these conditions. Consequently the use of water as a 
biotransformation medium type was dismissed. Despite promising results in 
shake flasks (Figure 3.14), the biocatalyst performs best in terms of viability 
and activity when maintained in broth medium.
Media types are pictured in Figure 3.16 post clarification. There is a clear 
difference between all the types including the 2L and 7L spent broth types, 
despite the complex broth medium being identical in both cases. Spent broth 
from the 7L fermenter was distinct from that of the 2L. The fermentation 
process yields different biocatalyst concentrations (section 3.2.2.2) and this is 
reflected in the spent media constituents.
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Figure 3.13: Shake flask experiments on various biotransformation
media. Lactone produced (g/L) over time. (□) Spent fermentation broth. 
( )Spent fermentation broth (+) Defined. (A) Phosphate buffer, (o) 
Phosphate buffer with biocatalyst washing step.
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Figure 3.14 Profile of a low (1.5g/L dew) E.coli Top10 [pQR 239] 
biotransformation carried out in spent fermentation broth. (□) Lactone, 
(O) ketone, (x) d02, (O) Biomass.
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Figure 3.15 Profile of a low E.coli Top10 [pQR 239] concentration 
biotransformation profile carried out in buffer (A) and water (B) 
medium. (□) Lactone, (O) ketone, (■) Biomass, (A) DO2.
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Figure 3.16. Picture of various clarified biotransformation media types: 
(1) 7L spent fermentation broth; (2) 2L spent fermentation medium 
type; (3) phosphate buffer medium type; (4) defined medium type; (5) 
water medium type.
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3.3. Discussion
3.3.1. Biocatalyst Production
The production of the CHMO biocatalyst was by way of a 2L or 7L batch 
fermentation of E.coli Top10 [pQR239]. The expression of CHMO during the 
late log phase of growth achieved 230 to 250 U.g dew"1, which is 
approximately half of the 500 U.g dew'1, expression level previously reported 
for E.coli TOP10 [pQR239] (Doig et al., 2001). The results reported here are 
the average typical CHMO titre and not optimised expression levels. In 
addition to the operation of the bioreactor there are differences in the medium 
used and E.coli TOP10 [pQR239] strain variation that could account for the 
lower CHMO achieved. For example, Doig et al (2001) found the percentage 
of cells not harbouring the plasmid (pQR239) at the end of this fermentation 
to be approximately 10%; a lack of plasmid stability could be a contributing 
factor in this case. Further work to optimise cell banking, and the 
fermentation step is necessary to achieve higher CHMO titres. However, the 
fermentation step described was acceptable for the purpose of achieving a 
robust model biocatalyst to undertake the Baeyer-Villiger type oxidation.
The protocol for the 2L (1.5L working volume) fermentation was developed 
from previously published work (Doig et al., 2001). E.coli Top10 (pQR239) 
fermentation characterisation and scale-up studies (Doig et a!., 2003b) were 
carried out using a similar complex glycerol-based medium. Under the 
optimum growth and induction conditions, the final biomass yield was 5.5 
g.dcw.l'1 and the maximum specific activity was 0.9h'1. The protocol 
developed for this work was based on the work of (Doig et al., 2001) except 
for the fact that batch growth of E.coli Top10 [pQR239] culture was to 
approximately 4 g.l'1 at which point the heterologous expression of CHMO 
was induced over a 3 hour period. Using this method the final biomass yield 
was higher at 7.6 and 12 g.l'1 for the 2 and 7L fermentations respectively. 
The 7L (5.3L working volume) process was scaled-up from the 2L process 
with the key objectives being to achieve a similar final biomass concentration 
and CHMO titre. To achieve this it was necessary not to limit oxygen transfer
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to the culture. The DOT was therefore maintained above 5% during growth 
and near zero during induction. A near zero DOT during induction was 
achieved whilst maintaining the maximum OUR level during this period. To 
achieve the relevant DOT the agitation rate was carefully controlled by a PLC 
or manually adjusted as necessary.
Initially scale-up of agitation from the 2L to the 7L fermentation was achieved 
by maintaining tip speed profiles of 1.7 - 2.5 m.s"1 (appendix VII) since this 
method keeps agitator shear-forces constant (Doran, 1998). Similar agitator 
shear forces between scales were preferable since any change in the 
constituents of the fermentation broth (caused as a result of shear damage to 
cells) between batches would result in increased variance during subsequent 
biotransformation operations. However at constant tip speed, reduced 
oxygen mass transfer in the larger vessel was restricting culture growth (data 
not shown) such that growth of cells prior to induction was slower. As a 
result, scale-up entailed keeping fermentation profiles as similar as possible; 
this was achieved by following similar stirrer speeds and times as in the 2L 
vessel. Airflow rates were scaled up based upon volumes of air per volume of 
broth per minute (vvm) and equalled 0.67 w m  in both examples. All other 
reagents were scaled-up proportionally based on volume.
The 7L LH2000 fermenter has a larger aspect ratio but a lower ratio of vessel 
diameter to impeller diameter when compared to LH210_a. Consequently the 
larger fermenter would be expected to have improved mixing and mass 
transfer flows, which would contribute to improved growth characteristics. 
However, higher tip speeds were required at the large scale to achieve a 
similar specific growth rate and profile. An analysis of fermenter specification 
is given in Table 3.2, and indicates that the higher tip speeds encountered in 
LH2000 resulted in improved mixing (higher Reynolds number). It is the 
improvement in agitation which is responsible for the increased OTR (at the 
7L scale), observed indirectly from the OUR profile of the culture growth. 
However, an undesirable consequence is the increased specific power input 
which results in a 4 fold increase in the shear rate, as determined by the
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calculations given in appendix VIII. This increased shear rate does not seem 
to have adversely affected the cells.
The amount of extracellular protein observed for the 7 L fermenter was more 
than for the 2L; 0.25 mg.ml-1 in the 2L and 0.38 mg.l'1 in the 7L fermentation. 
This difference can be explained by the increased biomass concentrations 
achieved in the larger fermenter since the mean specific protein 
concentration is the same for both fermenter cultures at 0.03 g.gdcw'1. 
Regardless of which production scale is used to produce the biocatalyst the 
cells can be stored in the fridge for a period of 7 days before use.
Parameter LH210a LH2000
Volume (I) 1.6 5.3
Tip speed (m.s-1) at N = 
1000 rpm
2.1 3.3
Re (minimum) 2393 3556
PgA/ (maximum) (Wl‘1) 1.1 2.8
Shear rate (s'1) 476 1963
Table 3.2. Fermenter parameters were calculated from equations detailed in 
appendix VII and appendix VIII. It was necessary to assume broth density 
(1100 kg.m3), and the viscosity (0.01 Pa.s) of the fermentation medium.
3.3.2. The Model Biotransformation
Though the whole-cell bioconversion is possible in a number of media types 
a rapid loss of biocatalyst stability was observed when using phosphate and 
water medium. A loss of viability limits the period during which maximum 
activity can be maintained during a biotransformation reaction. Maintaining 
maximum volumetric activity is required if the yield of combined lactone is to 
be optimised. The whole-cell Baeyer-Villiger type oxidation was
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representative of other biotransformations in that the biocatalyst viability is 
diminished under operating conditions (Chen et af.y 2002). Maximum 
biocatalyst activity is limited to a period of 4 hours (Figure 3.7) under typical 
biotransformation conditions. It might be the case that an improvement of 
biocatalyst stability can be affected by a change in the operating conditions; 
for instance temperature. Nevertheless, there will be a finite period during 
which the process can be operated efficiently.
The model biotransformation is also constrained by both substrate and 
product inhibition. The effect of inhibition was demonstrated (Figure 3.11) 
during a bioconversion in a STR. The production of lactone peaked at 175 
minutes as ketone concentration reached inhibitory levels. This example 
used a strategy of continual feeding of the substrate. To develop the process 
a strategy of controlling the ketone feed so as not to over or under feed 
substrate to the reactor was proposed. This would eliminate the problem of 
substrate inhibition, and improve the yield of lactone produced per gram of 
substrate used. The model Baeyer Villiger biotransformation like many 
potentially important biotransformations cannot be implemented as 
economically viable processes because of low volumetric productivities 
(Cheetham, 1994). In many cases this constraint on the bioconversion is due 
to accumulation of product and or substrate during the bioconversion 
(Chauhan e ta /., 1997). In most cases, the biocatalyst may be inhibited by the 
reaction substrate and products at the biochemical level through a natural 
feedback mechanism aimed at controlling metabolic activity (Liese et al, 
1993). Substrate and product inhibition for the Baeyer-Villiger 
monooxygenase biotransformation model was previously described. The 
optimum ketone concentration was between 0.2 and 0.4 gl'1 and at product 
concentrations above 4.5 to 5gl"1 the specific activity of the whole cells fell to 
zero (Alphand etal., 2003).
The variation in yield of biocatalyst and therefore variation in constituents of 
the spent medium between fermentation scales will be transferred to any 
subsequent biotransformation step. Such variation is not desirable for 
monitoring by NIR spectroscopy. To limit these effects the cells can be
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resuspended in fresh biotransformation medium. Biotransformation medium 
exchange was expected to enable the concentration of biocatalyst, and 
glycerol to be controlled whilst reducing the variability of fermentation 
products including protein, dissolved in the medium. The results, however, 
indicated lower viability and activity of the biocatalyst in alternative media 
types, whilst at low concentration in complex medium E.coli Top10 [pQR239] 
was observed to grow. To minimise variation in biotransformation sample 
sets for NIR spectroscopic analysis the complex spent fermentation medium 
type was used, from either the 2 or 7L scales.
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3.4. Conclusion
•  E.coli Top10 [pQR239] biocatalyst production was undertaken at a 2L 
and 7L scales. The developed procedure included the batch growth of 
E.coli Top10 [pQR239] culture to approximately 5g.l'1 at which point 
the heterologous expression of CHMO was induced over a 3 hour 
period.
• Though both the 2L and 7L fermentation methods produced similar 
specific intrinsic CHMO concentrations, the total yield of cells and 
therefore yield of CHMO differed between scales.
•  The larger 7L scale fermenter required increased agitator tip speeds to 
achieve a similar DOT and cell growth profile. The increased tip speed 
meant greater power input, which contributed to a marked increase in 
the concentration of E.coli Top10 [pQR239].
•  Stored biocatalyst suspended in spent fermentation medium in a 
refrigerator at 4°C is stable for 170 hours without a reduction in the 
CHMO titre. The biocatalyst was shown to be stable under operating 
conditions for 4 hours after which a loss in CHMO activity was 
observed.
•  All routine biotransformations require glycerol as a reductant.
•  Baeyer-Villiger bioconversions of ketone to combined lactone were 
achieved using the method described in section 3.1.2. To maximise 
the volumetric activity of the biocatalyst, control of substrate feeding is 
required.
•  The model biotransformation was successfully carried out on a 
number of biotransformation media types. The complex medium type 
is considered the least favourable for NIR spectroscopic analysis but 
the most favourable for the biocatalyst in-terms of activity and viability.
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4. Near Infrared Spectroscopic Monitoring of the
Biotransformation
This chapter examined the application of NIR spectroscopy to monitoring the 
whole-cell Baeyer-Villiger biotransformation of a cyclic ketone to regio- 
isomeric lactone products. The NIR instrument was employed at-line (rapid 
off-line) and on-line (in situ). At-line analysis required samples to be 
withdrawn from the bioreactor before the sample contents (matrix) could be 
analysed. On-line analysis interfaced the analyser directly to the bioreactor 
contents (matrix) and as such, the bioreactor did not require samples to be 
withdrawn. The development of a NIR sampling method and subsequent 
calibration of spectra to the GC reference method was pursued through a 
feasibility study that examined spectral responses to known samples.
4.1. Materials and Methods
4.1.1. NIR Spectral Sampling
A fibre optic transmission immersion probe (FOSS UK Ltd, Warrington, 
Cheshire, UK), with a total path length of 1.5 mm was used for all at-line and 
on-line sample analysis. During on-line work, the probe was fitted to the 
head-plate of the reactor through a 20 mm port and was situated so that the 
cell-path was 3.0 cm from the reactor base. A Foss NIR systems model 6500 
visible/NIR spectrophotometer equipped with a halographic concave 
diffraction grating, and a lead sulfide (PbS) detector was used to measure the 
spectra (Figure 4.0). VISION software (FOSS UK) was used with a PC 
workstation to control spectra collection. On-line samples were ratioed to air 
background at regular intervals using 64 co-averaged scans per sample 
throughout the bioconversion process. At-line sampling required a 5 ml 
volume of broth to be removed from the reactor at regular intervals and 
immediately centrifuged at 10,000 rpm for 2 minutes (section 3.1.2.2) before 
NIR spectra (referenced to air) were recorded unless stated otherwise. 
Samples taken at-line consisted of 32 co-averaged scans, unless stated
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otherwise. Off-line spectra of lyophilised lactone1 were ratioed to a ceramic 
background using a Foss NIR systems reflectance probe.
Monochromator
Light source
m m % +-
Detector
Fibre optic 
transmission 
cable
:■ Transmission 
j  probe
On-line At-line
Figure 4.0 The NIR system for monitoring the bioconversion.
4.1.2. NIR Multivariate Calibration
NIR spectroscopy is an optical technique that involves measurement 
between the visible (700 nm) and the mid-IR (2200 nm) region. In 
quantitative NIR spectroscopy, empirical relationships (calibration models) 
are derived between the absorption (or transmission) of NIR radiation and the 
corresponding reference assays for the variable of interest. Calibrations 
between 2nd derivative (segment size of 20 nm and gap size of 0 nm) 
mathematically treated spectra and associated reference analytical data were 
produced using a partial least-square (PLS) approach. Calibration was 
undertaken in the 1550 to 1820 nm region of the electromagnetic spectrum. 
The PLS method employs factor analysis and then uses a subset of the 
resulting factors to complete the regression equation. The best possible 
regression models were achieved by a cross validation procedure optimising 
the number of factors such that either a minimum prediction residual error 
sum of squares (PRESS) is reached or the fewest factors required to achieve 
a standard error of calibration (SEC) similar to the associated gas
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chromatography standard error (Appendix IX). Cross-validation involved each 
calibration sample being dropped out of the calibration set, generating 
regression equations on the reduced calibration set and then subsequently 
predicting the value of the dropped standard (Chalmers et al., 1997). VISION  
2.22 software (FOSS UK Ltd, Warrington, Cheshire, UK) was used in 
conjunction with a PC workstation for the storage and reduction of all data. 
Using the regression models, quantitative predictions of variables were made 
on sets of unknown process samples.
4.1.3. Qualitative NIR Analysis
For qualitative analysis, data was displayed using VISION 2.22 software. The 
data matrix for any given spectra or 2nd derivative mathematically treated 
spectra was able to be exported from VISION 2.22 where necessary.
Spectral sample data from VISION 2.22 was exported as a text file to MatLab 
5.3 (Math Works, MA, USA) where the data matrix was transposed before 
exporting as an ASCII file.
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4.2. Results
4.2.1. Feasibility Study
The feasibility study was designed to provide information on the absorbances 
expected in the process sample matrix and to demonstrate that a quantitative 
analysis is possible. The process sample matrix of undefined 
biotransfomation medium type is highly complex and so it is not possible to 
scan all the ingredients in the mixture independently. However, by knowing 
the unique absorbance of the substrate and product material a focus on 
where in wavelength terms to perform the NIR analysis is provided. Spiking 
samples with analytes was used to provide a range of absorbances, which 
were used to check for NIR response linearity and accuracy. Finally, the 
feasibility study was used to decide on the regression method to be used and 
on how to present and take samples using the NIR system.
4.2.1.1. NIR Spectra of Substrate and Products
NIR absorption bands are associated with the overtone’s and combination 
bands of the -C H , -NH, and -O H  fundamental vibrational absorptions that 
occur in the mid-infrared region. The overlapping absorptions found in the 
NIR region are weaker in intensity than comparable mid-IR bands (Brimmer 
et al., 1996, Stallard, 1997). Thus, chemometric techniques are required in 
quantitative analysis of NIR spectra (Vaidyanathan et al., 1999b). The CHMO 
biotransformation was undertaken in aqueous fermentation broth, resulting in 
some relevant information being masked by strong water absorption bands 
as can be seen in Figure 4.1.
The substrate (ketone) was analysed using a NIR spectrophotometer fitted 
with a transmission probe. An enantiomer of the lyophilised lactone1 was also 
analysed using NIR spectroscopy fitted with a reflectance probe. The ketone 
and lactone1 spectra were compared to that of water as shown in Figure 4.1. 
Lactone1 is commercially available but the combined lactones ((-) 1 (S), 
5(R)2-oxabicyclo(3.3.0)oct-6-en-3one and (-) 1(R), 5(S) 3-
oxabicyclo(3.3.0)oct-6-en-2-one) are not. Lactone1 was therefore used during
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feasibility analysis to locate wavelength regions for calibration of the ketone 
and lactone. As the regio-isomers of combined lactone are distinct molecules 
with different physical properties, individual IR vibrational signatures would 
be expected. However, because the regio-isomeric disparity is only the site of 
oxygenation on the cyclic-ketone (Shipston et al., 1992) no distinction of 
these forms was made during NIR analysis. The NIR region contains first 
order, second order and combinations of fundamental vibrations occurring in 
the mid-IR region, resulting in broad overlapped spectral bands such that the 
spectra of lactone1 was able to provide a good indication of the wavelength 
region for combined lactone calibration.
The spectra of both the ketone and lactone1 (Figure 4.1) are similar with 
significant peaks in the first overtone region 1666nm, 1750nm, 1900nm and 
1950 nm. The combination band region also contains peaks including 2150 
nm and the region 2250-2300 nm. The majority of the vibrations result from 
CH - CH2 bond stretches that are common to both the ketone and the 
lactone. It was therefore apparent that selection of unique spectral features 
for calibration was not possible. It is because of the chemical complexity of 
the biotransformation processes and the lack of distinct spectral features of 
analytes that it is difficult to relate spectral variation observed in the broth 
spectra to changes in concentration levels of analytes (Arnold et al 2002). A  
multivariate partial least squares (PLS) method was therefore used during 
quantitative calibration development (Osborne e ta i,  2002). Distinctive peaks 
of water at 1450 nm and 1950 nm limit the wavelength region available for 
calibration. This is because the wavelength regions at which water absorbs 
result in overwhelming water absorption bands such that no or very little 
electromagnetic radiation in this region reaches the detector. In addition, the 
use of fibre-optics to facilitate on-line monitoring limits the calibration region 
further as the fibre-optic cable absorbs NIR radiation above 2200 nm. This is 
seen in Figure 4.1 as the absorption peak at 2400nm.
Since absorption of NIR rays by biotransformation medium is dominated by a 
water band, only the region of 1500 to 1850 nm, between the peaks was 
applied to the monitoring of ketone and combined lactone. To distinguish
123
further the absorption spectra of ketone and lactone1 the spectra in Figure 
4.1 was converted to the 2nd derivative (Figure 4.2). A 2nd derivative 
absorption spectra were used instead of raw spectra to reduce the effects of 
baseline differences (Brimmer et al., 1993) and to improve the resolution of 
distinctive wavelength features (Arnold et al. 2002). Figure 4.2 indicates 
differences between the ketone and lactone analytes absorption bands in the 
wavelength region 1650 to 1750 nm. It isn’t possible to precisely identify 
bands associated with the analytes of interest using Figure 4.2, as the 
absorption bands of the analytes in aqueous solution will differ from the 
corrseponding raw material (Osborne et al., 2002). However, the results 
enable a wavelength region to be assigned on which to develop quantitative 
calibration models.
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Figure 4.1 NIR reflectance spectra of lyophilised lactone1 (blue) 
referenced to a ceramic cell. NIR transmission spectra of ketone (brown) 
and water (red) referenced to air.
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Figure 4.2 A 2nd derivative NIR reflectance spectra of lyophilised 
lactone1 (blue) referenced to a ceramic cell. NIR transmission spectra 
of ketone (yellow) and water (red) referenced to air.
4.2.1.2. NIR Spectra Background
In order to identify the characteristic absorptions of the individual 
components in the biotransformation medium, the NIR spectra of a series of 
ketone, lactone and glycerol concentrations were collected. Glycerol was 
included since this was a major constituent of all biotransformation media 
types. Figure 4.3 shows the second-derivative spectra of ketone at a 
concentration of 1.3 and 13 gl'1 (12.0 & 120mM), lactone at 2.4 and 12 gl"1 
(19.2 & 96.0 mM), and glycerol at 15 and 30 gl'1 (161.3 & 322mM), 
respectively. The key features of the spectral region; 1600-1740nm are 
attributed to the C-H first overtone stretching vibration. The absorption at 
around 1654, 1678, and 1720 nm are mainly due to ketone. Two absorption 
regions were observed at around 1666 and 1702 nm, which depend on 
lactone. The absorption of glycerol was observed at 1700 nm.
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Fig. 4.3 The second derivative NIR spectra (referenced to water) of 
ketone, lactone and glycerol samples.
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4.2.1.3. Amplitude Response
Identification of absorption bands of interest associated with the analytes of 
interest was achieved by spiking lactone and ketone into the 
biotransformation matrix (section 4.2.1.2). This procedure was then used to 
investigate the linearity of the NIR response taking a wavelength value of 
1664 nm and 1678 nm for lactone (Figure 4.4) and ketone (figure 4.5) 
respectively. A plot of analyte concentration at the wavelengths of interest 
(Figure 4.6) describes a linear response in both cases with a standard 
deviation of 0.14 gl'1 for lactone and 0.13 gl'1 for ketone.
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Figure 4.4: A 2nd derivative NIR transmission scans of aqueous
lactone1 samples referenced with RO H20. Including: green = 0.625 gl' 
1; pale blue line = 1.25 gl'1; red line = 2.5 gl'1; yellow line = 5 gl'1; blue 
line = 10 gl"1.
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Figure 4.5: A 2nd derivative NIR transmission scans of aqueous ketone 
samples referenced with RO H20. Including green = 0.4 gl"1; pink = 0.8 
gl'1; dark blue = 1.6 gl'1; light blue = 2.0 gl'1; yellow = 4.0 gl'1. black = 
8.0 gl'1; red = 10 gl"1.
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Figure 4.6 (A): amplitude linearity of a 2nd derivative NIR signal at 1678 
nm for ketone. (B); amplitude linearity of 2nd derivative NIR spectra at 
1664 nm for lactone.
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4.2.1.4. NIR Response Time
Spectra were collected using a fibre-optic transmission probe (section 4.1) 
rather than a fixed cell. The advantage of using a transmission probe is that it 
can be positioned to sample either at-line or on-line. For each method, a 
sufficient number of sample absorption scans was co-averaged to obtain a 
suitable signal to noise level (accuracy) for quantitative monitoring. However, 
as the number of co-averaged scans increase so does the sampling time 
(Figure 4.7). At 1.5 minutes the sample time to co-average 128 scans is fast 
when compared to the 35 minutes to prepare and run a GC sample (section 
3.1.3.5). However, at-line NIR sampling involves removing a volume of 
process fluid from the reactor and clarifying it by centrifugation (section 4.1). 
The cell-free at-line sample is then presented to the NIR transmission probe. 
The time taken to sample and clarify an at-line sample took 4 minutes, in 
addition to the NIR spectral acquisition time. On-line sampling was achieved 
with the transmission probe in the reactor, so sampling was equal to the time 
taken to collect and co-average the required number of scans.
NIR monitoring of the biotransformation system was used to enable an 
improvement in biotransformation process control. To achieve this, the 
monitoring system needed to be both reliable and rapid. It was therefore 
necessary to collect sample spectra using an optimal method of sample 
presentation. For on-line sampling, increasing the number of co-averaged 
scans significantly reduced the standard deviation (SD) associated with the 
signal reproducibility (Figure 4.8). The optimum signal to noise ratio for on­
line sampling was calculated as being 64 co-averaged scans, giving a 
sample time of approximately 50 seconds. The at-line sample signal 
reproducibility was not significantly improved (Figure 4.8) and so to limit the 
total at-line sample time to <5 minutes, 34 scans were co-averaged. 
Nevertheless the signal reproducibility of on-line NIR analysis was not as 
accurate as that of at-line (Figure 4.9). A loss of signal reproducibility is 
evident when the on-line water spectra are compared to the at-line results 
(Figure 4.9b).
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Figure 4.7 NIR transmission scan time vs number of co-averaged 
scans.
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Figure 4.8 Increasing NIR scan number improves signal reproducibility. 
The mean SD was calculated between transmission spectra of water 
between 1550 to 1820 nm. (0) on-line in a STR at 37 °C with agitation, 
stirrer speed 800 rpm. (+) at-line sampling.
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Figure 4.9. (A): Four 2nd derivative transmission spectra of H2O 
sampled at-line. (B): Four 2nd derivative transmission spectra of H20 
sampled at-line and four 2nd derivative transmission spectra of FhO 
sampled on-line. Intensity of the NIR spectra has arbitrary units (III). 
On-line sampling was in a STR with aeration at 0.67 vvm.
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4.2.1.5. Profile of Fed-batch Baeyer-ViNiger Bioconversion
The results of a standard biotransformation experiment monitored using NIR 
transmission spectroscopy at-line is shown in Figure 4.10. The 20 samples 
were taken at intervals over a 3-hour experiment. The shape of the un­
processed spectra is of the solvent water (data not shown). The 2nd derivative 
of the same spectra over the identified wavelength region of interest for 
quantitative calibration (section 4.2.1.2) indicates a change in the spectra 
over time. However, the complexity of the biotransformation matrix and 
similarity of the analytes of interest have resulted in broad bands with no 
identifiable peaks associated with either ketone or lactone. The 
spectroscopically complex nature of the biotransformation matrix means that 
multivariate chemometric methods were chosen to translate these primary 
spectra into useful correlated quantitative models.
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Figure 4.10. At-line 2nd derivative NIR spectra profile of a series of 20 
biotransformation samples taken at-line and referenced to air -  
calibration wavelength region. T = time (h).
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4.2.2. Quantitative Analysis
The NIR spectral region is situated between the end of the visible spectral 
region at 700nm and the beginning of the fundamental IR spectral region at 
2500nm. Quantitative NIR spectroscopic empirical relationships (calibration 
models) were derived between the absorption (or transmission) of NIR 
radiation and the corresponding reference assays for the variable of interest. 
The calibration was then used to predict the properties of unknown process 
samples from the output of the NIR spectrophotometer. Both the construction 
and prediction stages are vital in the generation of calibration models for NIR 
(Osborne et al., 2002). This section reports the first example of the 
application of fibre-optic NIR spectroscopy for the monitoring of analytes at 
low concentrations during a whole-cell E.coli bioconversion (Bird et al., 
2002a). Calibration for substrate and product concentrations both at-line and 
on-line is discussed.
4.2.2.1. Quantitative PLS Model Building
Production of the whole-cell E.coli biocatalyst (Doig et al., 2001, Doig et al., 
2002) was by way of fermentation (section 3.1.1) prior to utilisation for 
bioconversion (section 3.1.2). In this example the Baeyer-Villiger reaction 
was undertaken in the fermentation broth. Any batch variation from the 
fermentation step was transferred to the subsequent bioconversion and 
resulted in increased batch to batch variation in the bioconversion step 
(section 3.2.1). Variation between three separate bioconversions was 
included in the calibrations, which incorporated 52-53 spectra taken both at- 
line and on-line. Calibration models were built for ketone and lactone using a 
PLS method (section 4.1.2). Predicted Residual Error Sum of Squares 
(PRESS) analysis was used to optimise the equations for number of principle 
component factors (Appendix IX).
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4.2.2.2. Calibration Wavelength Selection
Wavelength regions to be used during calibration of the process sample sets 
were selected by generating calibration models on a set of 23 samples 
spiked with ketone and lactone1. The wavelength region was expanded 
iteratively to improve the SEC. The region with the optimal SEC was chosen 
as the wavelength region of choice for PLS analysis on process samples. 
Figure 4.11 shows two results of this method during analysis of ketone and 
demonstrates how the SEC for ketone was improved by careful selection of 
the wavelength region.
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Figure 4.11. Parity plots of calibration model for ketone over 2 
wavelengths (A) 1550 -  1820 nm, (B) 1500 -  2100 nm. Models were 
constructed using 2nd derivative spectra of spiked water samples 
referenced to water, n = 23. Models are based on 3 factors. Model (A) 
SEC = 0.056 gl'1, (B) SEC = 0.172 gl'1.
4.2.2.3. NIR Calibration of the Model Biotransformation
Calibration of predicted and measured (gas chromatography) concentrations 
for lactone and ketone using data taken on-line from three bioconversions 
resulted in standard errors of calibration (SEC); equation A, 0.111 gl"1 (1.02 
mM) ketone (Figure 4.12) and equation B, 0.182 gl'1 (1.452 mM) lactone 
(Figure 4.13). Validating the on-line equations with a fourth, independent 
sample data set revealed SEP of 0.130 gl'1 (1.200 mM) ketone (Figure 4.12) 
and 0.177 gl'1 (1.425 mM) (Figure 4.13) combined lactone. The SEC of at- 
line spectra to gas chromatography data was significantly lower than on-line 
values with equation C, 0.074 gl'1 (0.689 mM) ketone (Figure 4.14) and 
equation D, 0.119 gl'1 (0.958 mM) lactone (Figure 4.15). Validation of at-line 
equations for ketone and lactone resulted in SEP of 0.088 gl"1 for ketone and 
0.101 gl'1 for combined lactone. Figure 4.16 and Figure 4.17 compare the 
predicted and measured concentration profiles for ketone and lactone. The 
calibration methods are outlined in Table 4.0 and the validation results in 
Table 4.1.
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Equation Analyte n
wavelength
(nm) Factors R2
SEC
(gi'1) F
A Ketone 53 1510-1800 4 0.955 0.111 254
B Lactone 52 1550-1820 4 0.952 0.182 240
c Ketone 52 1510-1800 5 0.983 0.074 522
D Lactone 52 1550-1820 3 0.979 0.119 728
Table 4.0: Calibration of NIR spectra to gas chromatography data. All spectral 
data was mathematically treated; 2nd derivative before PLS regression to build 
online equations A & B, and atline equations C & D. Three independent 
Baeyer-ViNiger biotransformation data sets were used to build equations. A 
fourth set was used to perform an external independent validation (Table 4.1).
Equation Sampling n SEP (gl'1) R2
A On-line 20 0.1296 0.907
B On-line 21 0.1767 0.967
c At-line 16 0.0875 0.957
D At-line 19 0.1095 0.991
Table 4.1: Validation of NIR calibration models was performed using an
external validation set that was independent of the calibration set.
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Figure 4.12. Concentration correlation plots. (A) Online ketone 
calibration equation A. SEC = 0.111 gl'1. (B) Prediction of unseen 
online data using equation A. SEP = 0.130 gl'1 external validation 
method.
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Figure 4.14 Concentration correlation plots. (A). At-line ketone 
calibration equation C. SEC = 0.074 gl'1. (B). Prediction of unseen at- 
line data using equation C. SEP = 0.088 gl'1, external validation 
method.
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Figure 4.16. 2L fed batch microbially catalysed Baeyer-Villiger 
bioconversion profile monitored using on-line NIR analysis.: Lactone: 
(■) on-line NIR, (□) gas chromatography, ketone: (♦) online NIR, (0) 
gas chromatography.
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Figure 4.17. 2L fed batch microbially catalysed Baeyer-Villiger 
bioconversion profile monitored using at-line NIR analysis.: Lactone: (■) 
at-line NIR, (□) gas chromatography, ketone: (♦) at-line NIR, (O) gas 
chromatography.
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4.3. Discussion
4.3.1. Feasibility Study
NIR spectra of spiked study samples and process samples were taken using 
a transmission immersion probe. A reflectance probe was used only to 
analyse a commercial lyophilised sample of Lactone1. A reflectance NIR 
accessory would have been inappropriate for process samples as it depends 
on diffuse reflectance being absorbed by the sample and re-radiated. Some 
radiation is absorbed and some is scattered back in the direction of 
illumination. Liquid systems will affect little diffuse scatter and so no useful 
information can be obtained (Foss, 1998). Reflectance NIR probes are 
typically used for qualitative analysis of biological products (Blanco et al., 
1999, DeBraekeleer et al., 1998, Herkert et al., 2001).
The path length of the transmission cell controls the amount of NIR radiation, 
which is absorbed by a given matrix (sample) and therefore the amount of 
radiation reaching the instrument detector. The FOSS NIR 
spectrophotometer is equipped with a holographic concave diffraction grating 
and a lead sulfide (PbS) reflectance detector module. A matrix that absorbs 
strongly NIR radiation can result in no radiation imparting on the detector; the 
detector is said to flood. This results in loss of analytical information from all 
or part of the ensuing spectra. The water peak of 1850-2050nm in Figure 4.1 
shows the detector flooding as the peak is shown to be flat. The correct path- 
length for the transmission cell should limit detector flooding whilst 
maintaining the absorber of interest below two absorbance units (S. Halsey, 
FOSS, personnel communication). To achieve a good response in the 
wavelength region of interest it was necessary to flood some parts of the 
spectrum in order to get extra sensitivity for the absorbance in the region of 
interest. With this in mind, a transmission path-length of 1.5mm was fixed for 
all at-line and on-line sampling.
The wavelength region of interest for quantitative NIR analysis of the 
analytes of interest was found to be 1550 to 1850 nm; the 1st overtone region 
of absorption. The NIR spectrophotometer was demonstrated to respond
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linearly in the concentration range of interest for lactone (Figures 4.4), and 
ketone (Figures 4.5). The collected sample spectra was referenced to water, 
not air, in this example so that any observable absorption differences due to 
analyte concentration within the spectral data set could be clearly identified. 
There was also found to be significant contribution by glycerol within this 
spectral region (Figure 4.3). The absorption of NIR radiation by glycerol 
meant that even in the simplest biotransformation medium; water, there were 
at least four absorbers in addition to any cellular biocatalyst components. 
Water as a biotransformation medium does not allow the reaction to proceed 
(section 3.2.2) unlike the more complex medium type. The undefined 
complex medium type contains many components many of which absorb NIR 
radiation in the wavelength region of interest. Since the contribution to 
intensity of wavelength variables is additive and the biotransformation matrix 
complex, a multivariate approach to quantitative calibration was chosen 
(section 4.1.2).
At-line samples were found to be more reproducible than on-line samples 
(Figure 4.8) but had the disadvantage of a longer sampling time (Figure 4.7). 
The absence of cells, agitation and aeration from the at-line sample removes 
a source of radiation scattering. Scattering of NIR radiation causes base-line 
shifts, which is attributable to the reduced reproducibility of on-line scans 
compared to at-line scans (Figure 4.9). Analysis of the sensitivity of the NIR 
instrument in both the at-line and on-line configuration was important since 
the sampling error is carried over into any multivariate calibration models.
The bioconversion medium included undefined medium of the preceding 
E.coli Top10 [pQR 239] fermentation with the batch addition of glycerol and 
fed-batch addition of ketone (section 3.2.2). Such a bioprocess sample is a 
highly complex NIR matrix containing numerous constituents. The on-line 
sampling environment also included biomass and sparged air, both of which 
cause scattering of NIR radiation. The baseline differences between spectra 
result from scattering of radiation. Conversion of spectra to the second 
derivative reduced these effects (Hall et al., 1996). As process sample 
spectra were presented as a ratio to air background (despite background
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spectral information being predominately due to water) the second derivative 
calculation also served to enhance weak spectral features. A common 
procedure both in the application of near and mid-IR is to remove 
background (water) information such that spectral information attributable to 
the constituents of interest is not swamped by bands associated with the 
solvent (Osborne et al., 2002). However, the spectrophotometer was more 
precise when a spectrum was ratioed to air rather than water. The standard 
deviation of intensity values between 2nd derivative spectra at 10 
wavelengths in the region of 1500-1700nm was 0.00559 for spectra ratioed 
to air and 34.43 intensity units for spectra ratioed to water (data not shown). 
The substantial increase in precision when spectra were ratioed to air can be 
explained by the fact that air is a stable background matrix compared to 
water.
Pollard and coworkers (Pollard et al., 2001) presented their mid-IR sample 
spectra as a ratio to water, as this was the major solvent in the fermentation 
broth. They were able to achieve very good precision using the major 
absorber as a background. The use of air as a background for the weaker 
NIR absorbance allows for increased instrument sensitivity. A major 
requirement of the background is stability. The background should be the 
same every time in order to reduce the addition of noise to the spectral data. 
The spectrum of water as it exists in the sample is likely to be not the same 
as pure water, due to the change attendant upon the interactions of the water 
molecules with the solute. The indirect analysis of sodium chloride by NIR is 
an example of this. Despite sodium chloride having no absorption bands 
whatever in the NIR, Hirschfeld, (1985) was able to measure the salinity of 
seawater indirectly by the shifts induced on the water bands by the dissolved 
salts.
4.3.2. Quantitative Analysis
The NIR region is ideally suited to the analysis of the biotransformation broth 
since the weak absorption of NIR energy by organic molecules enables direct 
spectral acquisition without dilution or the requirement of short optical path 
lengths (section 1.2).
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Fermentation broths are initially translucent matrices which progress to highly 
light scattering, opaque systems as the cells multiply. The Baeyer-Villiger 
biotransformation system described in section 3 occurs during the stationary 
phase of growth and so a gross change in the properties of the matrix due to 
fermentation does not occur. However the Baeyer-Villiger system utilises a 
viable whole-cell culture of E.cofi Top10 [pQR239] expressing CHMO to 
convert the cyclic ketone to the lactone product at low concentrations. That is 
concentrations of ketone <1.0 gl'1 and combined lactone <5.0 gl'1 (section 
3.2.2). NIR analysis of fermentation processes has involved monitoring 
analyte concentrations in multiple gram quantities and so instrument 
sensitivity is less of an issue (Riley et al., 2000). A biotransformation is the 
selective enzymic modification of a defined pure ketone into defined final 
products, whereas in a fermentation process the product is typically a 
metabolite produced by the growing cells from a mixture or material supplied 
to the culture. The substrate and product(s) in the model biotransformation 
are similar molecules (section 4.2.1) and so a sensitive technique is required 
to specifically analyse the compounds present in the complex 
biotransformation medium.
The absence of large changes in the sample matrix is favourable for NIR 
monitoring, although the low concentrations of the substrate and product are 
not. In addition, glycerol is consumed during the biotransformation together 
with medium components, which are utilised during cellular metabolism. 
Where large changes have occurred during a fermentation process, NIR 
monitoring has involved segmentation of the process based on time periods 
so that multiple NIR calibration models can be developed (Arnold et al., 
2003). Such an approach has enabled monitoring even where large 
rheological changes occur. Temperature, pH, viscosity and other process 
variables fluctuate during a biotransformation process. When IR spectra are 
measured on-line the fluctuations influence the shape of the spectra (Wulfert 
eta!., 2001).
The complexity of the NIR spectra of the broth samples makes it difficult to 
determine the association between the observed spectral features and
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concentration differences of the individual broth constituents (section 4.3.1). 
As NIR models are derived from the NIR spectra of unmodified samples, it is 
necessary to compensate for overlapping absorption bands, matrix effects 
and light scattering differences, which were all identified in the feasibility 
study. A variety of statistical regression techniques are available for deriving 
suitable spectroscopic models (section 1.2). PLS is one such technique, 
which can be applied to quantification of constituents whose spectral features 
are highly overlapped by bands of other matrix constituents. A robust PLS 
model will contain the fewest number of chemically relevant spectral factors, 
which provide a SEC that is of the same order of magnitude as the GC 
reference method used to derive the calibration algorithm. The number of 
PLS factors is critical to the success of the model since too few factors will 
not adequately model the spectroscopic data and too many factors will over 
fit the data set. This will increase the SEP calculated on unknown process 
data. A description of the principles used to select the appropriate number of 
factors is given in Appendix IX. For ketone monitored at-line, a 4 factor PLS 
regression model provided a correlation coefficient (R2) of 0.955 and an SEC 
of 0.111 g.l"1. The SEC achieved for ketone compares well with the standard 
error (SE) for the GC reference method; 0.04 g.l-1 (section 3.1.3). The 
optimum SEC of 0.18 g.l'1 for lactone at-line was achieved with 4 factors and 
compares to 0.07 g.l'1 for the GC reference method. NIR spectroscopic 
determination of acetate, ammonium, biomass and glycerol at-line in an 
industrial E.coli fermentation achieved SEC of 1.1 to 1.3 g.l'1 using 
multivariate calibration models (Hall et al., 1996). This level of accuracy was 
sufficient for fermentation analysis since the constituents of the data-sets 
varied as much as 68 g.l'1 for the biomass example. However, it is suggested 
(Doig et al., 2003a, Doig et al., 2003b) that ketone and lactone both inhibit 
the CHMO enzyme and so the biotransformation requires monitoring at 
concentrations of < 1 gl'1. It was therefore important to maximise the 
sensitivity of the NIR transmission technique.
Validation ensured that the derived spectroscopic models (Table 4.0) were 
representative of the ketone and lactone analytes under investigation and not 
unique to the three biotransformation batch data sets used to construct the
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models. So that validation data was independent of the calibration model 
data, a separate biotransformation data set was reserved for the validation 
work. The results of the validation given in Table 4.1 therefore demonstrate 
the ability of NIR spectroscopy to simultaneously generate immediate and 
accurate trend concentration data for ketone and lactone both at-line (Figure 
4.17) and on-line (Figure 4.16). The measure of accuracy of prediction (SEP) 
achieved near parity with the GC reference method (Figure 4.12 to Figure 
4.15) and this was similar to the SEC indicating optimal monitoring of 
analytes for this model.
The SEP is considered a reliable measure of performance of the calibration 
equation, but should be considered alongside the multiple correlation 
coefficient (R2). The correlation coefficient indicates a measure of the lack of 
error of the calibration, and for all the equations, the R2 values were greater 
than 0.95 indicating >95% of the variation within the data was modelled 
(Table 4.0). At-line models gave R2 values closer to unity (approximately 
0.98) than on-line models. On-line monitoring included biomass, agitation 
and aeration leading to light scattering, which produced spectral baseline 
offsets (Brimmer et al., 1993) (section 4.2.2.4). This variation explained the 
higher SEP values and lower R2 values. The robustness of the at-line system 
is further exemplified by the disparity between online and at-line F-values 
(Table 4.0). F-values give an indication of how well the accuracy of the 
calibration model (SEC) can be expected to hold up when unknown samples 
not included in the calibration are measured.
The independent validation of equations A-D (Table 4.1) by predicting 
unknown samples independent to the calibration sets indicated that the at- 
line NIR system is more accurate, as expected, at predicting values than the 
on-line method (Table 4.2).
The characteristics of at-line and on-line monitoring are given in section 1.2. 
Disadvantages of at-line monitoring include the increased response time (5 
minutes) and the requirement for sampling of the reactor. A decision on the 
most appropriate sampling method (at-line or on-line) for NIR analysis of the 
Baeyer-ViNiger bioconversion would therefore have to include, in addition to
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control accuracy requirements, the response time required to maintain 
control within defined threshold values. There is an interest here to monitor 
the ketone and lactone at low concentrations so that strategies can be 
implemented to remove the effect of inhibition of the biocatalyst by the 
substrate. The at-line method would allow process monitoring at sub mM 
levels whilst on-line monitoring is less accurate but significantly quicker.
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4.4. Conclusion
•  This work has indicated that NIR spectroscopy can be applied to 
monitoring whole-cell biocatalytic reactions at-line and on-line.
•  NIR has been applied to monitor simultaneously analytes at low 
concentration demonstrating the utility of NIR for control of 
bioconversion processes, which are characterised by inhibitory and or 
toxic substrates or products.
•  At-line sampling was significantly quicker than the reference technique 
used to monitor the Baeyer-Villiger reaction and is accurate enough to 
detect mM quantities of the substrate and product.
•  The ease of rapid monitoring on-line provides the potential for 
intelligent control strategies to be applied to bioprocesses with rapid 
reaction rates.
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5. Bioprocess Monitoring and Control Using NIR
In this chapter, the development of the baeyer-Villiger process through the 
implementation of a rapid NIR monitoring and control strategy is described. 
The stereoselective biotransformation represents an important technology for 
the production of chiral chemical products and intermediates. The reaction is 
characterised by inhibition of the biocatalyst at useful substrate and product 
concentrations. Control strategies that minimise issues of biocatalyst 
inhibition require rapid monitoring of the substrate and products. NIR 
spectroscopy was used to monitor the biocatalytic process and facilitate a 
control strategy, which resulted in a productivity gain. The design and 
implementation of the monitoring and control strategy was directed by a 
bioprocess model that served to establish a systematic approach to 
development.
The NIR monitoring technique achieves rapid and simultaneous quantitative 
analysis of ketone and lactone concentration (section 4). The at-line 
approach was more accurate than on-line analysis (section 4.3.2). However, 
on-line analysis benefited from a significantly faster sample time. This is 
because unlike the at-line method there was no requirement for withdrawing 
and preparing samples for analysis. This chapter details a method to improve 
the accuracy of the on-line NIR method.
5.1. Materials and Methods
All materials and methods have been previously described in section 3.1 and
4.1. All biotransformation sample data generated for the NIR models in 
section 5.2 was generated using the 2L fermentation method (section
3.1.1.3.1). For section 5.3 and 5.4 the 7L E.coli TOP10 [pQR239] 
fermentation method was used (section 3.1.1.3.2). NIR sampling was by the 
at-line NIR method (section 4.1.1), which consisted of thirty-two co-averaged 
scans of each sample being ratioed to thirty two co-averaged scans of air. 
Multivariate PLS calibration models were constructed on the resulting data as 
described (section 4.1.2). To achieve accurate, precise and robust NIR
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measurements the same at-line sampling method was used followed by 
manipulation of the spectral data to the second derivative of the absorption.
In section 5.3 and 5.4 the biocatalyst concentration in the spent broth 
medium was manipulated by diluting a concentrated suspension of 
biocatalyst with supernantant of the fermentation broth. The concentrate and 
supernatant were produced by microfiltration. The concentration of E.coli 
TOP10 [pQR239] in the fermentation broth was increased to between 17-19 
g.dcw.l"1 by microfiltration. A ProFlux®M12 microfiltration rig (Millipore 
Corporation, Bedford, MA, USA) fitted with a 0.1m2 Durapore PVDF cassette 
membrane and holder (Durapore, Pellicon 2 mini, Millipore (UK) Ltd, Watford, 
UK). The membrane had a molecular weight cut-off of 0.22 pm.
5.2. Results
5.2.1. NIR Directed Control of the Biotransformation
In this section, the development of the Baeyer-Villiger process through the 
implementation of a rapid monitoring and control strategy is described. The 
reaction is characterised by inhibition of the biocatalyst at useful substrate 
and product concentrations (section 3.2.2). Control strategies that minimise 
the issues of biocatalyst inhibition require rapid monitoring of the substrate 
and products. NIR Spectroscopy was used to monitor the biocatalytic 
process and facilitate a control strategy, which resulted in a 30% volumetric 
productivity gain. The design and implementation of the monitoring and 
control strategy was directed by a bioprocess model that served to establish 
a systematic approach to development.
In order to achieve the most robust and accurate NIR monitoring system the 
at-line method of sampling was used.
5.2.1.1. At-line NIR Calibration Model
At-line NIR calibration models were produced (3 in total), all containing 
spectra taken from 7 bioprocess batches (Table 5.0). The calibration models 
for combined lactone contained 158 samples taken from the 7
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biotransformation processes. The calibration curve for the evaluation of 
ketone (Figure 5.0) has a SEC of 0.088 gl‘1 and a correlation coefficient (R2) 
of 0.89. Calibration of the lactone data (Figure 5.1) achieved SEC values of 
0.098 and 0.116 gl"1, which are comparable to the previous at-line model 
(Table 4.0). The SEC was achieved on a larger data set. This affected the F 
value, which at 3704 (Table 5) is significantly increased compared to the 
results given in Table 4.0.
Model n wavelength (nm) Factors R2 SEC (g.l-1) F
Lactone (1) 158 1550-1820 3 0.988 0.098 3704
Lactone (2) 174 1550-1820 4 0.988 0.116 3169
Ketone (3) 144 1590-1800 5 0.89 0.088 226
Table 5.0: Calibration of at-line NIR spectra to gas chromatography data. All 
spectral data was mathematically treated; 2nd derivative before applying PLS 
regression to build at-line equations. Seven independent Baeyer-Villige 
bioconversion data sets were used to build equations.
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5.2.1.2. Spiked At-line NIR Calibration Model
In addition to the 158 biotransformation samples, calibration model 2 (Table
5.0) contained 16 spectra taken from samples spiked with the commercial 
lactone1. This enabled the lactone concentration range to be extended from 
2.8 to 4.2 gl'1 (Figure 5.2). Since neither of the lactone regioisomers 
produced during the stereoselective Baeyer-Villiger oxidation of ketone were 
available commercially, lactone1 was used to spike the samples. The spiked 
model (model 2) had a SEC of 0.116 gl'1, which was achieved using 4 PLS 
factors. The extra calibration factor and higher SEC compared to model 1 
resulted in a lower F factor rating of 3169.
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Figure 5.2. Concentration correlation plot for lactone (spiked) at-line. 
SEC = 0.116 gl'1 Lactone calibration B.
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5.2.1.3. At-line NIR Monitoring and Control
Applying the calibration models (Table 5.0), the NIR spectrophotometer was 
used to measure simultaneously the concentrations of ketone and combined 
lactone at-line during a Baeyer-Villiger biotransformation experiment. The 
quantitative data generated using the NIR monitoring system was used to 
control the feed of ketone to the bioreactor to maintain the substrate 
concentration below inhibitory levels (<0.5 gl'1). The models were later 
validated to establish the accuracy and robustness of the calibration models. 
Validation was as before (section 4.3.2), comparing the NIR data to GC 
reference data. The SEP is used to measure the accuracy of the NIR 
monitoring system. The SEP for ketone was 0.073 gl"1 (Figure 5.3, Table
5.1), which is similar to the SEC (Table 5.0) and so optimal for this calibration 
model. The results for the two lactone models differ markedly, with SEP of 
0.223 and 0.118 gl"1 for model 1 and model 2 respectively (Figure 5.4, Table
5.1). The monitoring of the biotransformation using model 3 to quantify the 
ketone concentration at-line resulted in the control of the substrate below 
inhibitory levels. Under these conditions, a final lactone concentration of 3.6 
gl"1 was achieved (Figure 5.5).
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Model Concentration 
range gl'1
Number of 
spectra in model
SEP (gl'1)
Lactone (1)
00c\iIo 158 0.223
Lactone (2)
olo 158 + 16 spiked 0.118
Ketone (3) 0 - 1 . 0 144 0.073
Table 5.1 Quantitative NIR calibration models were built for prediction of 
reactant ketone and the product lactone during a microbially catalysed 
Baeyer-Villiger bioconversion. The ability of each model to predict 
unknown at-line samples taken from an independent biotransformation 
is indicated by the standard error of prediction (SEP).
Validation batch : NIR predicted vs GC measured
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Figure 5.3. NIR calibration model validation: ketone at-line monitoring. 
SEP = 0.073 gl'1.
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Figure 5.5. Profile of a E.coli Top10 [pQR 239] biotransformation 
process monitored and controlled using NIR spectroscopy: Ketone: ( • )  
at-line NIR, ( • )  gas chromatography. Lactone: (O) at-line NIR, (O) gas 
chromatography. The ketone was fed into the reactor by way of a 
peristaltic pump, using the NIR profile to effect supervisory control.
164
5.2.2. On-line NIR: Membrane Covered Transmission Cells
The ability to monitor the whole-cell Baeyer-Villiger oxidation of ketone to 
combined lactones has been demonstrated at-line and on-line using NIR 
(section 4.0). The NIR monitoring technique achieves rapid and simultaneous 
quantitative analysis of ketone and lactone concentration. The at-line 
approach was more accurate than on-line analysis. However, on-line analysis 
benefited from a significantly faster sample time. This section details a 
method to improve the accuracy of the on-line NIR method.
During the development of a calibration model enough samples are included 
to capture the process variation (Arnold et al., 2002). Where process 
samples are not available spiking can be used to improve calibration (section
5.2.1). During on-line calibration model development NIR sampling occurs 
approximately every one minute. Off-line sampling for GC analysis occurred 
approximately every 10 minutes. This meant only 1 in 10 NIR samples were 
used during calibration model development. In order to improve an NIR on­
line calibration model GC reference data was interpolated increasing the 
available number of NIR samples for calibration. This extends the initial 
calibration data set leading to a more economically effective development 
method.
The onlinememb technique involved sampling on-line in transmission mode. 
The transmission cell was covered by an absolute 0.4 pm rated membrane 
fabricated to fit the probe (section 5.1). The results of 7 sequential water 
samples taken on-linememb and at-line is depicted in Figure 5.6. The on-line 
NIR spectra can be visually distinguished from the at-line spectra, however 
the 7 individual samples of each sampling method have a similar SE. The SE 
for at-line and onlinememb analysis was 2.6x1 O'4 III and 3.2 xIO-4 III 
respectively. This contrasts significantly to on-line analysis (Figure 4.9) where 
a membrane is not used. The SE for this samples method was 8.0 xIO*4 IU.
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Figure 5.6. NIR 2nd derivative transmission spectra of H20 sampled at- 
line (red) and on-linememb over the wavelength calibration region. 
Intensity of the NIR spectra has arbitrary units (III).
A whole-cell Baeyer-villiger biotransformation process was sampled using 
NIR onlinememb, NIR at-line sampling and GC. The results of this single 
biotransformation experiment were used to generate NIR calibration 
algorithms using the method described in section 4.1.2.9. Unlike previous
calibration models, only 1 biotransformation sample data set was acquired.
Calibration models were developed on a proportion of the at-line and on- 
linememb experimental data set for ketone (Table 5.2) and lactone (Table 5.3). 
The remainder of the data set was reserved for model validation. For the 
onlinememb method the calibration data set was artificially expanded by 
interpolating the GC reference data set. The results of this interpolation are 
shown in Figure 5.7. This enabled calibration equations K3 and L3 to be 
developed using previously unusable NIR sample data. The results of the 
calibration experiments are given in Table 5.2 and 5.3.
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Equation Sample
method
n - 
calibration
Factors R2 SEC F
K1 At-line 28 5 0.99 0.062 309
K2 Onlinememb 29 5 0.97 0.085 156
K3 Onlinememb
extended
135 6 0.97 0.083 584
Table 5.2: Comparison of NIR calibration methods for ketone analysis. 
Wavelength region for calibration, 1590 -  1800nm.
Equation Sample
method
n - 
calibration
Factors R2 SEC F
L1 At-line 27 4 0.99 0.093 333
L2 Onlinememb 28 5 0.98 0.091 247
L3 Onlinememb
extended
135 6 0.98 0.090 1071
Table 5.3: Comparison of NIR calibration methods for lactone analysis. 
Wavelength region for calibration, 1550 -  1820nm.
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Figure 5.7. A Baeyer-villiger E.coli Top10 [pQR 239] biotransformation 
analysed by GC for ketone (•) and (A ) lactone. GC data was 
interpolated (ketone (+) and (O) lactone) expanding the number of data 
points that could be correlated to the results of NIR onlinememb analysis.
An internal method for validating the calibration models was used since all 
the sample data was the output of 1 biotransformation experiment. All 9 
validation samples were removed from the model data set prior to calibration 
and the validation samples were chosen to be within the concentration range 
of ketone and lactone described by the calibration data set. These enabled 
predictions to be made for the purpose of validation where the data values 
lay within the variability of the model developed.
For both ketone and lactone analytes the SEP of validation was lowest for 
the at-line method; 0.06 and 0.11 gl'1 for ketone and lactone respectively. 
Prediction of validation samples online were significantly improved using 
equations K3 and L3 which were developed using the expanded data set. 
The improved SEP and correlation between GC (including interpolated data) 
and NIR predictions pertain a similar accuracy to that of the at-line sampling 
method; 0.12 and 0.15 gl'1 for ketone and lactone respectively.
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Equation Sample
Method
n - validation R2 SEP
K1 At-line 9 0.99 0.062
K2 Onlinememb 9 0.94 0.153
K3 Onlinememb
extended
9 0.98 0.118
Table 5.9: Validation of NIR calibration methods for ketone analysis. An 
internal validation method was used.
Equation Sample
Method
n - validation R2 SEP
L1 At-line 9 0.99 0.114
L2 Onlinememb 9 0.86 0.43
L3 Onlinememb
extended
9 0.99 0.149
Table 5.10: Validation of NIR calibration methods for lactone analysis.
An internal validation method was used.
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5.2.3. Bioprocess Development Through Process Model Validation
Industrial implementation of biological catalytic reactions has thus far been 
restricted due to a variety of factors, including a lack of process engineering 
models. The aim of this work was to develop quantitative and predictive 
models to evaluate process performance, with particular emphasis on the 
effects of biocatalyst concentration and process design improvements which 
could then be used to help define process limitations and guide further 
experimental research.
The whole-cell CHMO catalysed Baeyer-ViNiger oxidation of ketone to regio- 
isomeric lactones using E.coli Top 10 [pQR239] was modelled in a study at 
UCL (Doig et al., 2003a). The model used process inputs of product and 
substrate inhibition data, oxygen mass transfer data, and stoichiometric & 
kinetic assumptions. The outputs of the model were product evolution rate, 
final yield on biomass and reaction completion time.
The modelling work was carried out as part of a research study at the 
Advanced Centre for Biochemical Engineering, UCL and is reproduced in 
part here with the permission of the authors (Doig etal., 2003a).
5.2.3.1. Modelling
In the development of the process models several assumptions about the 
process, kinetics and stoichiometry were made:
• Typical maximum oxygen transfer rates in stirred tank fermenters are 
between 50 and 150 mmol.I'1.h'1, (Atkinson etal., 1983) in the model a 
figure of 85 mmol.I'1.h'1 was used to describe the mass transfer limited 
volumetric reaction rate.
•  For the stoichiometry of lactone production it was assumed that the 
experimentally determined ratio of 6.91 mole O2 : 1 mole lactone, 
measured using 5 gl'1 biocatalyst, is valid at all other biocatalyst 
concentrations (Doig et al., 2001).
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•  The inhibitory effect of product is not dependent on the biocatalyst 
concentration.
Based on these assumptions, the oxygen transfer rate limiting volumetric 
activity (R, g.r1.min'1) was calculated according to the stoichiometry shown in 
Equation 5.0;
R = - ^ — x — ——  (Equation 5.0)
1000 6.91x60
where M = 124 is the molecular weight of product. The mass transfer limiting 
product formation rate is 1.53 g.l'1.h"1. This rate is similar to the experimental 
results reported in section 3.3.2.2.
Artificial neural networks (ANNs), which can map nonlinear relationships, 
were used to model the specific biocatalyst activity, as a function of product 
and substrate concentrations. Data previously collected at 20ml and 1 litre 
scales (Doig et al., 2001) was used. This data was normalised between 0 
(min) and 1 (max) and then divided into two groups: input -  product and 
substrate concentrations, and output -  residual biocatalyst activity. The 
methodology used for the ANN is given in (Doig et al., 2003a). The work 
carried out to develop the ANN was by Dr.B.Chen of UCL’s Advanced centre 
for Biochemical Engineering. Figure 5.8 shows the comparison of the 
resultant simulation of the trained ANN with the experimental data.
A three term polynomial function was used to approximate the time 
dependent stability of the whole-cell biocatalyst. The approximation has the 
form of function shown in section 3.2.1.3 (Figure 3.7).
Together with the model of specific biocatalyst activity, as a function of 
product and substrate concentrations, the stability expression was used to 
predict product evolution profiles. Figure 5.9 shows the predicted 
biotransformation time course using biocatalyst concentrations ranging from 
11 to 1790 U.l'1 (0.2 to 32.5g dew.I-1). Also shown on this figure is the oxygen 
limiting product evolution rate of 1.53 g.l"1.h'1.
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The ability of the process model to investigate a number of scenarios for the 
Baeyer-Villiger oxidation directed further validation bioconversions, where the 
biocatalyst concentration was increased after microfiltration. Validation of the 
model required the controlled feeding of the ketone to the reactor using near 
infrared spectroscopy to monitor and control the substrate concentration. 
This method of monitoring and control has been described previously (Bird et 
al., 2002b).
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Figure 5.8 E.coli Top10 [pQR 239] modelled product inhibition. (0) 
experimental data derived at 1 gl'1 ketone over range of combined 
lactone concentrations, (— ) fitted curve. (Doig et al., 2003a)
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Figure 5.9 Baeyer-Villiger E.coli TopIO [pQR 239] biotransformation, 
modelled product evolution -  effect of [biocatalyst] on product evolution 
profile and accounting for product inhibition. The tangent depicts the 
oxygen limiting product evolution rate of 1.53 g.l'1.h'1
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5.2.3.2. Biotransformation Operating Modes
The at-line NIR technique was applied to the monitoring and control of 
biotransformation experiments with the purpose of testing process model 
assumptions given in section 5.2.3.1.
The fed-batch biotransformation can be operated in a number of ways. NIR 
spectroscopy was used to monitor and control the ketone concentration in 
the reactor, as shown in Figure 5.10. In this example, the ketone 
concentration is maintained below a control threshold of 1.0 gl"1 ketone. The 
formation of lactone under these conditions is linear yielding 5.1 gl'1 lactone 
on completion of the experiment at 300 minutes. The ketone concentration at 
300 minutes is 0.56 gl'1.
Alternatively, where the concentration of ketone was allowed to rise above 
the 1.0 gl'1 threshold, a loss of biocatalyst activity is observed (Figure 5.11 A). 
A subsequent reduction of the ketone concentration was not matched by a 
recovery in the reaction rate. At 300 minutes, the lactone and ketone 
concentrations were 4.3 and 0.5 respectively. Stopping the ketone 
concentration prior to the threshold limit and allowing the remaining ketone 
concentration to be exhausted resulted in the biotransformation terminating 
at 200 minutes at a lactone and ketone concentration of 4.0 and 0 gl'1 
respectively (Figure 5.11B).
The maximum rates of product formation for profiles A and B in Figure 5.11 
are similar at 1.5 and 1.3 g.l'1.h'1 respectively. The biocatalyst material used 
for the experiment depicted in Figure 5.11 was the same, although profile A 
had double the biocatalyst concentration. This suggests that the 
biotransformation reaction was not being limited by a low biocatalyst 
concentration, and the process model (section 5.4.1.1) suggests this is due 
to limiting oxygen mass transfer. In contrast, the profile in Figure 5.10 has a 
maximum product formation rate of 1.0 g.l'Vh'1. The biocatalyst material used 
in this experiment (Figure 5.10) was from a different fermentation batch to 
profiles A and B (Figure 5.11). The lower product formation rate cannot be 
explained by a lower biocatalyst concentration (350 Ul'1). However, it is
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possible that poor expression of the CHMO gene due to process deviations 
in the fermentation step resulted in a lower specific activity on this occasion.
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Figure 5.10.. Profile of a fed-batch E.coli Top10 [pQR 239] 
biotransformation, biocatalyst with NIR substrate feed-control. (□) 
Lactone. (O) ketone. (—) Upper ketone threshold.
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Figure 5.11. Profile of a fed-batch E.coli Top10 [pQR 239] 
biotransformations: (A) biocatalyst concentration 288 U/L where 
substrate concentration is allowed to reach inhibitory levels (> 1 gl"1) 
and (B) biocatalyst concentration 519 U/L where substrate monitoring 
and control fails and substrate concentration decreases to 0 gl'1. (□) 
Lactone. (O) ketone. (-■-) Upper ketone threshold.
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5.2.3.3. Volumetric Activity and Biocatalyst Concentration
The process model assumes the oxygen transfer rate to the reactor limits the 
volumetric activity. This assumption was tested by investigating the effect of 
changing biocatalyst concentration on the volumetric activity. So that the 
ketone concentration was neither exhausted or inhibiting the biocatalyst NIR 
at-line monitoring was used to control ketone feed rate. Seven reactions were 
run at biocatalyst concentrations between 1g.dcw'1.l'1 and 20 g.dcw"1.!'1. The 
required concentrations were achieved by diluting a concentrated 
fermentation broth sample with spent clarified medium (section 5.1). The 
initial specific activity was found to be linear over a region of approximately 
100 minutes for all 7 reactions. Figure 5.12 shows the lactone evolution rate 
of the 500 U/L (12 gl'1) reaction and a reaction run at 99 U/L (1.3 gl'1) at 
points free from substrate inhibition or limitation. The lower biocatalyst 
concentration reaction (1.3 g.l'1) clearly has a lower initial volumetric activity,
95.2 pmol rriin'1!'1 whilst the activity per gram has increased to 73.2 pmol min' 
1g'1. Plotting the initial volumetric activity against biocatalyst concentration 
(Figure 5.13) a maximum activity is observed, which is related to a mass 
transfer limiting product formation rate of 205 pmol/min/L. In the model a 
figure of 85 mmol.I'1.h"1 was used to describe, the mass transfer limited 
volumetric reaction rate.
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Figure 5.12 . The initial volumetric rates of activity at biocatalyst 
concentrations of (x) 99 UL~1 and 500 III'1.
220 
200 
180 
|  160 
O 140
<3 120 
£* 100
o
<
JQo
80
T3 
0) 60 
£
S 40
i I 
I
20
200 400 600 800 1000
Biocatalyst concentration (U T 1)
Figure 5.13. Baeyer-Villiger E.coli Top10 [pQR 239] biotransformations 
at various biocatalyst concentrations. Volumetric biocatalyst activity 
against biocatalyst concentration. Dashed line indicates a mass 
transfer limiting product formation rate of 205 pimol.min'1.L"1.
179
5.2.3.4. Specific Activity and Biocatalyst Concentration
The effect of increasing the biocatalyst concentration has a dramatic effect 
on the specific activity of the biocatalyst (Figure 5.14). This implicates the 
optimisation of the bioprocess for product on biocatalyst given that the 
biocatalyst has a defined stability. Stability is given as 450 minutes in the 
process model.
The biocatalyst concentration (U.l"1) was calculated based on the reaction run 
at 1.3 gl' 1 biocatalyst since it was found that this reaction was not limited by 
feed or oxygen mass transfer. The dissolved oxygen tension throughout the 
experiment was around 60 % rising to 80% at a point when the reaction 
became substrate inhibited, whereas all other reactions had a dissolved 
oxygen tension of zero.
The biocatalyst concentration was then calculated using this initial lactone 
evolution rate over its linear range and multiplied by biomass concentration 
for each reaction to provide the concentration in U.l'1. This can be seen in 
equation 5.1 below, where Rx is the lactone evolution rate for reaction x in 
pmol.min'1.!'1, R1.3 is the unlimited lactone evolution rate per gram of 
biocatalyst and is equal to 73.2 |imol.min"1.g' 1 and [biomasst]x is the 
biocatalyst concentration of reaction x in g.l'1.
Equation 5.1
Rx ~R\3g r 1 x \b i°ccttalyst~\x
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Figure 5.14. E.coli Top10 [pQR 239] 2L biotransformations at various 
biocatalyst concentrations. The specific activity of the biocatalyst 
depends on biocatalyst concentration.
5.2.3.5. Bioprocess Performance and Process Model Validation
The process model was validated against bioconversions controlled by NIR 
spectroscopy. The lactone profile process-model prediction vs experimental 
data for a bioconversion with 690 Ul'1 (13 g dew) of biocatalyst present is 
shown in Figure 5.15. Figure 5.15 indicates that the model is accurate up to 
3.5 gl'1 of combined lactone product, a point that coincides with the model’s 
predicted drop in cellular activity i.e. 150 minutes into the experiment.(Figure 
3.7) However at lactone concentrations above this point parity between the 
experimental and model predicted data was lost.
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Figure 5.15. Parity of lactone profile: process-model prediction vs 
experimental data for a bioconversion with 690 UL'1 (13 g dew) of 
biocatalyst present. The experimental data shown is representative of 
one of three bioconversions that were run at cell concentrations 
between 13.0 and 19.0 g dew.I'1.
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5.3. Discussion
5.3.1. Accurate and Robust NIR Calibration
A key element in the design of any calibration model is that of accuracy and 
robustness. The quantitative model developed is required to contain enough 
of the process variability that is to be expected when running the process 
(Ciurezak et al., 2001). The matrix for NIR sampling of the biotransformation 
is the broth of the preceding fermentation and so the model is required to 
capture batch to batch variation introduced from both the fermentation and 
the biotransformation steps. If spent broth medium is replaced with another 
medium type this variation can be controlled. However, using an alterative 
medium type had an adverse effect on the biocatalyst stability and activity. A 
difficulty in calibration model building is knowing when enough samples are 
taken to ensure enough of the process variation is captured.
To alleviate this problem process variation was kept to a minimum. 
Fermentation processes used to produce the biocatalyst were fixed, in this 
example (section 5.1) only biocatalyst from the LH210 fermentor was used 
(section 3.1.1.3.1) and the reactor was tightly controlled (section 3.2.2). 
Including samples from 7 Representative biotransformation experiments 
provided data for the PLS calibration of ketone and lactone to the GC 
reference data. The results (Table 5.0) generated models of sufficient 
accuracy for monitoring the analytes with the purpose of controlling the 
ketone concentration below the inhibitory level of 0.5 g.l"1. The number of 
samples (and batches) required to achieve a predictive model for process 
control was partly intuitive. However, the calculation of the F factor from the 
results provided a level of confidence since this statistic (Appendix IX) 
indicates robustness. Calibration models containing a large numbers of 
samples and which demonstrate the required accuracy (SEC) with the fewest 
factors scores a higher F statistic. A high F statistic indicates robustness. The 
ketone model in Table 5.0 has a low F statistic because of the increased 
number of factors used in the PLS model. The models containing sample 
data from 7 batches (Table 5.0) were therefore considered more robust than
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those containing process samples (and therefore variation) from 3 batches 
(Table 4.0).
The utility of the monitoring system was demonstrated during a bioconversion 
where samples were withdrawn every 10 minutes for analysis by NIR. 
Monitoring allowed the ketone concentration to be maintained below the 
inhibitory levels defined by the bioprocess map. Substrate feed control was 
achieved by intermittent pump feeding (Figure 5.5). Operation of the process 
with monitoring and control resulted in 3.6 gl'1 of lactone. This represents a 
30% improvement in productivity compared to continuous fed-batch 
operation, where substrate inhibition curtailed the biotransformation at 
reduced lactone yields (Bird et al.} 2002b). Analysis of the process samples 
using the gas-chromatography reference assay confirmed the result and 
enabled calculation of standard errors of prediction for each NIR calibration 
model. The ketone SEP (Table 5.1) was sufficiently low (0.073 gl"1) to allow 
the ketone concentration to be maintained within a 0.5 -  0.75 gl'1 threshold 
range. The spiked lactone method resulted in a significantly lower prediction 
error compared to the lactone model (1). Improved prediction with the spiked 
calibration model was due, in part, to the calibration data-set representing 
more closely the changes expected in the process matrix. This results in the 
prediction of unknowns during monitoring being interpolated and not 
extrapolated from the calibration model. As multivariate calibration models 
characterise variance, if the variability that is expected changes during 
bioprocess development then calibration model modifications are required.
5.3.2. Improving On-line NIR Analysis
The on-line monitoring system requires the NIR transmission probe to be 
permanently immersed in the biotransformation matrix within the STR. This 
means unlike at-line monitoring both cells (including cell matter) and sparged 
air are included within the sample matrix. Agitated cells and air cause 
scattering of the NIR radiation reducing the accuracy of the analysis (section 
4.3). A filtration membrane was used to isolate the transmission probe from 
the cellular and aeration components of the biotransformation matrix. Using a 
single data set PLS regression generated calibration models for both ketone
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and lactone. These models were validated using an internal but independent 
data set. The onlinememb model generated was not as accurate as the at-line 
model. However, the robustness of the predictive model was improved by 
expanding the calibration data-set by interpolating the reference GC data.
The successful use of a membrane system to remove sources of noise from 
the sample spectra improves on-line analysis of the biotransformation. 
Optimising the sensitivity of the NIR method is important since the whole cell 
Baeyer-Villiger process operates most effectively at low concentrations of 
substrate and product.
5.3.3. Bioprocess Development
Using the Baeyer-Villiger process models described above it is possible to 
predict product - time evolution profiles using varying concentrations of 
biocatalyst. Figure 5.19 shows the predicted biotransformation time course 
using biocatalyst concentrations ranging from 11 to 1790 U.l"1 (0.2 to 32.5g 
dew. I'1). Also shown on this figure is the oxygen limiting product evolution 
rate of 1.53 g.l'1.h"1. It is clear that in each case the biotransformation is 
completed after 450 minutes, since at this point the specific activity is zero 
(Figure 5.9) reflecting a loss of whole-cell viability (Figure 3.7). However, as 
the biocatalyst concentration increases, the biotransformation endpoint (the 
time point at which no further product is formed) decreases. For example, 
using 11 U.l"1 (0.2g dcw.l"1), product formation ceases after 450 minutes, 
whilst with 1790 U.l'1 (32.5g dcw.l'1), production is virtually complete after 250  
minutes. These differences are due to product inhibition. At the low 
biocatalyst concentrations the biotransformation is limited by catalyst stability, 
whilst at the higher concentrations it is limited by product inhibition. This 
effect can also be seen from the diminishing return of final product with 
respect to increasing biocatalyst concentration. Nevertheless, the predicted 
space time yield using 1790 U.l'1 (32.5g dcw.l'1) biocatalyst over the 450 
minute reaction time is 0.6 g.l'1.h'1 (4.8 mmol.I'1.h"1) which is comparable to 
values previously reported (Doig et al., 2001, Doig et al., 2002). The space 
time yield reported here (Figure 5.15) was 1.2 g.l'1.h'1 (9.6 mmol.I'1.h'1) over
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260 minutes. The improvement is realised by stopping the biotransformation 
at 4.3 hours when the reaction rate is observed by NIR monitoring to slow.
Figure 5.15 shows the relationship between an experimental bioconversion 
and model predicted data for validation. The reaction shown is thought to 
proceed to a greater lactone concentration due to the greater control of 
ketone feed rate conferred by the NIR monitoring of the reaction. Parity is 
displayed initially, but is lost at approximately 3.5 g.l"1, which occurs at 150 
minutes into the reaction. This coincides with the process model’s predicted 
drop in cell activity, which was influenced by previous data used to train the 
ANN model with respect to biocatalyst stability.
The ability to control the Baeyer-Villiger oxidation using NIR monitoring 
enabled the process model to be validated and model assumptions to be 
verified including the mass transfer limiting product formation rate of 1.53 g.r 
\h -1.
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5.3.4. Conclusion
■ NIR at-line monitoring was able to monitor and control a fed-batch 
Baeyer-Villiger biotransformation such that the substrate concentration 
was not under or over-fed.
■ The control of the substrate feed to the bioreactor, allows ketone 
concentration to be controlled below inhibitory levels enabling the yield 
of product on substrate and biocatalyst to be optimised..
■ The NIR calibration models can be extended using a spiking method 
where process samples are not available. The spiked NIR calibration 
model for the combined lactone product extended the calibration 
range such that validation process data was interpolated not 
extrapolated from the predictive model resulting in improved SEP 
values.
■ Online NIR spectroscopy using a 0.4 pm membrane to separate the 
NIR transmission cell from solid phase and air bubbles in the STR was 
demonstrated. This novel technique achieved comparable SEC to at- 
line NIR calibration ketone and combined lactone model data.
■ NIR monitoring and control of the whole cell Baeyer-Villiger reaction 
was used to validate a predictive bioprocess model which used ANN 
to predict time dependent product evolution profiles. The ANN process 
model was accurate up to 3.5 gl"1 of combined lactone, at a time point 
when the ANN model described a predicted drop in biocatalyst activity.
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6. Discussion
6.1. NIR Monitoring and Control
The modelling of the Baeyer-Villiger bioprocess reaction in terms of the 
cumulative effect of ketone and lactone on CHMO activity has been 
represented graphically in a bioprocess-map (Chen et al., 2002). The 
bioprocess map plots experimental data or data driven model results on a 
two-dimensional plot of one operating parameter against another (substrate 
concentration against product concntration). Process performance 
parameters e.g. biocatalyst activity, are then plotted on these axis. A process 
model for the studied BaeyerVilliger biotransformation model shows control 
of the bioprocess within an area of defined high enzyme activity (Figure 6.0) 
which leads to increased yields of lactone. High CHMO activity is defined as 
the area of the process map where enzyme activity is >70% of maximum 
CHMO activity after a certain time. Process-maps have particular application 
in controlling bioprocesses, especially where a number of time dependent 
variables, such as catalyst viability are of interest (Lilly et al., 1996, Lye et al., 
2002, Woodley et at., 1996).
Monitoring of ketone and lactone has traditionally been undertaken by gas 
chromatography, which has a response time of 35 minutes (including 
sampling -  section 3.1.3). Such a response time negates advanced process 
control, especially given high CHMO activities or where there is a significant 
loss of enzyme activity. Loss of enzyme activity occurs when the ketone 
concentration is no longer maintained in the optimal concentration range 
(section 5.4.2). Rapid monitoring is critical in the case of the Baeyer-Villiger 
type oxidation. The flexibility of the control system is dependent on the time 
taken to determine the new values of any perturbed variable. The theoretical 
data in Figure 6.1 assumes the ketone concentration in the reactor to be 0.5 
g.l'1 and the upper control threshold 0.75 g.l"1; so as to optimise CHMO  
activity with respect to ketone concentration (Doig et al., 2003b). For a 
CHMO activity of 1.22 g.l'1 .h"1 (10 mmol.h'1) as depicted in Figure 3.12, there 
is only 6 minutes in which the control system must respond (if all the catalyst
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activity were to be lost) before the ketone concentration rises above the 
control threshold. If the biocatalyst activity is increased to 20 mmol.h'1 then 
the necessary response time drops to 3 minutes.
This work (Bird et al., 2002a) indicated (section 4.3) that NIR spectroscopy 
can permit the sensitive and robust monitoring of analytes during a 
microbially catalysed Baeyer-Villiger lactone synthesis. To achieve this, 
multivariate calibration was employed, the purpose of which was to develop a 
spectral calibration model to predict the properties of interest (substrate and 
product concentrations). Multivariate calibration of all NIR and reference data 
was achieved using a partial least-square method (PLS). This factor based 
method (unlike multiple linear regression) does not require the user to 
prepare a calibration data-set where all the interfering species are known. 
This is especially important for bioprocesses, like the CHMO mediated 
Baeyer-Villiger lactone synthesis, where the considerable complexity of the 
reaction matrix (in particular from the spent aqueous medium of the 
preceding fermentation) leads to no detectable distinctive spectral peaks of 
analytes (section 4.2). The calibration data-set made up of samples 
characteristic of the process should ideally allow for all process variability and 
span the concentration range expected when running the process routinely. 
However, for CHMO mediated Baeyer-Villiger lactone synthesis, the 
expected (process map) lactone calibration range was not achievable using 
previous process samples as control of ketone concentration (which was not 
achievable without monitoring) resulted in an increased yield of lactone. 
Where expected process samples are not obtainable for the purpose of 
creating a spectral calibration data-set, then process samples spiked with 
lactone to extend the analyte concentration range can be used.
Using the bioprocess map as a development tool the calibration data set from 
which the NIR predictive model was originally built was suitably modified. The 
effect of monitoring lactone with the improved model can be seen in Figure
5.5. Operation of the process with monitoring and control resulted in 3.6 g.l'1 
of lactone, a 30% improvement in productivity over continuous fed batch 
operation (section 5.2) at that time. Productivity was improved further still
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using this monitoring and control method (section 5.4) achieving yields of > 
5.0 g.r1.
The often-dominant constraint of substrate and product inhibition requires 
careful consideration if scaleable biocatalytic reactions are to become 
standard options in complex syntheses. For the whole-cell Baeyer-Villiger 
catalysed lactone synthesis, productivity is restricted by inhibition at low 
concentrations. Efficient and productive operation of the process requires the 
controlled addition of the substrate and implementation of methods to remove 
the lactone product from the reactor. Such a scheme is depicted by Figure
6.2 - substrate is fed into a bioreactor in such a way that underfeeding as well 
as overfeeding is avoided. Likewise, lactone product is removed from the 
reactor using an in situ product removal technique (ISPR) (Lye et al., 1999). 
Both the addition and removal of the analytes requires control of feed-back 
loops, which can only be realised by rapid, quantitative monitoring of both the 
substrate and product.
The ability to monitor rapidly requires rapid at-line or on-line monitoring. On­
line monitoring is favourable since the sampling time is < 1 minute compared 
to 5 minutes at-line. However, the online technique when compared to at-line 
sampling has poorer signal reproducibility resulting in higher SEP and less 
robust calibration models. To overcome this, the Onlinememb technique can be 
applied to bioprocess NIR systems monitoring online where multiple phases 
make-up the reaction matrix. This could be especially useful for the design of 
biotransformation processes, which seek to apply advanced control systems 
such as ISPR because the NIR Onlinememb transmission probe can potentially 
be used rapidly and robustly to monitor a number of co-dependent operations 
where current probes cannot (Figure 6.2). The control of such a process is 
discussed in section 6.4.
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Figure 6.0. Process map for the Baeyer-Villiger bioconversion of the 
Baeyer-Villiger reaction in terms of the cumulative effect of ketone and 
lactone on CHMO activity (Chen etal. 2002).
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Figure 6.1. The response time required in order to implement a control 
action for a percentage drop in biocatalyst activity. The plot assumes a 
ketone concentration of 0.5 gl'1 and a maximum control threshold for 
ketone of 0.75 gl'1. For a CHMO activity of 1.22 g.l'1 .h"1 there is only 6 
minutes in which the control system must respond. If the biocatalyst 
activity is increased to 2.44 g.l'1 .h"1 then the necessary response time 
drops to 3 minutes.
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Figure 6.2. Efficient and productive operation requires the controlled 
addition of the substrate and an in-situ product removal (ISPR) 
technique. It is envisaged that monitoring of the substrate and product 
within the biocatalytic reactor could facilitate the control of the 
operations depicted in blue. Maintenance of the biocatalyst activity 
would also allow productivity improvements through biocatalyst 
recovery and re-use (— ).
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6.2. Bioprocess Development Using NIR
A joint study at UCL’s Advanced Centre of Biochemical Engineering 
modelled the Baeyer-Villiger bioprocess (Doig et al. 2003a). The models 
developed were used to predict -  time profiles at various biocatalyst 
concentrations (section 5.4). The process model accounted for product 
inhibition, biocatalyst stability, and oxygen mass transfer limitations and they 
were verified by comparison to experimental data.
The ability of the process model to investigate a number of scenarios for the 
Baeyer-Villiger oxidation directed further validation bioconversions, where the 
biocatalyst concentration was increased after microfiltration (section 5.4). 
Validation of the model required the controlled feeding of the ketone to the 
reactor using NIR to monitor and control the substrate concentration.
The ketone substrate was fed periodically by adjustable peristaltic pump from 
an external reservoir at varying flowrates. Flowrate was controlled by the use 
of NIR analysis which predicted concentrations of lactone and ketone in broth 
samples taken at 10 minute intervals, bicycloheptanone concentration could 
therefore be kept at approximately 0.5 -0.75 g.l'1 and thereby prevent 
substrate inhibition.
Figure 5.9 shows the predicted biotransformation time course using 
biocatalyst concentrations ranging from 11 to 1790 U/L. The figure indicates 
that the final product concentration at high biocatalyst concentration 
approaches 4.5 gl"1 lactone. Experiments using NIR monitoring achieved 
lactone concentrations approaching 6 gl'1 (section 5.4). Validation of the 
process model indicated that parity with experimental data was lost at a time 
point of 150 minutes when the lactone concentration reached 3.5 gl'1 . 
(section 5.4.2). At this same time point the process model describes a loss of 
biocatalyst activity (Figure 3.7). The difference between experimental and 
model data is therefore likely to be due to incorrect modelling of the viability 
of the biocatalyst.
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In this instance the process model was shown not to be completely accurate, 
however there is a prospect of iteratively updating the model to give a 
process development strategy that is outlined in Figure 6.3. The ability to 
control the effect of substrate inhibition throughout the period of the 
biotransformation resulted in biocatalyst stability and lactone inhibition 
limiting the yield of product on biocatalyst (rather than substrate inhibition) at 
the given oxygen mass transfer rate. Product inhibition could be overcome by 
employing an efficient ISPR technique. The use of ISPR to control the effects 
of lactone inhibition is discussed in (section 6.4). Alternatively, it may be 
possible to express the CHMO in a host less susceptible to inhibition, or to 
use protein engineering to lessen the inhibitory effect on the enzyme itself 
(Lye et al., 2002).
The oxygen transfer limitation may be reduced by using oxygen enriched air, 
or pure oxygen itself, to increase the driving force and thus the volumetric 
flux. The effect of this would be to increase the mass transfer limiting 
volumetric activity, and thus allow a greater process efficiency at the higher 
biocatalyst concentrations, Improvements to the biocatalyst’s stability would 
allow the biotransformation to occur for a greater time. In this way, the 
maximum yield of product on biocatalyst could be increased beyond the 
current limit of about 2 g.g'1 (Doig et al., 2003a).
Fermentation
Microfiltration
DSP
Biotransformation Process Modelling
Biocatalyst Removal
I
Product
Figure 6.3.. A schematic of the whole cell BVMO bioprocess including 
proposed process operations (grey boxes).
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6.3. Bioprocess Design Improves NIR Monitoring and Control
Where synthesis of products with multiple chiral centers is required, the use 
of a biotransformation step circumvents the need for multiple chemical 
protection and deprotection steps. The Baeyer-Villiger oxidation has only 
recently been achieved using transition metal chemistry and only with 
moderate selectivity (Peng et al., 2001). Development of biotransformations 
with high productivity, and robust process strategies will enable 
biotransformations to be exploited alongside conventional chemistry to 
produce highly complex optically pure intermediates and products.
The capacity to monitor the biotransformation process has provided 
immediate advantages for process control, which result in increased 
productivity. However, it is recognised that the major advantages of rapid 
process monitoring will result from monitoring-enabled development of the 
bioprocess. For example, commercial bioprocess operation will depend on 
maximising the yield of product on the biocatalyst. To achieve this, multiple 
turnovers during the life of the whole-cell catalyst will be necessary. Optimal 
use will therefore require use of the biocatalyst under optimum kinetic 
conditions. Without rapid monitoring of the substrate and products to follow 
and control the process this cannot be achieved.
In addition to controlling ketone by feed-back control, lactone too could be 
controlled within the optimum activity window of the bioprocess map (Figure 
6.0). This could be achieved by in-situ product removal (ISPR). ISPR allows 
the product to be removed from the vicinity of the biocatalyst during a 
biocatalytic reaction. Figure 6.4 schematically shows a flow sheet with an 
ISPR column, separate from the reactor, through which the reaction medium 
flows. A matrix with an affinity for the lactone allows for the removal of the 
product from the reaction stream so that the lactone concentration is 
maintained below the inhibitory concentration of 4.5 g.l'1. Such an ISPR 
technique would require careful control of the flowrates through the column 
so as to maximise column loading and avoid the breakthrough of product 
back into the stirred tank reactor. Amberlite XAD4 is a suitable affinity matrix 
for ISPR of the lactones in the example discussed here (Simpson et al.,
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2001). However, with this matrix the ketone binds competitively with lactone 
to the column. This raises the prospect of lactone yields during the product 
recovery stages being dependent on minimising the ketone concentration in 
the reaction stream. Such a holistic approach to process operation can be 
developed using rapid NIR monitoring during the biocatalytic step to direct 
the downstream processing, as shown in (Figure 6.3).
The process model has been developed (Doig et al., 2003a) with product 
inhibition negated in the simulation. It was assumed that ISPR could be used 
efficiently (i.e. remove 100% of the product formed) without adversely 
affecting the specific and /or volumetric activity. Given this scenario the 
model predicts greater return of final product for increasing biocatalyst 
(Figure 6.5). Nevertheless, the bioconversion is still limited in time by the 
stability of the E.coli TOP10 [PQR239] biocatalyst and at high concentrations 
by oxygen mass transfer. Figure 6.4 depicts a Baeyer Villiger bioprocess that 
can be controlled within the process map (Figure 6.0).
Commercial biotransformations developed for synthesis of novel compounds 
require a robust and fast development strategy. Such a systematic approach 
to biocatalytic process design is being built (Lye et al., 2002) and 
acceleration of such technology integration can be achieved through 
increased application of process modelling. As has been demonstrated in this 
study using NIR spectroscopy, the value of modelling to analyse process 
constraints can sometimes only be realised through advanced monitoring 
and control systems.
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Figure 6.4. Optimum operation of the biotransformation requires the 
substrate and product to be monitored at or online. Monitoring by NIR 
spectroscopy enables feedback strategies (— ) to control ketone 
(feed) and lactone (in-situ product removal) to be developed.
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Figure 6.5.. Modelled product evolution -  effect of [biocatalyst] on 
product evolution profile assuming product inhibition is circumvented by 
efficient in situ product removal.
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An Innovative Enterprise Proposed Using NIR Technology
The wider use of NIR spectroscopic technology was explored as part of a 
study to accelerate bioprocess development in the pharmaceutical industry. 
The study, which was conducted at London Business School, constitutes the 
enterprise element of this PhD thesis. It was based on the recognition that:
•  High throughput screening and the human genome project has 
already revolutionised the drug discovery process and enabled 
thousands of target compounds to be analysed compared to the 
traditional 50 to 100 per year for a large pharmaceutical and chemical 
companies.
•  The chosen candidates from a given screen progress to developing a 
manufacturing capacity for clinical trials, and if successful, full scale 
production.
•  To date there has been gross under-investment in manufacturing 
development, which now represents the bottleneck in getting a 
candidate to market.
•  Time taken at this stage increases time to market, reduces useful 
patent life, delays decision-making and increases risk for investment.
•  This process can take several years, even before clinical trials have 
started.
The RBD new technology reported is summarised below. The full report is 
given in appendix X.
6.3.1. Technology
Rapid Bioprocess Development (RBD) consists of accurately simulating 
fermentation and biotransformations at a very small scale. Using robotics 
one can automate thousands of these small bioreactors at the same time, 
and analyse the results generated using advanced instrumentation and 
software. The time taken in conventional optimisation (development) and
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experimentation with new product candidates is largely due to the number of 
experiments required. Simultaneously performing these experiments allows 
a significant decrease in development time (equating to millions of dollars 
e.g. reduced time to market, extended useful patent life, higher NPV for 
each product).
RBD will target the biopharmaceutical and chemical bioproduct development, 
by bringing together three different technologies:
•  Robotic liquid handling of ultra scale-down reactors,
•  Advanced instrumentation for monitoring, control and analysis,
•  Software for modelling and directing iterative cycles of the development.
6.3.2. Driving Force
Each year in pharmaceutical development means one more year before a 
patient can benefit from the drug and one less year of profit for its inventor 
before its patent expires and generic competitors jump in. As this patent 
clock winds down potential sales of well over $1 million are lost for every 
extra day spent in bringing the drug to market. The slowness in the 
development process is a result of the numerous steps that a drug must pass 
through en route to commercialisation. Not surprisingly all players involved in 
the drug development process are attacking this time expenditure.
6.3.3. Market
There are three key markets to which RBD would be targeted:
•  large pharmaceutical and chemical companies
•  bioprocesses consultants and contract manufacturers
• drug discovery research groups
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RBD addresses the existing market of drugs and/or bio-substances 
development process, and in that case, RBD will replace existing, under 
performing practices in the drugs development industry. Drug development 
costs have risen to over $600 million per drug whilst 53 leading drugs will 
come off patent by 20052 There therefore exists pressure for the 
pharmaceutical and chemical industry to re-asses the route to producing 
new-drugs.
6.3.4. Commercialisation Strategy and Recommendations
The technology to date is not sufficiently integrated for RBD to be 
commercialised without a development and incubation of the concept. 
However, the potential of RBD to deliver innovative solutions to current 
bioprocess development issues has led to the following recommendations:
1. Integrate and develop RBD technology
a. Expand and define capabilities of robotically operated micro­
reactors
b. Develop a near infrared analyser for 12 well and then 96 well 
micro-titre plates
c. Evaluate with UCL ventures the IPR issues surrounding RBD 
including the business model.
d. Establish the demonstration of RBD as a milestone towards a spin­
out business venture.
2. RBD product should be structured to deliver value to each customer 
segment
a. Sell platform product to large pharmaceutical companies
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b. Small to medium sized biotechnology/ chemical companies a sale 
can include service, partnership or license agreement.
c. RBD technology should integrate into customer development 
pipeline.
3. Submerge RBD into customer culture to reduce barriers to market entry
a. Paradigm shift in drug discovery programmes should be reflected 
in bioprocess development phase
b. Communicate value of RBD to customers in terms of man hours 
saved, expenditure saved, reduction in investment risk and 
reduction in time to market.
c. Replacement of existing expertise and resources by RBD 
maximise existing capabilities and not challenge them.
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7. Future Work
The whole cell Baeyer-Villiger oxidation of a cyclic ketone is an important 
reaction of organic chemistry and demonstrates the exquisite 
enantioselectivity that can be achieved by application of biocatalysis. The 
possible commercial utility of biotransformation processes to the asymmetric 
oxidation of prochiral ketones is progressing (Alphand et al., 2003) including 
the example of a dynamic resolution process to overcome the intrinsic 50%  
yield limitation normally imposed on a resolution process (Berezina et al.,
2002). Many potential commercial biotransformations including the BVMO 
example are currently prevented from large-scale manufacture because of a 
number of bottlenecks, including: lack of large scale availability of the 
biocatalyst; the inhibitory nature of the substrate and products; and the down 
stream recovery of products and substrate.
The expression of enzymes heterologously can potentially lead to 
recombinant organisms with improved characteristics with regard to whole­
cell biocatalyst stability. This is particularly true as far as substrate and 
product inhibition problems are concerned. A more stable biocatalyst 
operating at an increased volume to produce the desired quantity of product 
is also required to operate at higher concentrations to minimise the expense 
of down stream product recovery (Straathof et al., 2002). Recombinant DNA 
technology such as site directed mutagenesis and directed evolution could 
facilitate such improvements (Bornscheuer et al., 2001, Burton et al., 2002, 
May et al., 2000). The use of NIR spectroscopy to monitor and control 
biotransformations has enabled bioreactors to be operated to control 
substrate feed rates below inhibitory concentrations and potentially to control 
the feed rate such that the substrate concentration can be optimised for down 
stream recovery of products.
Together with the use of process maps and models to describe and optimise 
bioprocess design NIR monitoring should be used to facilitate the control of 
biotransformations such that the maximum yield of product on biocatalyst is 
achieved. This is based on the prediction that recombinant whole cell
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biocatalysts will continue to represent a significant proportion of a process 
cost (Tramper, 1996). To achieve this, re-use of the biocatalyst material 
should be considered. Nevertheless, a key limitation to the Baeyer-ViNiger 
biotransformation example was product inhibition (Doig et al., 2002), and so 
to achieve higher product concentrations in excess of 10 gl'1 for example, 
alternative process techniques such as two-liquid phase biocatalysis and 
ISPR should be investigated (Lye et al., 1999). An ISPR technique used 
successfully during the biotransformation of bicycloheptanone was also found 
to bind substrate (Simpson et al., 2001). In this case, the resin acted as a 
sink for product and reservoir for substrate enabling substrate concentrations 
as high as 20 gl'1. The presence of multiple phases in bioreactors tends to 
complicate further NIR monitoring due to radiation scattering. This makes it 
difficult to distinguish analytes of interest from, gas bubbles, cells and 
particulate matter (Vaidyanathan etal., 1999a). However, NIR onlinememb was 
shown to alleviate scattering issues attributed to vessel aeration and cell 
matter. It should therefore be possible to use this innovative NIRmemb 
technique to monitor biotransformations in the presence of absorbent resins. 
There also needs to be an effort of further investigation regarding the 
construction of calibration data sets, including the use of sample spiking and 
interpolating on-line data, which should aim to improve the robustness of 
predictive NIR models.
Compared to the chemical route biotransformation processes can often be 
slow to implement whereas chemical routes, although often more expensive 
and less selective are better understood due to the amount of knowledge and 
experience available (Rozzell, 1999). To compete with chemical routes, new 
process development strategies are required for biotransformations. The use 
of automated systems at a microlitre scale to obtain key process design data 
has the potential to shorten development times and improve design data for 
biotransformations (Lye et al., 2003). The pharmaceutical industry has 
invested heavily in the use of microplate technology for screening purposes 
(Rich, 2002, Stahl, 2000) and now microscale techniques are emerging as a 
means to develop biotransformations processes based on identified 
candidates. Data collected at the microscale level can be used to study
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engineering operations such as equilibrium stage separation processes (Lye 
et al., 2003). As described in Appendix X, the use of microscale technologies 
for quantification of process development variables is likely to be limited by 
the time required to assay the many samples generated using microplates. 
Traditional techniques, which include GC and high-pressure liquid 
chromatography, are not going to be applicable if the speeds of analysis are 
going to lag considerably the speeds of sampie collection. NIR can provide 
sensitive and robust monitoring of complex bioprocesses on-line and rapidly 
(<1 minute). Currently however appropriate NIR instrumentation is only 
commercially available in a size designed to interface with a standard stirred 
tank reactor port (20mm) and not a microwell (<8mm). The process of 
adapting the NIR instrument to interface a modified microtiter plate is 
necessary. At the same time, further work on alternatives to quantitative 
calibration models such as PLS could address the requirement for large 
calibration sample data sets. For example the use of the orthogonal 
projection approach has been used to follow a polymorph conversion 
reaction to detect the end point on-line (Braekeleer et al., 1999). These 
techniques could be the focus of future work to monitor using NIR the 
equilibrium parameters of biotransformations such as partition coefficients.
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Conclusions
■ Baeyer-Villiger monooxygenases (BVMOs) are a group of redox
enzymes capable of the nucleophilic oxygenation of a wide range of 
linear and cyclic ketones yielding esters and lactones respectively. 
Cyclohexanone monooxygenase (CHMO) is the best characterised of 
over twenty BVMOs that have been identified. For the purpose of this 
work, CHMO was expressed heterologously in Escherichia coli TOP10 
[pQR239] (Doig et al.} 2002). The biotransformation characteristics for 
the oxidation of bicyclo[3.2.0]hept-2-en-6-one to its corresponding 
regio-isomeric lactones (-) 1(S), 5(R), 2-oxabicyclo[3.3.0]oct-6-en- 
3one (ee = 94%) and (-) 1 (R), 5(S), 3-oxabicyclo[3.3.0]oct-6-en-2one 
(ee = 99%) has been investigated (Doig et al.} 2003b). The key kinetic 
characteristics of this strain were found to be severe substrate and 
product inhibition. Substrate and product inhibition of biocatalysts is a 
frequently observed phenomenon.
■ A sensitive and robust method has been developed using near
infrared spectroscopy (NIR) to monitor both at-line and on-line the
reactants and product of the Escherichia co//whole cell Baeyer-Villiger 
biotransformation of a cyclic ketone to optically pure lactones. The 
development of a system capable of precise and rapid measurements 
of individual components of a complex bioprocess will facilitate the 
realisation of improved control strategies and therefore improve 
productivity. Quantitative multivariate calibration of a NIR 
spectrophotometer for ketone and lactone resulted in a standard error 
of prediction at-line of 0.088 gl"1 and 0.110 gl'1 and on-line of 0.130 gl'1 
and 0.180 gl'1, respectively (Bird et al., 2002a). The concentrations of 
substrate and product could be simultaneously monitored by NIR, 
which had a response time of 5.0 and 0.75 minutes at-line and on-line, 
respectively.
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■ Monitoring of ketone and lactone was previously being undertaken by 
a gas chromatography method, which has a response time of 35 
minutes (including sampling)(Doig et al., 2002). The developed NIR 
method satisfied the requirements for biotransformation monitoring. It 
was rapid, reagentless, and suitable for light scattering, 
heterogeneous, complex mixtures. NIR was also capable of online 
monitoring of the ketone substrate and combined lactone product 
simultaneously. The NIR spectral features of sample data were found 
to be broad and overlapped and so resolution of spectral data for 
analyte calibration to reference data required chemometric techniques 
for multivariate analysis.
■ NIR calibration training data should include all process variability and 
span the concentration range expected when running the process 
routinely. There was found to be an issue with regard to 
biotransformations where substrate and product inhibition reduced 
productivity such that expected process samples were not obtainable 
for creating a spectral training data set for subsequent model 
development. A lactone NIR calibration model containing spiked 
bioprocess samples (in addition to sampled spectra) was generated. 
The inclusion of spiked samples improved the SEP for combined 
lactone from 0.22 to 0.12 gl"1 (Bird et al., 2002b). It is considered that 
calibration training-sets can be designed using the spiked method to 
achieve a robust monitoring method for concentration ranges only 
feasible through advanced control[5].
■ The monitoring and control of the Baeyer-Villiger bioconversion by NIR 
has allowed intermittent feeding of ketone such that the concentration 
of substrate does not rise above a threshold of 0.5 gl"1. Using this 
feeding strategy >5.0 gl'1 of lactone product was produced from a 
single fed-batch biotransformation. This represented a 2 fold increase 
in productivity (Doig et al., 2003a). It was apparent that without 
adequate monitoring and control the route to developing new 
biotransformation processes would be increasingly difficult.
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■ NIR monitoring was used to validate a process model of the Baeyer- 
Villiger biotransformation (Doig et al., 2003a). The work indicated that 
the process model was accurate up to a product concentration of 
3.5gl‘1 after which the model underestimates combined lactone 
production.
■ Improvements to NIR on-line monitoring were sought with the use of a 
membrane to separate the transmission sample cell from the adverse 
effects of radiation scattering caused by suspended cells, particulates 
and air bubbles present in the bioreactor. This innovative sampling 
technique achieved standard error of calibrations values similar to that 
of the at-line NIR technique.
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I. Appendix: Bioreactor specification
The following is the specification for the two fermenters (LH210_a and 
LH2000) used to grow E.coli Top10 [pQR239] and the bioreactor used for the 
biotransformation (LH210_b).
Bioreactor LH210_a LH2000 LH210_b
Vessel working 
volume (L)
1.6 5.3 1.5
Vessel height 
(mm)
212 400 -
Vessel diameter 
(mm)
130 160 -
Aspect ratio 1.63 2.5 1.83
No. of impellers 2 2 2
Impeller diameter 
(mm)
40.4 62.3 -
Tip dimensions 
(mm)
1=10.5, W=1.0, 
H=7.9
L=16, W=2, H=3 -
Ratio of the 
vessel diameter 
to the impeller 
diameter
3.2 2.6 2.4
Tip speed (m/s) 
at N = 1000 rpm
2.12 3.16 -
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II. Appendix: Standard Error
The standard error provides a measure of the error that exists in a normally 
distributed sample set. Unlike the standard deviation, the error is not 
calculated using the deviation from a mean value but rather differences 
between a pair of sample scores or residual values. The sum of the 
differences are squared and then divided by the number of samples. The 
square-root of this value calculates the standard error as described by 
Equation 11.1.
SE = ]l~ h
Equation 11.1
Where, y  and z are duplicate results analysed from a split sample and n is 
the number of un-split samples.
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III. Appendix: Calibration of OD550 with Protein Concentration
A calibration curve linking the OD595 to protein concentration was constructed 
using a series of standard samples of known protein concentration. An 
example calibration curve is shown in Figure 111.1.
|  0.8
in
S 0.6
4-»
03
0.2
0.40 0.2 0.6 0.8 1 1.2
Protein concentration (mg/L)
Figure III. 1: Calibration of OD595 measurements to protein 
concentration for series of standard bovine albumin samples. 
Measurements were determined as described in section 3.1.3.2. The 
fitted line has a correlation coefficient of 0.95.
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IV. Appendix: Standard Deviation
The standard deviation is a measure of how widely values are dispersed from 
the average value (the mean). STDEV assumes that its arguments are a 
sample of the population. The standard deviation was calculated using 
Equation IV. 1.
1=1
Equation IV. 1
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V. Appendix: GC Calibration Curves
Concentrations of ketone and lactone in the ethyl acetate phase of samples 
were found using predetermined calibration curves. Figure V.1 and V.2 show 
typical calibration curves of solute concentration against FID response 
(integrated peak area) for ketone and lactone respectively.
3.5x10 -i
3.0x10 -
2.5x10*-
3  2.0x10*-
15x10*-
5.0x10* -
0.0
0.2 0.4 0.8 10 1.20.0 0.6
Ketone (g/L)
Figure V.1: Typical calibration curve for ketone in ethyl acetate. 
Samples were prepared and analysed as described in section 3.1.3.5. 
R = 0.98. Error bars show standard error of GC analysis (section
3.1.3.5.1).
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Figure V.2: Typical calibration curve for lactone1 in ethyl acetate. 
Samples were prepared and analysed as described in section 3.1.3.5. 
R2 = 0.98. Error bars show standard error of GC analysis (section
3.1.3.5.1).
234
VI. Appendix: FID response chromatogram
The flame ionisation detector (FID) response time from gas chromatography 
of samples prepared in ethyl-acetate is shown for ketone and combined 
lactone (Figure V I.1). A commercial lactone was used to calculate calibration 
curves for the prediction of combined lactone process samples. The 
commercial lactone (Figure VI.2) has the same retention time as the 
combined lactone (Figure VI. 1).
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2 4 6 8 1Q 12 14 18
Figure VI.1. GC chromatogram of ketone and biotransformation 
combined lactone products.
2 O 8 10 1 2 14
Figure VI.2. GC chromatogram of lactone1; 1 (R), 5(S) 2- 
oxobicyclo(3.3.0)oct-6en-3one.
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V II. Appendix: Scale-up of E.coli T o p 1 0  [p Q R 2 3 9 ]  Batch Growth
Scale-up of agitation from the 2L to the 7L fermentation was achieved initially 
by means of constant tip speed (Ts). Tip speeds calculated using Equation
VII. 1 for LH210_a and LH2000 are given in Table VII. 1.
Ts = 7r • N  ■ di
N = speed of agitator (s'1) 
di = diameter of impeller (m)
Equation VII. 1
N (rpm)
Tip speed (ms'1)
LH210_a LH2000
500 1.06 1.63
600 1.27 1.96
700 1.48 2.28
800 1.69 2.61
900 1.90 2.94
1000 2.12 3.26
1100 2.33 3.59
1200 2.54 3.91
Table VII. 1: Agitator tip speeds for fermenter LH210_a and LH2000. The 
shaded areas depict the actual range of tip speeds used during the batch 
fermentation of E.coli Top10 [pQR239],
237
VIII. Fermentation Parameters
An analysis of the fermentation parameters for batch growth of E.coli Top10 
[pQR239] is given in Table 3.2 (section 3.3.1). The Reynolds number (Re) 
was calculated using Equation VIII. 1. Reynolds number is proportional to 
inertial force/ viscous force and is used in mass transfer to account for 
dynamic similarity. For a given geometry, the Reynolds number based on 
impeller diameter is convenient for describing the hydrodynamics of the 
system. A fermenter system with Re > 104 is characterised by turbulent flow 
where Power number (Po) is independent of Re (Rushton et al 1950). A 
broth density of 1100 kg.m3 and a viscosity 0.01 Pa.s was assumed from 
bioprocess principles ((Doran, 1998)).
A
p = density (Kg.m'3)
Njdj = characteristic velocity (Pa.s)
dj = characteristic length (impeller diameter)
Equation VIII. 1
The volumetric un-gassed and gassed agitator power requirement of the 
fermenter’s was calculated using Equation VIII.2 and VIII.3 respectively. The 
Pg results are given in Table VIII. 1. An impeller Po of 5 is typical for a 
Rushton turbine type impeller operating in the turbulent regime ((Doran, 
1998)).
P o= Pug
p - N 3d i5
Pug = impeller ungassed power requirement (watts) 
Equation VIII.2
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Pg/Pug = 0.4 
Pg = impeller ungassed power requirement (watts) 
Equation VIII.3
N (rpm)
PgN  (watts/L)
LH210_a LH2000
500 0.076 0.204
600 0.136 0.356
700 0.212 0.564
800 0.32 0.84
900 0.456 1.196
1000 0.624 1.64
1100 0.828 2.184
1200 1.076 2.832
Table VIII. 1: Volumetric Pg for fermenter LH210_a and LH2000 over a ranger 
of agitation speeds. The shaded areas depict the actual range agitator 
speeds used during the batch fermentation of E.coli Top10 [pQR239],
To understand better the potential effect of the respective maximum 
calculated power inputs for each fermenter on the E.coli cultures the 
maximum shear rate (() was calculated using Equations VIII.4, VIII.5 and
VIII.6.
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E  _ Pug _ Pug
pV  V
E  = Average energy dissipation per unit mass (W.Kg'1) 
Equation VIII.4
( =  shear rate (s'1)
< = kinematic viscosity, Equation VIII.6 (m2.s'1) 
Equation V III.5
P
v = kinematic viscosity, (m2.s"1) 
Equation VIII.6
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IX. Model Validation
To estimate the optimal number of factors in any given PLS calibration model 
a cross-validation approach was used. The PLS factor based methods find 
linear combinations of the independent variables (wavelength responses) 
which account for variation in the data set. The linear combinations are the 
factors, which can be considered new orthogonal variables. If in a given 
model an insufficient number of factors are retained in the model, future 
predictions are unreliable because important quantitative information is 
missing. However, if too many factors are included in the model, future 
predictions are misleading because random variation (noise) has been built 
in to the model. The best possible regression models were achieved by a 
cross validation procedure optimising the number of factors such that either a 
minimum prediction residual error sum of squares (PRESS) is reached 
(Figure IX. 1) or the fewest factors required to achieve a standard error of 
calibration (SEC) similar to the associated gas chromatography standard 
error. Cross-validation involved each calibration sample being dropped out of 
the calibration set, generating regression equations on the reduced 
calibration set and then subsequently predicting the value of the dropped 
standard to calculate a PRESS.
To calculate the SEC on a data set the residual standard error (a) is 
calculated using Equation IX. 1 based on the fitted line y -  a + bx. The 
residual standard error is a root mean square average of the errors about a 
fitted line and as such represents a typical discrepancy from the line. For the 
calculation of SEC, n-2 rather than n allows for the fact that the constants a 
and b have been calculated from the same data that are used for the errors. 
For the calculation of the PRESS and SEP, Equation 11.1 is used. The SEC is 
likely to be an underestimate of the true error (SEP) since the equation used 
to for prediction is a line of best fit for the particular sample set. This is the 
reason why it is important for the sample set to represent the expected 
variation of the process samples.
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The correlation coefficient (R2) measures the extent to which the fitted 
straight-line relationship explains the variability in the y-values. It depends on 
the spread of the y-values as much as it does on the goodness of fit and so it 
measures the predictive ability of the equation relative to the range of y- 
values in the calibration set. It is therefore possible to affect the R2 value by 
manipulating the range of values. An extended range of values might 
improve the R2 whilst prediction errors actually become bigger. The R2 value 
can be calculated using Equation IX.2.
<J = 2 0^, -  a -  bxt f  /(n -  2)
i =1
Equation IX. 1
2 > i - * ) ( * - * )
R 2 =
Equation IX.2
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Figure IX. 1: An example of PRESS analysis on ketone calibration data.
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1. Executive Summary
1.1. Technology
Rapid Bioprocess Development (R B D ) consists o f accurately simulating fermentation and 
biocatalysis at a very small scale. Using robotics one can automate thousands o f these small 
bioreactors at the same tim e, and analyse the results generated using advanced instrumentation and 
software. The tim e taken in conventional optimisation (development) and experimentation w ith  
new product candidates is largely due to the number o f experiments required. Simultaneously 
performing these experiments allows a significant decrease in development tim e (equating to 
m illions o f dollars e.g. reduced tim e to market, extended useful patent life , higher N P V  for each 
product).
R B D  w ill revolutionise the biopharmaceutical and chemical bioproduct development, by bringing 
together three different technologies:
•  Robotic liquid handling o f ultra scale down reactors,
•  Advanced instrumentation for monitoring, control and analysis,
•  Software for modelling and directing iterative cycles o f the development.
R B D  is a technical breakthrough that w ill enable drug discovery companies to better control the 
risks associated w ith drug development.
1.2. Driving Force
Each year in pharmaceutical development means one more year before a patient can benefit from  
the drug and one less year o f profit for its inventor before its patent expires and generic 
competitors jum p in. As this patent clock winds down potential sales o f w ell over $1 m illion are 
lost for every extra day spent in bringing the drug to market. The slowness in the development
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process is a result o f the numerous steps that a drug must pass through en route to 
commercialisation. N ot surprisingly all players involved in the drug development process are 
attacking this tim e expenditure.
1.3. Market
There are three key markets to which RBD would be targeted:
•  large pharmaceutical and chemical companies
•  bioprocesses consultants and contract manufacturers
•  drug discovery research groups
R B D  addresses the existing market o f drugs and/or bio-substances development process, and in  
that case, R B D  w ill replace existing, under performing practices in  the drugs development 
industry. Drug development costs have risen to over $600 m illion per drug w hilst 53 leading drugs 
w ill come o ff patent by 2005 *. There therefore exists pressure for the pharmaceutical and chemical 
industry to re-asses the route to producing new-drugs.
1.4. Commercialisation Strategy and recommendations
The technology to date is not sufficiently integrated for R BD to be commercialised without a 
development and incubation o f the concept. However, the potential o f R B D  to deliver innovative 
solutions to current bioprocess development issues has led to the follow ing recommendations:
1. Integrate and develop R BD technology
a. Expand and define capabilities o f robotically operated micro-reactors
b. Develop a near infrared analyser for 12 w ell and then 96 w ell m icro-titre plates
c. Evaluate w ith U C L  ventures the IPR  issues surrounding RBD including the business 
model.
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d. Establish the demonstration o f RBD as a milestone towards a spin-out business venture.
2. R B D  product should be structured to deliver value to each customer segment
a. Sell platform  product to large pharmaceutical companies
b. Small to medium sized biotechnology/ chemical companies a sale can include service, 
partnership or license agreement.
c. R B D  technology should integrate into customer development pipeline.
3. Submerge R B D  into customer culture to reduce barriers to market entry
a. Paradigm shift in drug discovery programmes should be reflected in bioprocess 
development phase
b. Communicate value o f R B D  to customers in terms o f man hours saved, expenditure 
saved, reduction in  investment risk and reduction in  tim e to market.
c. Replacement o f existing expertise and resources by R B D  maximise existing capabilities 
and not challenge them.
1 Arlington,S. Pharma 2005: the challenges.
Figure 1: THE PROCESS OF RED COMMERCIALISATION
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2. Concept definition of RBD
2.1. Overview of the Bio-industry
The simplest definition o f Biotechnology is ‘the manufacture o f  commercial products from  living  
organisms. '  In  their crudest form, biotechnological principles have been documented since 6000 
B.C . when the Babylonians and Sumerians used the fermentation o f yeast for the production o f 
alcohol. It is the advent o f genetic manipulation, however, that has led to massive growth in the 
use o f biotechnology in pharmaceutical and fine chemical sectors.
M illions o f years o f evolution have created thousands o f microorganisms containing enzymes 
known to catalyse almost every chemical reaction. Nature’s exquisite enzymatic chemistry tends 
toward the highly selective, efficient, temperate and environmentally benign. The chemical 
industry is amassing biocatalytic expertise to meet the needs o f pharmaceutical customers.
Fighting the clock: pharmaceutical drug development is slow, requiring years o f research and 
lengthy clinical trials. The drug industry group Pharmaceutical Research &  Manufacturers o f 
Am erica (PhR M A ) claims that drug companies invest from 12 to 15 years in each new drug2. In  
biopharmaceuticals, the Tufts Center for the Study o f Drug Development has determined that, 
w hile the number o f new products has been increasing steadily, clinical development times have 
doubled since 1982 to an average o f 68 months . The slowness in the development process is a 
result o f the numerous steps that a drug must pass through en route to commercialisation.
Products derived from the mapping o f the human genome in  2000 are expected to start entering the 
market from 2003 and it is anticipated that the number o f identified, tested and commercialised 
drugs w ill increase six-fold over the next 20 years4.
2 http://www.phrma.org/index.phtml?mode=web
3 Chemical and Industry. Reinventing Pharma. January 28,2002.
4 http://www.biocapital.com/en/investment/trends.shtml 14:40,17 March 2002
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Each year in  this protracted process means one more year before a patient can benefit from the 
drug and one less year o f profit for its inventor before its patent expires and generic competitors 
jum p in. As this patent clock winds down potential sales o f w ell over $1 m illion are lost for every 
extra day spent in bringing the drug to market5.
2.2. What is RBD?
2.2.1. Technical review of RBD
The R B D  product brings together three distinctive technological developments:
1. Robotic liquid handling o f ultra scaledown reactors.
2. Advanced instrumentation for monitoring, control and analysis
3. Software for modelling and directing iterative cycles o f the development process
Robotic liquid handling of ultra scaledown reactors. Parallel advances in molecular biology 
together w ith the use o f laboratory automation are now placing severe pressures on the process 
development stages o f the bioproduct life  cycle. The use o f robotic liquid handling 
experimentation at microscale to obtain key process design data has the potential to overcome this 
bottleneck and radically improve the speed at which bioproduct processes can be established. The 
ability to m im ic large-scale processes (>450 litres) at a microscale (<1 m illilitre ) has been 
demonstrated using a Escherichia Coli whole cell catalyst during a B aeyer-V illiger 
bioconversion6. In  this case the m icrowell approach represented a 4000-fold reduction in scale and 
material requirements .
5 Watkins, K  J , ‘Fighting the Clock’, Chemical and Engineering News, 27-34, Jan 8 2002
6 Lye,G.J., Dalby,P.A., Woodley ,J.M. Better Biocatalytic Processes Faster: New tools for the implementation of biocatalysis in 
organic synthesis. OPRD, submitted.
7 Pickering, S.C.R, Doig, S.D., Lye, G.L., Woodley, J.M. The use of microscale processing technologies for quantification of 
biocatalytic Baeyer-Villiger oxidation kinetics. Biotech. Bioeng. In Press
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Advanced instrumentation for monitoring, control and analysis. The use o f microscale 
technologies for quantification o f process development variables is likely  to be lim ited by the tim e 
required to assay for products and reactants. Traditional techniques, which include gas 
chromatography and high-pressure liquid chromatography, are not going to be applicable i f  the 
speeds o f analysis are going to lag considerably the speeds o f process operation. Near infrared 
spectroscopy (N IR ) can provide sensitive and robust monitoring o f complex bioprocesses on-line
O Q
(no sampling o f the bioprocess is required) and rapidly (<45 seconds) . This compares favourably 
to the traditional techniques, which are off-line (sampling o f the bioprocess is required) taking up 
to 35 minutes to complete. N IR  instrumentation, however, is only commercially available in a size 
designed to interface w ith a standard stirred tank reactor port (20m m ) and not a m icrowell 
(<8m m ). The process o f adapting the N IR  instrument to interface a modified m icrotiter plate is 
necessary before incubation and then demonstration o f the R B D  product can be realised. Such 
innovation represents an opportunity to attain intellectual property rights and to add value to the 
R B D  idea.
Software for modelling and directing iterative cycles of the development process. The
software component o f the RBD product can be divided into two components: i) the chemometric 
software, which enables N IR  quantification or qualification o f the bioprocess under study and ii) 
the software for modelling and directing the development o f the bioprocess. Currently 
commercially available software is being used under license to perform these tasks.
2.2.2. Theoretical concept vs. initial demonstration?
The R B D  concept requires a number o f distinct technological developments to be interfaced. The 
robotic liquid handling and ultrascale down reactors (e.g. 96-w ell plates, see appendix 1) are
8 Bird,P.A., Sharp,D.C.A., Woodley,J.M. Near-IR spectroscopic monitoring of analytes during a microbially catalysed 
Baeyer-Villiger bioconversion. OPRD, submitted.
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commercially available (Perkin Elmer, Packard Bioscience) without any customisation. The 
knowledge and expertise required to m im ic bioprocess conditions in 96-w ell plates using robotic 
liquid handling is present at the Biochemical Engineering Department o f University College 
London. This knowledge allows a reactor o f the 96-w ell plate (volume 400 p L ) to m im ic important 
operational variables o f a pilot-scale reactor (demonstrated up to 450 L ). The art o f m im icking a 
large process at a small scale provides the basis for rapidly optimising or developing bioprocesses. 
There is no intellectual property rights (IP R ) associated w ith this aspect o f R B D , despite the u tility  
and unique application o f the technology. It  is therefore considered that this application for 
robotic-liquid handling systems should form the basis o f a patent search and evaluation.
The use o f N IR  spectroscopy to monitor and control bioprocesses has been w ell documented both 
at U C L  and elsewhere. The technology is w idely available from a number o f vendors and for a 
number o f applications. FOSS NIRSystems, the leading manufacturer o f near-infrared (N IR ) 
spectrophotometers (and used at U C L ), designs and manufactures a complete range o f rapid- 
scanning, near-infrared spectrophotometers for laboratory and process applications. FOSS products
v
are designed for application in the agricultural, food, pharmaceutical and chemical industries. 
However, the FOSS spectrophotometer at U C L cannot be interfaced or m odified for use w ith 96- 
w ell plates (appendix 2). Conversations w ith Sheelagh Halsey an Industrial N IR  Applications 
Scientist (FOSS U K ) have indicated that there is no product available from FOSS for use w ith 96- 
w ell plates. Sheelagh was able to indicate that development o f N IR  systems for use w ith RBD by 
FOSS is unlikely without market research indicating relevant commercialisation potential. Collin  
D ye an applications manager o f Clairet Scientific Lim ited (U K ), the specialist supplier o f 
spectroscopic solutions to industrial problems confirmed that no N IR  product is commercially 
available specifically for 96-well-plates. C ollin was able to recommend manufacturers o f products,
9 Bird,P.A., Sharp,D.C.A., Woodley,J.M. Biocatalysis: process monitoring and control o f a microbially catalysed 
Baeyer-Villiger lactone synthesis. BioPharm. Submitted.
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which could be used to develop such a product (appendix 3). Since N IR , technology has such 
varied applications and since the application o f N IR  for RBD requires specialisation o f the 
technology it is considered that the development o f a 96-w ell plate N IR  reader should be the focus 
o f a development programme at U C L. This would represent an important R B D  value-creating step 
that has clear IP R  potential. Indeed a N IR  96-w ell plate reader could have novel u tility  other than 
that described by R B D . To facilitate this innovation three recommendations have been made:
•  Current U C L  N IR  technology should be developed to read 12-well plates as a bridging step 
to 96-w ell plate reactors.
•  Once a 12-plate N IR  reader is developed, this knowledge should be applied w ith the 
necessary capital investment to the invention and demonstration o f a 96-w ell reader.
•  The 12 and 96 w ell N IR  readers should be evaluated for there commercial potential in  
addition to R BD .
Pfizer Global Research the world-leading pharmaceutical company has a process analysis group. 
M artin  Warman o f the Pfizer process analysis group was able to discuss the issues for developing 
the N IR  instrument. It  was his opinion that existing N IR  instruments could be quickly adapted to 
read a 96 or 12 w ell plate. Using an instrument manufacturer e.g. Spectra-Alliance, M artin  
believed that a N IR  96-w ell plate reader could be demonstrated w ithin 3 months given the 
resources.
The outputs o f a system that operates and monitors a bioprocess in a m icrowell are process specific 
data. This data is then applied to the optimisation and development o f the process resulting in 
R B D . The software tools which w ill collect, reduce and visualise this output data represents an 
important aspect o f the R B D  technology. These software applications w ill allow the end-user o f 
R BD to translate the data into valuable process specific solutions. A  recommendation is therefore
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made to evaluate how the data generated through R B D  would best be presented to any identified  
customer.
Demonstration o f R B D  for operating and monitoring bioprocesses should become the focus o f 
efforts once the N IR  96-w ell reader was available. Validation and demonstration o f the R B D  
technology could take place to describe the u tility  for optimisation and development o f relevant 
bioprocess systems. It  would be desirable for a comparison o f the R B D  strategy to a traditional 
strategy to be made. The technology development plan is outlined in  figure 1.
12 well plate N IR  
analyser
Robotic liquid handling o f ultra scale down reactors
Integration and demonstration of N IR  monitored ultra scale down bioprocesses
96 well plate N IR  analyser
Development of data visualisation and bioprocess modelling RBD specific software tools
demonstration
3 m o n th s 6  m o n th s 9  m o n th s 12 m o n th s 15 m o n th s 18 m o n th s
F ig u re  1 -  T e c h n o lo g y  D e v e lo p m e n t  P la n
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2.2.3. Intellectual Property
Although R B D  integrates existing pieces o f equipment manufactured by existing companies, the 
use o f the pieces o f equipment together in the manner necessary to perform R B D  constitutes an 
innovative step and, as such, is capable o f being patented10. The general concept o f the R B D  
method cannot be patented, however. The disclosure o f the idea in basic principles was the subject 
o f academic grant proposals and has been discussed at academic conferences. This disclosure puts 
the R B D  concept in the public realm and, as such is considered to be ‘in the prior art’ for the 
subject o f future patenting issues.
Several patents could be written to protect both the process and the product11. The software written  
to perform the analysis, iteration and subsequent experimental design would also be subject to 
copyright. The algorithms developed to perform measurements from  the N IR  may be patentable or 
could be covered by the copyright on the software exploiting them. Simon Kremer recommended 
that the novel business models proposed by the implementation o f R B D  could form the basis o f 
patent applications. The process o f patenting business models has not been tested under U K  law, 
but has been landmarked under US patent law, and is being considered here.
2.2.4. The idea: Matching the market.
There are three key markets to which RBD would be targeted:
•  large pharmaceutical and chemical companies
•  bioprocesses consultants and contract manufacturers
•  drug discovery research groups
10 Simon Kremer, Partner for Lifesciences Mewbum Ellis, Patent Agency
11 Interview with Jeff Skinner, Commercial Director, UCL Ventures, Monday 11 March 2002
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The average tim e for biopharmaceutical development from  the date o f cloning to approval is 7.8
1 'X
years, w ith a minimum o f 4 years . Where the product is a small-chemical pharmaceutical, 
development takes 15 years. This includes approximately six years in discovery, pre-clinical 
testing, and toxicity studies; one and a h a lf years in  phase one trials to assess safety in healthy 
volunteers; then two years in phase two trials w ith a few hundred patients to evaluate the drugs 
effectiveness and side-effects. The development process continues w ith three and a h a lf years in  
phase three trials, then one and a h a lf years o f FD A  review. N ot surprisingly all players involved in  
the dmg development process are attacking this tim e expenditure.
Increasing global competition, and demands for lower drug prices from governments and health 
care providers are putting pressure on large pharmaceutical companies to reduce these 
development times. R B D  would allow development times to be significantly reduced, and allow  
earlier decision making when selecting which drug candidates to take forward.
Bioprocesses consultants and contract manufacturers could employ R BD to - quickly optimise 
processes. This is a goal in itself for the consultant, but would also allow faster delivery o f the 
product for contract manufacturers.
Companies or academic research groups w ith a single product could use R B D  to demonstrate that 
the product is capable o f being manufactured, which would add value to the product, both for 
proposals seeking investment, and licenses to produce the drug.
In  the area o f Biotechnology, Lonza Group is the world leader in exclusive custom manufacturing 
for the global life  sciences companies. In  addition to Lonza’s chemical custom manufacturing, 
Lonza Biotec offers microbial custom fermentation and biotransformation services. Lonza 
Biologies is focused on the production o f therapeutic monoclonal antibodies and recombinant
12 A  Biopharmaceutical is defined here as a large therapeutic drug e.g. protein molecule, antibody, vaccine.
13 F. Foo et al., “Biopharmaceutical Process Development: Part I, information from the First Product Generation,” Pharm Technol. 
Eur. 13(6), 58-64 (2001)
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proteins produced by mammalian cell cultures. This makes them a good indicator o f the 
consultant/contract manufacturer target market segment.
N ick  M urre ll14 is currently designing a new R & D  facility at Lonza Biologies. He has a keen 
interest in the ultra-scale down work at U C L, and is enthusiastic about the potential capabilities o f 
R B D . In  large pharmaceutical companies, manufacturing plants are generally built w ith a lifetim e  
o f 15 to 20 years for the production o f a single entity. Lonza, however, works on short production 
contracts, generally lasting from a few months to a few years. This means that their manufacturing 
facilities are generally more flexible, and the faster they can meet the requirements o f a contract, 
the faster they can re-engineer and re-validate their manufacturing plant. Using R B D  to speed up 
the development o f the design o f the manufacturing facility conveys the obvious benefit o f saving 
tim e so that there is less down-time between contracts for each facility.
A  generalised bio-product development pipe-line is described by Figure 2. It  can be seen that the 
development phase for a bioproduct is distinct from discovery but is necessary before a 
manufacturing phase can commence. RBD addresses the existing market o f drugs and/or bio­
substances development process, and in that case, R B D  w ill replace existing, under performing 
practices in the drugs development industry (Figure 3). Where the discovery phase require 
development o f a biocatalyst or bioprocess distinct from optimisation then the results o f R B D  w ill 
feed-back into the discovery phase (Figure 4).
14 Nick M urrell is a Senior Process Engineer at Lonza
Bio-prodact-DevetopnientJ’ipelinc
DISCOVERY
PHASE --------------------------------------- ^
MANUFACTURING
DEVELOPMENT
PHASE
MANUFACTURING
------------ ►
Chemical and 
pharmaceutical companies 
are generating bioprocess 
solutions for product 
synthesis. The bioprocess 
typically includes a number 
o f unit operations. Each 
unit operation requires 
development before the 
manufacturing goal can be 
met.
The primary objective of the development phase is to translate the 
bioprocess from concept to manufacturing. Development is 
constrained by a number of issues:
•  Robust &  scaleable development o f unit operations
•  Reaction constraints
•  Fixed capital and operating expenditure
•  M ultiple project scheduling
•  IPR
•  Regulation requires any bioprocess to be fixed, after 
which further changes are time and resource 
demanding.
Production might be for R & D , 
clinical trials, or sale and must 
remain w ithin the constraints 
imposed by:
Results o f each phase 
Q C /Q A  
Marketing 
Distribution  
Regulation 
Production ramping
Regulatory issues have the 
m ajor impact on any 
bioprocess and approval 
represents a significant 
additional development 
constraint and business risk.
Figure 2 -  Bio-product development pipeline.
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Sequencing for Pharmaceutical Development
D is c o v e r y
P re -c lin ic a l
P hase 1 Phase 2 P hase 3
►
M a n u fa c tu r in g B u lk  m a n u fa c tu r in gR B
R BR B R B R B R B
M a r k e t in g
S ales
►
B io p h a rm a c e u tic a l ~ 8  ye ars , S m a ll P h a rm a c e u tic a l D r u g  ~ 1 5  years  
Figure 3 - Sequencing for Pharmaceutical Development
T e c h n o lo g y  R ev iew  -  G ro u p  A ss ig n m en t
1. Sequencing for Bioprocess Development of Biocatalysis
D is c o v e ry D e v e lo p m e n t M a n u fa c tu r in g
Product discovery
Route/ reaction
Biocatalyst
Characterisation -  data collection
Define bioprocess
RBD - 
screening
Manufacturing
Figure 4 - Sequencing for Bioprocess Development of Biocatalysis
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2.2.5. Who are the players?
The current key players are Sam Pickering and Paul Bird. They are both in the final year o f 
researching PhDs in the department o f Biochemical Engineering at U C L, working in  m icrowell 
bioprocessing and automation, and N IR , respectively. U C L has a commitment to microscale 
bioprocessing, and is currently constructing a dedicated facility (£20M , due to open A p ril 2002) to 
explore this new and exciting technology. The department has links w ith Packard Bioscience and 
Tecan (Robotic liquid handling manufacturers) and Foss (N IR  equipment manufaturer), who could 
be consulted on integrating the necessary equipment to exploit R BD . The Biochemical 
Engineering Department is keen to publish new discoveries in peer-reviewed journals -th is  desire 
must be carefully controlled i f  the IP R  o f R B D  is to be the subject o f patent applications. The 
Department is a world leader in research which has made possible the production o f a new 
generation o f human therapeutic proteins. It  has also pioneered research on the use o f biocatalysis 
in the synthesis o f chemical medicines. The Department manages the interdisciplinary research 
collaboration o f ten U C L departments w ithin the Advanced Centre for Biochemical Engineering. 
The Centre conducts studies on materials for human protein, gene, cell and tissue therapy and on 
biocatalytic processes enhanced by directed evolution and metabolic engineering. A  history o f 
patenting its research makes the department more sensitive to the needs o f non-disclosure than 
many other departments in similar fields.
2.2.6. Applicable regulations.
The cost o f bringing complex drugs to market is increasing,, impacting on both the drug 
development pipeline and return on investment for drug development companies. The regulatory 
measures imposed by governments are hampering the long-term profitability o f the pharmaceutical 
industry. Regulatory authorities are insisting that good manufacturing practices (cG M P) are
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applied at a much earlier stage than previously required; the tim e available for bioprocess 
development has therefore been reduced further15. The development phase o f drug development 
requires no specialist regulation other than those that are required for containment and health and 
safety, however the requirement for early cGMP procedures and the consequential tim e constraints 
distinguish further the advantages o f R B D . Likewise, where the bioprocess under development is 
not a drug any regulation applicable to the manufacturing process w ill be associated w ith the end- 
use and are therefore unlikely to affect R B D  operation.
2.2.7. Who funds?
The current research by Sam Pickering and Paul Bird is financed by the Biochemical Engineering 
Department, the Biotechnology and Biological Sciences Research Council (BBSRC), and Pfizer. 
The funding covers salaries, premises, equipment costs and lab consumables. The rights to income 
from any patents stemming from this research would be divided, subject to negotiation, amongst 
the two researchers, U C L , and Pfizer.
2.3. From reality check to market.
2.3.1. Technical feasibility vs. commercial potential?
.As has been mentioned it is considered that an N IR  instrument capable o f monitoring a 
hioprocesses in 96-w ell plates could be demonstrated w ithin three months. I f  this development was 
conducted w ithin U C L for IP  and resource issues then this time might increase. Comment form  
David Walker UCL Optics group. It  therefore remains for a demonstration o f the RBD product to 
Ibe carried out in the context o f the customer. This would include a detailed analysis o f what 
Tbioprocesses can be developed using R BD . Are there particular bioprocesses, which cannot be
15Foo.F. et al. Biopharmaceutical process development: Part 1, Information from the first product generation.
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operated using m icro-well reactors? This evaluation should also include expected bioprocess 
conditions e.g. pH, temperature. A  potential customer m ight be a manufacturer o f protein 
bioproducts. Bio-products typically require a fermentation step. This fermentation step involves 
the growth o f single-cell organisms both eukaryotic and prokaryotic. The question remains as to 
which organisms can a 96-w ell plate bioprocess operation be applied.
Current research in  the department o f Biochemical Engineering is resolving the issues associated 
w ith  the control o f pH , temperature and sterility in the micro w ell environment. Ten hour 
fermentations have been carried out to exactly m im ic those at a larger scale, but longer 
fermentations w ith a need to control pH and feeding are proving to be more problematic. It  is 
anticipated that these problems w ill have been resolved by the end o f 2002.
Even in its current state the usefulness o f RBD has been demonstrated in biocatalysis w ith no 
fermentation step. Microscale processing techniques have been shown to be a useful tool for the 
rapid and efficient collection o f biotransformation kinetic data and as a basis for bioprocess design. 
Automated liquid handling systems can reduce labour intensity w hile the small scale reduces the 
demand for scarce materials such as reactant, product and biocatalyst. W e have demonstrated that 
the microscale processes in R B D  can be used for the collection o f quantitative kinetic data that is 
essential to robust development o f a bioprocess16.
2.3.2. RBD program development.
This development plan for R BD recognises that a significant investment o f tim e and resources is 
necessary before a R B D  product can be demonstrated but that at each stage o f development value 
is being created and that R BD represent only one way in which this value can be realised. Figure 1
'BioPharm, June 2001.
16 Pickering, S.C.R, Doig, S.D., Lye, G.L., Woodley, J.M. The use of microscale processing technologies for quantification of 
lbiocatalytic Baeyer-Villiger oxidation kinetics. Biotech. Bioeng. In Press
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depicts a recommended strategy for building the value o f RBD and figure 2 depicts the process o f 
technological development.
This program reflects the lack o f IP R  associated w ith the individual components o f the R BD  
technology and the overall concept. A  conversation w ith Simon Kremer a patent attorney w ith  
M ew bum  E llis highlighted the lack o f consideration that has been given to IP R  w ith regard to 
RPD. It  was Simon’s opinion that in  principle a patent could be filed based on the novel u tility  o f 
the technology for R B D . It  was impressed that the risk o f disclosure could complicate a patent 
application and an early patent file  would be advised. That is the technological detail o f the R B D  
technique should be clearly stated and the process o f acquiring IPR  should be instigated through 
U C L  ventures. Since it is only necessary to demonstrate technological feasibility and no 
(demonstration is required to file  a patent, it is recommended that the inventors discuss w ith U C L  
and U C L  ventures the IP R  issues surrounding RBD.
2.3.3. Customers approach.
The three target markets for R B D , as defined in  section 2.2.4, encompass huge number o f 
(companies. In  order for R B D  to be accepted, the large companies (Figure 5) listed in the table 
below, should be approached first.
Large Pharmaceutical Contract Manufacturer Research with no manufacture
AstraZeneca Lonza Academic research groups
Bristol-Myers Squibb Bayer Drug discovery
GlaxoSmithKline DSM Fine Chemicals Biotechnology companies
Aventis Solutia Research institutions
Merck & Co., Inc. Charybdis Technologies, Inc.
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Pfizer Inc. Chiron Contract Manufacturing
Roche Bioscience Q-One Biotech
Eli L illy Rhodia Chirex
Novartis Molecular Medicine 
BioServices, Inc.
BMS Formatech, Inc.
Sales expiring 2001 to 2005
R&D Spending Rank 
2000 (1999 rank in brackets)
P fizer t  I 
G S K  I 
A ventis t  I 
P harm acia t  I 
A straZeneca t  I 
Roche f I 
M erck  f I 
E li L illy  I 
B M S  -  I 
N ovartis  I
$0.0
2000 Product Sales Expiring 2001 - 2005 
Figure 5 -  Steve A rlington, Pricewaterhouse Coopers, Pharm a 2005 Presentation
T h e  v a lu e  o f  R B D  to  th e  c u s to m e r w i l l  r e f le c t  th e  a p p lic a t io n  o f  R B D  d u r in g  p ro d u c t  
d e v e lo p m e n t. I t  s h o u ld  b e  n o te d  th a t th e re  a re  tw o  d is tin c t u t il i t ie s  o f  R B D  (p le a s e  re fe r  to  se c tio n  
2 .2 .4 ) .  I f  R B D  is a p p lie d  to  m a n u fa c tu r in g  d e v e lo p m e n t ( f ig u re  3 )  th e  c u s to m e r w i l l  p o te n t ia lly  
a c h ie v e  u s in g  R B D  an  o p tim u m  s o lu tio n  fo r  m a n u fa c tu r in g , w h e re  p re v io u s ly  a  c o m p ro m is e
37 Country Universe
$ B illion
$1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 $7.5
% o f  
Corp Sales
30 
26 
29 
11 
54 
20 
40 
38 
27 
14
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solution was only possible due to resource and tim e constraints. In  addition, the optimum solution 
can be gained in a significantly shorter time. The value o f R B D  to the customer in this instance 
w ill include:
1. A  reduction in the time to market for the product o f the bioprocess
2. A  systematic and robust approach to bioprocess development
W here R B D  is applied to biocatalyst development (including screening -  figure 4) then the 
customer could use R B D  to characterise the biocatalyst. Biocatalysts are increasingly been sought 
as an important route to compound synthesis, especially where the product o f a reaction is required 
to be optically pure. Biocatalyst research discovery groups in  both the chemical and 
pharmaceutical industries screen libraries o f biocatalysts for specific characteristics including 
those detailed in  figure 2. One such biocatalyst library has recently been launched by Maxygen a
17  i  o
California based biotechnology company . M erck’s approach to introducing a biocatalytic step 
in the synthesis o f small pharmaceutical molecules is initiated by the discovery o f a specific 
synthetic step where a biocatalytic reaction could be o f interest. Once it is established that a 
biocatalyst would present technical or financial benefits, decisions o f technical feasibility are then 
made based on internal expertise. Procedures for screening microorganisms or enzymes that 
catalyze the desired step are then designed and implemented. A fter successful completion o f 
screening, a process is developed at laboratory scale and later scaled-up in the pilot plant. The 
value o f R BD to a customer who wants to characterise and develop a library o f biocatalysts would 
be attributable to
1. The efficient and cost-effective synthesis o f the product.
17 http://www.codexis.com/frames.htm
18 Chartrain et al., “Asymmetric bioreductions: application to the synthesis of pharmaceuticals”, Journal o f Molecular 
Catalysis B: Enzymatic 11, 502-512 (2001)
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2. Process development solutions that are conceived w ithin the discovery phase, (i.e. 
manufacturing issues are included in the discovery phase -  see Figure 2).
True quantitative evaluation o f the value o f R BD to the pharmaceutical and chemical industry is 
difficu lt to gauge, as R B D  is a concept from which practical u tility  is being foreseen. Tony Harrop, 
a leader o f a bioprocess development group at Pfizer Global Research signalled strong approval o f 
the R B D  concept when he asked, “when can we have it?”. Although Tony Harrop could not value 
R B D  quantitatively, he was able to confirm that there would be a significant competitive 
advantage to any pharmaceutical company, which could shorten and or reduce the risks o f product 
development. He detailed a scenario where the launch o f a product could have been delayed due to 
difficulties w ith manufacturing and that RBD could have provided an opportunity to reduce this 
risk.
Drug development costs have risen to over $600 m illion per drug whilst 53 leading drugs w ill 
come o ff patent by 200519. There therefore exists pressure for the pharmaceutical and chemical 
industry to re-asses the route to producing new-drugs. Steve Arlington o f Pricewaterhouse Coopers 
has published four targets, which the pharmaceutical industry needs to achieve to sustain total 
shareholder returns by 2005:
•  Double number o f drug leads w ith improved quality o f candidates entering 
development.
•  Double success rate in development w ith near zero attrition after phase II.
•  3 years additional peak sales w ith accelerated late development and launch.
•  20%  increase in revenues per drug.
As RBD aims to save tim e in the development phase and to improve the quality o f bioprocess 
solutions, there is an obvious contribution to be made by R B D  towards meeting these targets.
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2.3.4. VC consulting.
The equipment involved in carrying out RBD is relatively costly: a liquid handling robot costs 
£150,000 and an N IR  system costs £43,500. U C L  currently owns two liquid handling robots, an 
N IR  system, and other costly m icrowell measurement devices, and has funding to make other 
significant purchases as part o f a Joint Infrastructure Fund (JIF) award. A t this early stage it makes 
sense for the R B D  project to exploit these resources, rather than seek investment to purchase 
dedicated equipment. The U C L  owned equipment could also be used for early commercial 
contracts, before additional investment is requires. Jeff Skinner from U C L Ventures20 suggested 
that potential Venture Capital investors would be reluctant to fund a company that used U C L  
owned equipment as it is likely  that it would only be available for commercial use when it was not 
being used for academic research. A  likely financial model, therefore, would be to use the U C L  
owned equipment for the development o f R B D , testing, and early contracts. On the basis o f 
success up to that point, investment could be sought to supplement income form early contracts
: fr
and buy dedicated equipment and premises to spin-out an R B D  company.
3. RBD entry to market.
3.1. Capturing value.
3.1.1. RBD Services
W e have developed a method o f accurately simulating fermentation and biocatalysis at a very 
small scale. Using robotics we can automate thousands o f these small bioreactors at the same time, 
and analyse the results generated using advanced instrumentation and software. The tim e taken in 
conventional optimisation (development) and experimentation w ith new product candidates is 
largely due to the number o f experiments required. Simultaneously performing these experiments
19 Arlington,S. Phanna 2005: the challenges.
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a l lo w s  a s ig n if ic a n t  d e crea se  in  d e v e lo p m e n t t im e  (e q u a tin g  to  m il l io n s  o f  d o lla rs  e .g . re d u c e d  t im e  
to  m a rk e t , e x te n d e d  u s e fu l p a te n t l i fe ,  h ig h e r  N P V  fo r  each  p ro d u c t) . F ig u re  6  sh o w s  th e  k e y  
stages in  d e v e lo p m e n t fo r  a  la rg e  p h a rm a c e u tic a l c o m p a n y . R B D  c o u ld  b e  u sed  at ea c h  o f  th e  
d e v e lo p m e n t p h ases , s p e e d in g  u p  c o n v e n tio n a l d e v e lo p m e n t tim e s .
Company
Project 1 Project 2
Figure 6 -  Key stages in development process fo r a pharm aceutical company 
3.1.2. M a rk e t environm ent.
P h a rm a c e u tic a l c o m p a n ie s  a re  n o to r io u s ly  s lu g g is h  in  a d o p tin g  n e w  te c h n o lo g ie s  -  th is  m a y  b e  
th o u g h t to  b e  a b a r r ie r  to  e n try  in to  th e  m a rk e t. D e m o n s tra tin g  th a t R B D  w o rk s  w o u ld  o n ly  b e  o n e  
h u rd le  -  i f  th e  R & D  an d  M a n u fa c tu r in g  d e p a rtm e n ts  can  p ro d u c e  th e  p ro d u c t in  a  p ro f ita b le  fo rm ,
20 UCL Ventures is the technology transfer office responsible for the management, protection and commercialisation
Technology Review -  Group Assignment
without having to rely on new/unproven technology, then that is seen as preferable. A n example o f
this is large scale mammalian cell culture which is only just starting to be adopted by M erck,
despite having been present in academic laboratories for over a decade. Previous requirements
were met by duplicating the small-scale roller-bottle equipment in large warehouses, as demand
was low . It  is only the necessity to produce large amounts o f mammalian cells for their new H IV
0 1
vaccine that is forcing them to adopt large scale culture in their future plans .
3.1.3. Marketing Strategy
In  developing R B D  marketing strategy, we have first segmented the market and defined the value 
proposition R B D  w ill offer to each segment, now we are going to concentrate on the promotion 
strategy. It  is a ll about communications and advertising management, the objective is to ensure that 
all the elements o f the communications m ix are coordinated w ith the marketing strategy, delivering 
the same underlying positioning and value proposition to the target segment.
R B D  shall be promoted emphasising the need for changes in the drug development process, the 
pressure is strong to save costs and reduce time-to-market, which is exactly where R B D  brings 
value. The promotion o f RBD shall be focus on making R B D  a fundamental element in the 
redesign o f R & D  models, these new models being necessary to sustain the pharmaceutical and 
chemical companies’ shareholders value.
R & D  productivity is progressively declining; the amount o f money spent per drugs delivered to the 
market is increasing dramatically:
S  1990: $20bn spent in R & D  for 45 N C E 22’s launched per year,
of UCL's intellectual property.
21 Barry Buckland, Vice-president R&D M erck, 14 March 2002
22 NCE = New Chemical Entity
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S  2000: $45bn spent in R & D  for 25 N C E ’s launched per year,
This trend is participating in the decrease in shareholder returns, we can observe:
S  R & D  costs continue to increase at 10.8% p.a., where the average growth market is 
about 8.1% p.a., contributing to the erosion o f margin and though diminishing value,
S  Revenue per new drug launched averages $265 p.a., also in constant decrease,
S  Revenue from the existing portfolio diminishes at 5% p.a. due to patent expiries and
price constraints,
S  Total revenue from drugs grows at 7% p.a.
RBD w ill enable the development firms to reverse this trend, by bringing more drugs to the
market, quicker and cheaper. For a comparable R & D  budget, RBD enables a significant gain in
productivity and consequently better o ff the bottom line.
The other argument to be put forward is the lim ited number o f blockbusters, fewer than 4%  o f 
products generate sales o f $500 m illion or more, see table:
Sales Total per annum ($) % o f NCE's
1.8 bn 3.6 bn 1%
920m -  1.8bn 1%
460m -  920m 2%
180m -  460m 6%
<180m 90%
Source: Scrip Papers, PJB Publications Ltd 1995, Adjusted fo r  inflation to 1998
As RBD w ill enable a systematic and robust approach to bioprocess development, the odds are it 
w ill enable to higher the percentage o f money-making drugs.
Patent exposure is another source o f promotion for RBD:
S  In 2000, 13 o f the top 100 drugs, with 1998 worldwide sales o f $1 lbn came o ff patent 
and generic competition intensified,
S  In 2005, 53 o f today’s top 100 prescription drugs w ill be o ff patent, w ith 1998 
worldwide sales totalling $53bn.
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O Off patent 
*  Patent protected
0  Off patent 
■  Patent protected
Additionally to the budgetary constraints, to which RBD can play a great role, these are some 
social constraints for new development process, which can be a strong marketing vector for RBD:
S  Pharmaceutical drugs remain the 6th largest cause o f death in the US,
^  On average, only 40% o f individual benefit from a particular drug,
S  Drug development costs have risen to over $600m illion par drug, meaning the costs
o f PHI mega-trial failures is significant,
S  Many medical needs remain unmet,
S  Regulators struggling with risk versus benefit equation.
Again all these factors contribute at making RBD a necessary ingredient o f the new development 
process, for a new model to produce safer, more efficacious and cheaper drugs. In defining the 
marketing and promotion campaign o f RBD, these issue w ill be put forward the raise market 
awareness o f RBD and the advantages it can bring to its customers.
It is important that any promotion reflects the culture o f the customers being targeted. Large 
pharmaceutical companies make development investment decisions based on the business risk o f 
investing in a given project. Appendix 4, a Gantt chart describes the risk investments made by 
Pfizer Ltd during the development o f an unspecified product. This information, provided by an 
important potential customer allows an insight into the process o f decision making. Each risk 
investment phase (appendix 4) is broken down into project stages over time with the risk (to the 
business) described by the expenditure and number o f man hours used. As the number o f risk 
investment phases increases so does total expenditure and the number o f man-hours invested. The 
example given in appendix 4 required a total expenditure o f S I6.5 m illion and 119 man (person) 
years. The approach taken to promote RBD should communicate the value to the customer in
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terms o f person-years saved, and reduced expenditure. This translates to an overall reduction in 
investment risk at each stage o f pharmaceutical or chemical development.
3.1.4. RBD delivery to the market
The way in which R B D  is delivered to the customer w ill reflect directly the method in which the 
value created through incubation and demonstration o f the R B D  technology is best realised. Given 
the market segmentation o f large/ small molecules, large/ small customers and manufacturing 
optim isation/ biocatalyst development (or screening) there is potential for a diversified customer 
base. The method in  which each market segment is served by the RBD business requires further 
consideration. Large pharmaceutical companies are unlikely to consider a licensing agreement 
through which R B D  provides a manufacturing development service. Tony Harrop o f Pfizer Global 
Research agreed w ith this analysis. Pharmaceutical companies have a culture o f expertise, which 
m ight be undermined by a licence agreement that includes provision o f a service. A  U C L  start-up, 
Ensynthase, discovered that problems o f undermining expertise, sharing information and fixed 
internal budgets were all issues when trying to tender business with pharmaceutical companies. 
The delivery o f R B D  to the pharmaceutical industry would therefore be best served by sale o f the 
technology and operational expertise.
Small to medium sized customers including biotechnology companies might use R B D  to add value 
to their product candidates (section 2.1.a) before seeking a development partner. The customer is 
unlikely to want to purchase the RBD technology/ expertise due to a lack o f resources, time and 
practical requirement. In  this case, a licensing or service agreement should be considered where 
the business o f R B D  includes delivering a practical development solution or consultancy. An 
option would be to collaborate w ith companies, to create better bioprocesses and products o f
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bioprocesses. I f  R B D  retains a right to royalty from the developed bioprocess and or product then a 
potential for high returns sim ilar to that o f any biotechnology product exists.
Servicing both segments would require a significantly different approach that would be reflected in 
any business plan for RBD . A t this stage, it is recommended that no decision be made until IPR  
and a more precise evaluation o f market size and value can be conducted.
3.1.5. Pricing.
The price w ill match the perceived value customers are ready to pay for RBD . Given that there is 
no integrated direct alternative to R B D  then the price should reflect the tim e saving or value 
obtained through RBD . Where a R B D  product is sold to a customer the price should reflect not 
only the cost o f the technology but the knowledge base required to m im ic large bioprocesses at a 
microscale.
3.2. Marketing environment.
3.2.1. Who are the customers?
A ll m ajor potential customers, as identified in section 2.3.3, and selling approach (section 3.1.3) 
are defined in  order to conquer the market as the product nears this stage o f commercialisation. 
W hen this stage is reached we should structure our customer base, by planning the customers 
approach.
3.2.2. Company structure.
Presently there is no company and it has been recommended that RBD development be continued 
until demonstration w ithin the research environment. A fter demonstration, seed funding from
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Bloomsbury Bioseed or SPIM  could be used to spin-out a company. This would be an important 
milestone towards building sufficient value and potential that a significant investment round could 
be sought. Discussion w ith Jeff Skinner at U C L  ventures suggested that the structure o f the 
company reflect the ambitions for further investment.
3.2.3. What about the competition?
Current competition in the field o f ultrascaledown is lim ited to two University groups:
1. Biochemical Engineering, Saarland University, Saarbrucken, Germany24
People: Gemot. T . John, Christoph. Wittmann, Prof. Elm ar Heinzle  
Projects:
1. M icroplate cultivation o f Organisms w ith Optical Measurement o f pH  and dissolved oxygen
2. Mass Spectrophotometric Respiratory Measurements in M icrow ell Fermentations
3. Mass Spectrophotometric Respiratory Measurements in Mam m alian Cell Culture Microreactors
4. Microreactor Screening for Biochemical Conversions
5. Screening o f Biochemical Kinetics Using Mass Spectrometry
6. M etabolic Engineering
2. Department of Biochemical Engineering, Aachen University of Technology, Germany25
People: Tibor Anderlei, Robert Hermann, Stefan Lotter, U lrike M aier, Jochen Buchs 
Projects:
23 Sussex Place Investment Management
24 http://www.uni-saarland.de/fak8/heinzle/
25 http://www.biovt.rwth-aachen.de
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1. Characterization o f m icrotiter plates as small scale culture systems (oxygen transfer, 
evaporation...) for biological screening
2. Detection o f pH  in small scale culture systems w ith immobilized fluorescence dyes
3. Quantitative optical measurement o f hydrodynamics in small scale systems
4. power consumption, small scale bioreactors, flowsheet optimization
5. Fermentation under increased head space pressure
6. Developm ent o f a novel m illiscale bioreactor system for continuous (multistage) operation
7. Characterization o f the specific power input and gas/liquid mass transfer in  a self prim ing 
aeration system
8. Experimental investigation, m odelling and optimisation o f the maximum oxygen transfer 
capacity in  shaking flasks and shaking test-tubes
9. Design, analysis and optimisation o f shaken screening-systems
10. Influence o f foaming on the gas-liquid mass transfer in baffled shaking flasks
11. Investigation o f the hydrodynamics in  shaking flasks
12. characterization and optimization o f fermentation conditions in  small scale cultures (test tubes, 
shaking flasks)
13. development o f fermentation strategies for the production o f recombinant proteins w ith  
different m icrobial systems
Neither o f these research groups is thought to pose significant threat, due to the prohibitive costs o f 
financing equipment purchases on conventional academic grants.
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Currently bioprocess development is undertaken in house at large scale or using contract 
manufacturers and consultants. These companies have established links w ith the industry and are 
highly networked, but are themselves potential customers o f RBD . RBD represents a paradigm  
shift in  the approach that would be taken by these competitors, who are currently not delivering the 
same level o f service that is proposed by RBD.
3.3. Commercialisation strategy next step for RBD.
To conclude, we believe we have demonstrated through the report the commercial potential o f 
R B D , the market it addresses, the value it brings to its customers and the way to deliver its value 
proposition. The next step is to lay down a business plan to leverage R B D  potential to a fu ll market 
application, once the latest technical development have been completed; this could be achieved 
follow ing our recommendations.
R B D  is on its way to revolutionise the drug development industry.
Appendix 1 a) -  Microwell Plate Technologies
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Appendix lb )  -  Microwell shaking demonstration (high speed video pictures)
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Appendix 2 - FOSS NIRsystems spectrophotometer model 6500.
Flexible fibre-optic cable
Transmission immersion probe
Transmission cell
Spectrophotometer
T h e  F O S S  N I R  a n a ly s e r tra n s m its  n e a r in fra re d  ra d ia tio n  a lo n g  f ib re  o p tic  cab les to  a tra n s m is s io n  p ro b e . T h e  p ro b e  is im m e rs e d  in  a l iq u id  
s a m p le  o f  th e  b io p ro c e s s  so th a t th e  tra n s m is s io n  c e ll is  co ve re d . T h e  sa m p le  o f  a b io p ro ces s  absorbs th e  ra d ia tio n  such  th a t th e  tra n s m itte d  
ra d ia tio n  d e te c te d  b y  th e  s p e c tro p h o to m e te r rep resen ts  th a t s a m p le  at th a t t im e . T h e  F O S S  f ib re -o p t ic  p ro b e  a tta ch ed  to  th e  m o d e l 6 5 0 0  
s p e c tro p h o to m e te r  has an  o u ts id e  d ia m e te r  o f  21 m m  an d  d isp laces  a p p ro x im a te ly  5 m l o f  sa m p le . I t  is  th e re fo re  n o t s u ita b le  fo r  s a m p lin g  
o f  m ic r o w e lls  o f  a 9 6  w e l l  p la te , w h ic h  h a v e  an  in te rn a l d ia m e te r  o f  6  -  7  m m  and  ty p ic a lly  h o ld  a v o lu m e  o f  0 .5  m l.
Appendix 3 -  96-well plate NIR transmission analyser
There are a number o f technological developments required before a 96-w ell plate N IR  analyser can be demonstrated. The primary requirement 
is the procurement o f a suitable N IR  analyser w ith the potential to interface a transmission probe to a 96-w ell plate. C ollin Dye o f Clairet 
Scientific was able to recommend two instruments (Zeiss M CS 500, Germany and ABB Bomem, Canada) capable o f being fitted to m ono-fibre 
transmission probes. FOSS NIRsystems also produce a single fibre analyser. A  quote from Varian analytical systems (U K ), for the Varian Cary 
500 spectrophotometer (N IR  analyser) came to £40,800. This is a significant capital investment, which i f  funded through a research grant 
would take typically 12 months to arrange. A  research grant would be funded through a research council and there is no guarantee o f success. 
Dr.P.D alby o f U C L, Biochemical Engineering Department puts the chances o f a research proposal being accepted at 40% .
To the N IR  analyser a suitably modified transmission probe o f <6mm would be fitted. A  study o f products on the market has indicated that 
Hellm a W orldwide, Germany could supply this technology. A  quote from Hellm a for such a N IR  probe states that the cost o f such a device 
would be £2500. The conversion o f the FOSS model 6500 N IR  transmission probe to read a 12 w ell plate would not require purchase o f a new  
spectrophotometer or probe. It  is therefore recommended that a 12 w ell plate N IR  analyser be demonstrated before development o f the 96 w ell 
analyser.
iiP g
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Appendix 4 -  risk in—  <■» d n .rio p n rin , .4  n n ,p « in « . P— . t  P f« «
G lo b a l R esearch
CLN = Clinical Trials or Toxicology StudiesDR = Developmental Research 
DSE = Drug Safety and Efficacy
e.g. CLN 3 900K relates to clinical, 3 man years, $900,000 expenditure
